data_2rq2_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2rq2 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.423 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 46.2 Cg_endo -73.38 -44.74 0.5 Allowed 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 124.021 1.537 . . . . 0.0 110.419 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 13' ' ' VAL . 1.9 p -64.8 -71.24 0.19 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.236 -0.915 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.417 ' C ' ' O ' ' A' ' 12' ' ' SER . 65.2 t -42.64 -30.96 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.325 -0.859 . . . . 0.0 110.142 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.498 ' CZ3' HD21 ' A' ' 17' ' ' LEU . 46.4 t-105 -64.78 -56.7 11.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.181 -0.95 . . . . 0.0 110.106 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.34 -28.55 43.52 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.211 -0.93 . . . . 0.0 109.904 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -69.45 -47.33 64.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.922 . . . . 0.0 109.842 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.498 HD21 ' CZ3' ' A' ' 14' ' ' TRP . 0.1 OUTLIER -65.73 -21.68 66.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.688 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -78.23 -51.47 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 109.952 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.69 -39.98 82.27 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.311 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -66.76 -52.91 38.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.27 -0.894 . . . . 0.0 110.28 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.422 HG23 ' CD1' ' A' ' 17' ' ' LEU . 81.9 t -60.91 -21.47 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 110.34 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.34 -53.59 8.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -53.75 -40.25 66.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.197 -1.178 . . . . 0.0 110.241 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.69 -33.47 72.58 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.34 -17.24 60.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.313 -0.867 . . . . 0.0 110.167 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.8 t -98.48 -14.4 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.305 -0.872 . . . . 0.0 110.179 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 110.125 179.925 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.83 -59.3 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.93 1.489 . . . . 0.0 110.608 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 88.3 p -62.98 -49.28 75.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 110.251 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.2 t -51.97 -42.23 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.192 -0.943 . . . . 0.0 110.095 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 27.5 t-105 -66.7 -32.55 73.93 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 110.122 179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.64 -33.61 71.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.284 -0.885 . . . . 0.0 110.234 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -76.4 -30.11 57.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.259 -0.901 . . . . 0.0 110.307 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -76.24 -29.82 57.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.162 -0.961 . . . . 0.0 109.67 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 69.0 t -79.57 -45.97 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.454 -0.778 . . . . 0.0 110.081 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.17 -48.58 81.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.327 -0.858 . . . . 0.0 110.126 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 43.0 mt -62.08 -49.37 76.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.258 -0.901 . . . . 0.0 110.262 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.0 t -73.29 -8.24 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 110.391 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.72 -33.24 13.33 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.64 -37.3 70.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -1.208 . . . . 0.0 110.427 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.46 -16.86 47.32 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.224 -0.923 . . . . 0.0 110.462 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.66 4.43 24.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.229 -0.92 . . . . 0.0 110.406 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 96.1 t -100.26 -15.92 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.12 -0.987 . . . . 0.0 110.253 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 110.293 179.983 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -75.82 -52.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 124.017 1.535 . . . . 0.0 110.435 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -61.92 -58.07 9.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.328 -0.857 . . . . 0.0 110.32 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 77.2 t -46.48 -34.37 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.905 . . . . 0.0 110.35 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.43 ' O ' HG23 ' A' ' 18' ' ' VAL . 23.2 t-105 -68.5 -58.4 4.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.19 -0.944 . . . . 0.0 110.229 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.67 -23.44 28.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.904 . . . . 0.0 110.376 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.33 -41.57 33.19 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 0.0 110.311 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.462 ' O ' HD11 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -70.61 -25.87 63.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.915 . . . . 0.0 109.693 179.903 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 14' ' ' TRP . 21.4 t -83.35 -37.05 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 110.088 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.04 -22.66 60.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.992 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 mt -87.9 -53.48 4.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.385 -0.822 . . . . 0.0 110.279 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.1 t -62.07 -16.77 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.309 -0.87 . . . . 0.0 110.362 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.52 -29.78 63.24 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.31 -20.53 63.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.255 -1.144 . . . . 0.0 110.249 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.45 ' O ' HG23 ' A' ' 27' ' ' THR . . . -87.33 -17.94 31.25 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.887 . . . . 0.0 110.171 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.3 -1.05 21.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.216 -0.927 . . . . 0.0 110.194 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.63 -11.54 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.297 -0.877 . . . . 0.0 110.172 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.45 HG23 ' O ' ' A' ' 24' ' ' ALA . 8.9 t . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.327 -0.858 . . . . 0.0 110.327 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.454 ' O ' ' HB3' ' A' ' 14' ' ' TRP . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.349 -1.501 . . . . 0.0 109.349 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.416 ' O ' ' HB2' ' A' ' 15' ' ' ALA . 46.2 Cg_endo -73.41 -52.76 0.14 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 124.023 1.538 . . . . 0.0 110.571 -179.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.52 -48.6 60.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.231 -0.918 . . . . 0.0 110.515 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.561 ' CG1' ' N ' ' A' ' 14' ' ' TRP . 2.9 p -59.64 -45.41 94.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.159 -0.963 . . . . 0.0 110.38 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.561 ' N ' ' CG1' ' A' ' 13' ' ' VAL . 49.3 t-105 -63.17 -36.88 85.09 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.116 -0.99 . . . . 0.0 110.013 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.416 ' HB2' ' O ' ' A' ' 11' ' ' PRO . . . -69.48 -23.48 63.64 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.332 -0.855 . . . . 0.0 110.089 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -78.13 -36.57 47.66 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.228 -0.92 . . . . 0.0 110.185 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.508 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.06 -26.1 56.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.209 -0.932 . . . . 0.0 109.583 179.802 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -81.52 -39.1 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.452 -0.78 . . . . 0.0 110.212 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.9 -38.15 67.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.225 -0.922 . . . . 0.0 110.139 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.2 mt -72.24 -39.18 68.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.935 . . . . 0.0 110.173 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.6 t -88.28 -4.77 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.307 -0.871 . . . . 0.0 110.195 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.26 -19.94 31.61 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -78.53 -29.78 46.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.226 -1.161 . . . . 0.0 110.244 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.445 ' O ' HG22 ' A' ' 27' ' ' THR . . . -81.54 -19.92 41.06 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.251 -0.906 . . . . 0.0 110.214 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.36 -15.8 60.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.284 -0.885 . . . . 0.0 110.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.5 t -83.7 -13.95 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 110.109 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.445 HG22 ' O ' ' A' ' 24' ' ' ALA . 10.1 t . . . . . 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 110.058 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.424 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.41 -41.72 3.25 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 O-C-N 124.013 1.533 . . . . 0.0 110.461 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 t -68.72 -56.08 9.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 110.137 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.72 -29.11 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.339 -0.851 . . . . 0.0 110.138 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.461 ' O ' ' CG2' ' A' ' 18' ' ' VAL . 44.0 t-105 -64.12 -42.5 96.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.253 -0.904 . . . . 0.0 110.142 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.405 ' O ' ' HB2' ' A' ' 19' ' ' ALA . . . -66.82 -25.41 66.43 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.182 -0.949 . . . . 0.0 110.103 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -73.95 -42.52 60.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 110.193 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.407 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.15 -27.88 59.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.641 179.863 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.461 ' CG2' ' O ' ' A' ' 14' ' ' TRP . 68.9 t -76.64 -36.3 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.284 -0.885 . . . . 0.0 109.999 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.405 ' HB2' ' O ' ' A' ' 15' ' ' ALA . . . -73.69 -32.49 63.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 110.014 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.1 mt -70.09 -51.21 33.57 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.294 -0.878 . . . . 0.0 110.225 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 49.0 t -64.32 -47.1 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -0.915 . . . . 0.0 110.258 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.52 -45.35 67.23 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.52 -22.39 60.12 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.286 -1.126 . . . . 0.0 110.205 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.13 -14.68 53.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.301 -0.874 . . . . 0.0 110.254 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.05 -12.34 58.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.924 . . . . 0.0 110.307 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.9 t -89.29 -13.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -0.9 . . . . 0.0 110.157 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 99.6 m . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.184 -0.947 . . . . 0.0 110.164 179.851 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.98 -47.7 0.31 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.944 1.497 . . . . 0.0 110.397 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 0.3 OUTLIER -67.05 -60.68 2.42 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -0.915 . . . . 0.0 110.191 -179.988 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.413 ' C ' ' O ' ' A' ' 12' ' ' SER . 54.3 t -43.21 -47.81 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 110.122 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.416 ' O ' HG21 ' A' ' 18' ' ' VAL . 21.4 t-105 -55.83 -56.2 23.45 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.927 . . . . 0.0 109.912 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -53.93 -23.92 14.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -0.938 . . . . 0.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -75.0 -38.61 61.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.2 -0.937 . . . . 0.0 110.351 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.445 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -73.89 -25.6 60.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.835 179.939 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.416 HG21 ' O ' ' A' ' 14' ' ' TRP . 5.9 t -86.24 -28.33 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.319 -0.863 . . . . 0.0 110.097 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.56 -35.93 60.52 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.261 -0.899 . . . . 0.0 110.054 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.9 mt -83.15 -40.07 20.23 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.283 -0.886 . . . . 0.0 110.177 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.438 HG22 ' O ' ' A' ' 17' ' ' LEU . 90.7 t -79.25 -17.6 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.224 -0.923 . . . . 0.0 110.196 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.53 -30.18 64.74 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.57 -26.6 68.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.152 . . . . 0.0 110.201 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -66.01 -40.3 90.99 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.204 -0.935 . . . . 0.0 110.203 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.4 -11.89 60.62 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 110.25 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.409 ' O ' HG11 ' A' ' 26' ' ' VAL . 38.1 t -84.95 -17.37 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.175 -0.953 . . . . 0.0 110.241 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.7 t . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 110.097 179.777 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.2 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.93 -47.57 0.44 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.989 1.521 . . . . 0.0 110.295 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 m -61.47 -55.69 28.44 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.904 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 t -54.04 -37.57 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 109.87 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 46.4 t-105 -59.07 -52.18 66.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.215 -0.928 . . . . 0.0 109.922 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.2 -19.73 65.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.757 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -75.8 -40.25 55.4 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 110.095 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.45 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.7 -29.64 56.36 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.596 179.811 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.3 t -75.36 -29.65 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.393 -0.817 . . . . 0.0 109.87 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -77.05 -40.16 47.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.912 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.3 -36.4 81.44 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 110.042 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.405 HG23 HD11 ' A' ' 17' ' ' LEU . 84.8 t -77.51 -35.3 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.16 -0.963 . . . . 0.0 110.223 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.13 -12.32 68.49 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.43 -28.83 37.66 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -1.153 . . . . 0.0 110.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.99 -22.98 31.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.2 -0.938 . . . . 0.0 110.307 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.88 -0.91 17.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -0.889 . . . . 0.0 110.236 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 41.6 t -99.62 -2.34 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.267 -0.896 . . . . 0.0 110.113 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.151 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.37 -42.69 0.85 Allowed 'Trans proline' 0 C--N 1.305 -1.728 0 O-C-N 123.992 1.522 . . . . 0.0 110.234 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.0 m -67.51 -55.62 12.79 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.22 -0.925 . . . . 0.0 110.186 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.7 t -53.99 -45.02 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.971 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.449 ' CE3' HD22 ' A' ' 17' ' ' LEU . 26.5 t-105 -58.33 -47.17 84.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.802 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.07 -23.73 21.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.323 -0.861 . . . . 0.0 109.979 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.531 ' CE1' HD13 ' A' ' 20' ' ' LEU . 0.2 OUTLIER -76.83 -51.17 11.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 110.006 179.916 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.453 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -59.53 -22.86 62.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.757 179.904 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.9 t -85.36 -44.12 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -0.905 . . . . 0.0 110.078 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.72 -24.73 67.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.333 -0.854 . . . . 0.0 110.084 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.531 HD13 ' CE1' ' A' ' 16' ' ' TYR . 0.9 OUTLIER -88.02 -39.29 14.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.23 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -72.12 -21.44 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.232 -0.918 . . . . 0.0 110.158 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.06 -18.32 69.89 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.61 -18.45 60.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -1.168 . . . . 0.0 110.22 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -88.75 -29.27 19.92 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.929 . . . . 0.0 110.31 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.61 -4.13 32.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.206 -0.934 . . . . 0.0 110.213 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 47.4 t -84.43 -20.17 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.249 -0.907 . . . . 0.0 110.22 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 110.161 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.523 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.523 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 44.3 Cg_endo -72.65 -58.66 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.025 1.539 . . . . 0.0 110.63 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.415 ' O ' ' C ' ' A' ' 13' ' ' VAL . 5.4 t -55.71 -63.68 1.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -0.918 . . . . 0.0 110.195 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.415 ' C ' ' O ' ' A' ' 12' ' ' SER . 60.6 t -42.88 -51.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.344 -0.847 . . . . 0.0 110.245 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.46 ' O ' HG23 ' A' ' 18' ' ' VAL . 40.9 t-105 -48.43 -47.13 38.19 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.232 -0.918 . . . . 0.0 110.276 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.52 -34.77 74.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.262 -0.899 . . . . 0.0 110.424 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.8 t80 -67.14 -48.35 68.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.235 -0.915 . . . . 0.0 110.417 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.435 HD21 ' CE3' ' A' ' 14' ' ' TRP . 0.1 OUTLIER -64.96 -24.26 67.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.114 -0.991 . . . . 0.0 109.982 -179.901 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 14' ' ' TRP . 29.9 t -73.52 -62.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.337 -0.852 . . . . 0.0 110.248 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.55 -28.96 34.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.27 -0.894 . . . . 0.0 110.213 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.454 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 5.0 mt -67.87 -49.52 61.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 110.217 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.5 t -55.56 -48.48 77.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.216 -0.927 . . . . 0.0 110.204 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -62.73 -32.93 85.29 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.454 ' HB1' ' O ' ' A' ' 20' ' ' LEU . . . -62.04 -30.12 70.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.185 -1.185 . . . . 0.0 110.39 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.46 -34.89 18.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 110.265 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.92 -13.17 14.11 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.208 -0.932 . . . . 0.0 110.25 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 65.6 t -93.77 -23.59 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 110.26 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 m . . . . . 0 N--CA 1.492 1.64 0 O-C-N 121.257 -0.902 . . . . 0.0 109.962 179.822 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.46 -40.24 1.65 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.963 1.507 . . . . 0.0 110.24 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.6 t -73.37 -59.19 2.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.434 -0.791 . . . . 0.0 110.302 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 53.1 t -53.36 -40.42 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.256 -0.903 . . . . 0.0 110.317 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.471 ' CE2' HG21 ' A' ' 18' ' ' VAL . 36.2 t-105 -58.65 -36.95 74.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.353 -0.842 . . . . 0.0 110.119 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.88 -32.41 69.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.931 . . . . 0.0 110.257 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.442 ' O ' HD12 ' A' ' 20' ' ' LEU . 0.3 OUTLIER -70.74 -41.02 72.38 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.136 -0.978 . . . . 0.0 110.064 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -72.43 -30.64 64.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.213 -0.93 . . . . 0.0 109.469 179.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.471 HG21 ' CE2' ' A' ' 14' ' ' TRP . 72.9 t -77.92 -27.78 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.435 -0.79 . . . . 0.0 109.891 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.72 -45.13 38.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 110.138 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.442 HD12 ' O ' ' A' ' 16' ' ' TYR . 0.3 OUTLIER -66.1 -52.12 51.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.866 . . . . 0.0 110.211 179.901 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.442 ' O ' ' HB3' ' A' ' 25' ' ' ALA . 45.5 t -69.21 -12.28 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 110.262 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.414 ' O ' HG21 ' A' ' 26' ' ' VAL . . . -75.18 -41.45 31.52 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.74 -33.57 68.61 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.25 -1.147 . . . . 0.0 110.149 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.22 -23.87 24.61 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.268 -0.895 . . . . 0.0 110.275 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.442 ' HB3' ' O ' ' A' ' 21' ' ' VAL . . . -77.5 -1.46 30.56 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.931 . . . . 0.0 110.192 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.459 HG11 ' O ' ' A' ' 26' ' ' VAL . 86.4 t -113.66 -6.83 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.231 -0.918 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.8 t . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.131 -0.981 . . . . 0.0 110.193 179.954 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.1 -48.05 0.29 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.045 1.55 . . . . 0.0 110.373 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.51 -59.37 2.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.327 -0.858 . . . . 0.0 110.127 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.5 t -48.22 -29.49 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 110.161 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.0 t-105 -73.64 -59.47 2.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 110.158 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -57.76 -16.42 11.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.263 -0.898 . . . . 0.0 109.947 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.435 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.3 t80 -82.38 -42.3 18.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 110.104 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.477 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.2 -23.0 57.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.34 -0.85 . . . . 0.0 109.676 179.861 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -79.31 -56.69 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.48 -0.762 . . . . 0.0 109.941 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.76 -33.93 70.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.319 -0.863 . . . . 0.0 110.062 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 7.3 mt -67.86 -47.71 68.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.101 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 26.4 t -64.05 -16.28 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 110.175 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.29 -53.08 9.33 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -19.81 62.09 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -1.151 . . . . 0.0 110.209 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.62 -9.06 59.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.908 . . . . 0.0 110.134 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.29 3.85 26.01 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.36 -0.838 . . . . 0.0 110.122 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 20.8 t -101.58 -16.59 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 110.084 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.1 t . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.836 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.477 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.477 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 46.1 Cg_endo -73.25 -47.5 0.3 Allowed 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 123.973 1.512 . . . . 0.0 110.337 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 4.4 m -62.45 -66.93 0.47 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 110.086 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.413 ' C ' ' O ' ' A' ' 12' ' ' SER . 21.8 t -44.03 -39.09 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 109.984 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.51 ' CZ3' HD22 ' A' ' 17' ' ' LEU . 30.6 t-105 -56.35 -52.22 65.37 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -56.83 -25.62 56.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.167 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 7.3 t80 -74.56 -34.22 62.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 110.198 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.51 HD22 ' CZ3' ' A' ' 14' ' ' TRP . 0.1 OUTLIER -73.03 -34.61 66.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.335 -0.853 . . . . 0.0 109.734 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.62 -35.26 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.408 -0.807 . . . . 0.0 110.082 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.04 -47.37 74.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.956 . . . . 0.0 110.119 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 17.1 mt -62.37 -54.82 34.8 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.277 -0.89 . . . . 0.0 110.085 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.446 HG13 ' O ' ' A' ' 21' ' ' VAL . 58.4 t -64.71 -15.11 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 110.154 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.31 -36.74 49.53 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.27 -29.67 61.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 110.153 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.57 -34.07 73.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 110.233 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.67 -17.76 61.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.244 -0.91 . . . . 0.0 110.035 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 39.8 t -83.34 -6.73 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.378 -0.826 . . . . 0.0 109.959 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 110.057 179.874 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.99 -42.01 1.16 Allowed 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.974 1.512 . . . . 0.0 110.467 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.5 m -61.73 -61.75 2.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.905 . . . . 0.0 110.212 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.7 t -46.22 -39.13 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.28 -0.887 . . . . 0.0 110.256 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.488 ' CZ3' HD21 ' A' ' 17' ' ' LEU . 34.5 t-105 -63.09 -51.41 66.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.339 -0.851 . . . . 0.0 110.329 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.72 -26.99 67.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.122 -0.986 . . . . 0.0 110.254 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -69.91 -47.75 61.24 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.02 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.488 HD21 ' CZ3' ' A' ' 14' ' ' TRP . 0.1 OUTLIER -67.2 -30.22 70.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.204 -0.935 . . . . 0.0 109.742 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.402 ' O ' HG12 ' A' ' 18' ' ' VAL . 39.2 t -79.11 -27.07 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.447 -0.783 . . . . 0.0 110.107 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.98 -42.44 60.44 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.309 -0.87 . . . . 0.0 110.141 179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.2 mt -71.29 -48.03 53.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.174 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.0 t -71.77 -21.6 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 110.079 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -23.07 78.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.58 -29.67 41.31 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.16 -1.2 . . . . 0.0 110.15 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.32 -20.94 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 110.176 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.24 -17.02 64.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 110.15 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.41 ' O ' HG12 ' A' ' 26' ' ' VAL . 77.6 t -85.71 -19.24 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 110.097 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 67.1 m . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.353 -0.842 . . . . 0.0 110.033 179.877 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.465 ' O ' ' HB2' ' A' ' 14' ' ' TRP . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.57 -47.56 0.14 Allowed 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.002 1.527 . . . . 0.0 110.457 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 p -70.39 -63.22 1.13 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.296 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 91.2 t -47.8 -32.36 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 110.166 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.465 ' HB2' ' O ' ' A' ' 10' ' ' GLY . 63.6 t-105 -70.13 -41.8 73.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.928 . . . . 0.0 109.96 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.9 -23.35 65.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.471 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.7 t80 -77.53 -47.14 20.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.33 -0.856 . . . . 0.0 110.043 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.44 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -68.69 -21.5 64.42 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.292 -0.88 . . . . 0.0 109.709 179.885 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -82.6 -53.62 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -0.844 . . . . 0.0 110.207 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.47 -35.56 76.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.315 -0.866 . . . . 0.0 110.078 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 0.2 OUTLIER -72.1 -46.6 56.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.938 . . . . 0.0 110.171 179.935 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.416 HG22 ' CD1' ' A' ' 17' ' ' LEU . 37.2 t -66.95 -21.3 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.961 . . . . 0.0 109.902 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.16 -29.32 60.62 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.1 -22.98 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -1.078 . . . . 0.0 110.08 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.86 -35.98 75.15 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 110.207 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.51 -5.2 43.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 110.095 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.8 t -99.39 -13.54 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.207 -0.933 . . . . 0.0 110.223 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.1 t . . . . . 0 N--CA 1.492 1.63 0 O-C-N 121.205 -0.934 . . . . 0.0 110.239 -179.983 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.355 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.6 -54.57 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.047 1.551 . . . . 0.0 110.4 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -64.16 -51.26 64.68 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 110.146 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 38.5 t -57.48 -39.13 67.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.299 -0.876 . . . . 0.0 110.186 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 48.5 t-105 -64.88 -39.97 94.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.165 -0.959 . . . . 0.0 110.146 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.63 -25.66 64.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.181 -0.949 . . . . 0.0 110.196 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -75.79 -42.77 49.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 0.0 110.045 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -69.41 -29.85 67.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.321 -0.862 . . . . 0.0 109.827 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 32.3 t -77.26 -44.87 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.336 -0.852 . . . . 0.0 110.12 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -61.19 -36.76 80.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 110.1 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.4 mt -67.75 -48.22 67.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 110.044 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 64.0 t -77.43 -1.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.263 -0.898 . . . . 0.0 110.034 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.46 -21.51 31.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.17 -37.94 66.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.22 -1.165 . . . . 0.0 110.068 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 -7.05 58.4 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -78.3 -17.27 56.83 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.419 -0.8 . . . . 0.0 110.183 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.6 t -87.49 -16.29 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.371 -0.83 . . . . 0.0 110.031 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.311 -0.868 . . . . 0.0 110.102 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.03 -52.47 0.23 Allowed 'Trans proline' 0 C--N 1.307 -1.605 0 O-C-N 124.019 1.536 . . . . 0.0 110.394 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 p -65.71 -56.97 9.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.936 . . . . 0.0 110.132 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 67.0 t -49.32 -46.71 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.27 -0.894 . . . . 0.0 110.021 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.533 ' CE3' HD21 ' A' ' 17' ' ' LEU . 48.7 t-105 -56.02 -52.55 63.83 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 109.991 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.47 -22.65 55.5 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 109.878 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -70.75 -46.91 62.11 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.368 -0.833 . . . . 0.0 110.021 179.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.533 HD21 ' CE3' ' A' ' 14' ' ' TRP . 0.1 OUTLIER -65.43 -29.47 70.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.893 179.944 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.9 t -74.11 -63.41 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.89 . . . . 0.0 110.149 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.51 -23.27 9.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 110.36 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 10.5 mt -75.51 -46.06 34.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.144 -0.972 . . . . 0.0 110.187 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 92.9 t -67.8 -11.26 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.311 -0.868 . . . . 0.0 110.138 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.38 -26.52 27.76 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.88 -22.03 61.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 110.232 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.53 -24.54 17.22 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 110.136 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -76.37 -10.8 59.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.218 -0.926 . . . . 0.0 110.277 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 54.2 t -97.99 -1.85 10.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.256 -0.902 . . . . 0.0 110.319 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 25.2 m . . . . . 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.093 -179.982 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 44.9 Cg_endo -72.97 -54.58 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.951 1.501 . . . . 0.0 110.22 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -58.53 -58.86 6.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.268 -0.895 . . . . 0.0 110.01 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 t -47.88 -41.39 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.874 . . . . 0.0 110.108 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.44 ' O ' HG23 ' A' ' 18' ' ' VAL . 32.9 t-105 -57.08 -53.34 59.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.252 -0.905 . . . . 0.0 110.03 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.87 -22.55 65.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 110.293 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.41 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.4 t80 -75.27 -36.2 61.26 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.285 -0.885 . . . . 0.0 110.197 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.452 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -81.55 -28.53 33.85 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.165 -0.959 . . . . 0.0 109.805 179.964 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 14' ' ' TRP . 38.1 t -74.68 -32.48 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.37 -0.831 . . . . 0.0 109.979 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.1 -32.22 26.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.985 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 1.4 mt -68.4 -39.81 81.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.852 . . . . 0.0 110.159 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.5 t -64.58 -49.25 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -48.2 -40.54 21.84 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.72 -45.99 58.83 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -1.135 . . . . 0.0 110.176 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -66.0 -40.72 91.38 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.235 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.97 -8.01 40.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.169 -0.957 . . . . 0.0 110.205 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 99.4 t -96.6 0.28 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.299 -0.876 . . . . 0.0 110.248 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.217 -0.927 . . . . 0.0 110.258 -179.962 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -73.67 -42.43 0.85 Allowed 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 124.098 1.578 . . . . 0.0 110.388 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -69.42 -59.29 3.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.323 -0.861 . . . . 0.0 110.168 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.1 t -53.26 -30.12 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.85 . . . . 0.0 110.076 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 36.0 t-105 -64.8 -38.35 90.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 110.035 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.42 -29.06 65.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 110.111 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -73.12 -34.62 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.442 ' CD1' HG22 ' A' ' 21' ' ' VAL . 0.1 OUTLIER -77.24 -30.89 54.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.249 -0.907 . . . . 0.0 109.728 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -42.06 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.345 -0.847 . . . . 0.0 109.967 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.43 -49.67 68.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.28 -0.887 . . . . 0.0 109.854 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.1 mt -60.05 -54.93 40.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.907 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.442 HG22 ' CD1' ' A' ' 17' ' ' LEU . 53.6 t -63.6 -19.11 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.391 -0.818 . . . . 0.0 110.047 179.838 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.64 -30.48 36.0 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -75.73 -33.23 60.27 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.358 -1.084 . . . . 0.0 110.199 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.424 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -84.93 -13.11 51.8 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.191 -0.943 . . . . 0.0 110.254 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.15 -3.87 32.32 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 110.141 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 41.3 t -107.45 -7.7 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 110.243 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.424 HG22 ' HA ' ' A' ' 24' ' ' ALA . 11.0 t . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.288 -0.882 . . . . 0.0 110.144 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.5 -52.42 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.095 1.577 . . . . 0.0 110.426 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -48.52 -43.34 35.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.265 -0.897 . . . . 0.0 110.272 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.17 -37.53 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.225 -0.922 . . . . 0.0 110.174 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 28.3 t-105 -65.13 -42.52 93.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.4 -0.813 . . . . 0.0 110.092 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.74 -27.11 66.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.267 -0.896 . . . . 0.0 110.228 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.45 ' CE2' HD13 ' A' ' 20' ' ' LEU . 2.0 t80 -76.14 -30.55 58.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.942 . . . . 0.0 110.168 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.441 ' O ' HG21 ' A' ' 21' ' ' VAL . 0.1 OUTLIER -80.98 -29.47 35.28 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.952 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.1 t -79.03 -38.5 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.369 -0.832 . . . . 0.0 109.899 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.59 -49.72 44.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 109.985 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.45 HD13 ' CE2' ' A' ' 16' ' ' TYR . 13.7 mt -59.31 -50.72 72.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 110.224 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.441 HG21 ' O ' ' A' ' 17' ' ' LEU . 40.3 t -73.4 -17.51 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.286 -0.884 . . . . 0.0 110.174 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -77.37 -25.82 62.74 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -76.42 -39.91 52.23 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -1.12 . . . . 0.0 110.154 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -78.93 -28.97 43.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.353 -0.842 . . . . 0.0 110.168 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -69.73 -13.45 62.29 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.323 -0.861 . . . . 0.0 110.177 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 71.2 t -77.68 -15.68 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.255 -0.903 . . . . 0.0 110.161 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 86.2 m . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 0.0 110.182 -179.923 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.218 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.12 -60.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.001 1.527 . . . . 0.0 110.653 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -58.8 -47.2 85.59 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 110.327 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.76 -40.24 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 110.222 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.556 ' CE2' HG23 ' A' ' 18' ' ' VAL . 36.8 t-105 -64.75 -42.42 95.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 110.158 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.48 -29.64 70.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 110.24 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -74.72 -56.74 4.48 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.264 -0.898 . . . . 0.0 110.104 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.45 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -58.42 -22.3 53.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.198 -0.939 . . . . 0.0 109.954 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.556 HG23 ' CE2' ' A' ' 14' ' ' TRP . 55.9 t -83.22 -42.77 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.287 -0.883 . . . . 0.0 110.27 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.95 -23.57 67.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.338 -0.851 . . . . 0.0 110.262 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.88 -61.28 1.75 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.263 -0.898 . . . . 0.0 110.258 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.4 t -54.01 -30.07 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -0.967 . . . . 0.0 110.181 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.11 -44.34 67.29 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.09 -28.09 69.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -1.125 . . . . 0.0 110.194 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.82 -19.22 31.0 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.267 -0.896 . . . . 0.0 110.19 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.99 -9.53 59.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.221 -0.924 . . . . 0.0 110.149 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -105.83 -6.63 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.93 . . . . 0.0 110.253 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.6 t . . . . . 0 N--CA 1.492 1.66 0 O-C-N 121.269 -0.895 . . . . 0.0 110.194 -179.971 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.464 ' HG2' HG13 ' A' ' 5' ' ' ILE . 48.1 Cg_endo . . . . . 0 N--CA 1.496 1.651 0 N-CA-C 110.277 -0.701 . . . . 0.0 110.277 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -130.25 50.26 2.21 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.254 -0.904 . . . . 0.0 110.164 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.5 mt -106.84 -67.59 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.201 -0.937 . . . . 0.0 110.178 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -135.29 23.0 3.47 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-O 122.027 0.918 . . . . 0.0 110.013 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.464 HG13 ' HG2' ' A' ' 1' ' ' PRO . 43.2 mm -92.12 27.15 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 CA-C-O 121.899 0.857 . . . . 0.0 110.329 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.74 45.5 0.4 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -87.52 21.98 2.35 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.276 -1.132 . . . . 0.0 110.315 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.461 ' O ' HG22 ' A' ' 9' ' ' VAL . 1.1 t -114.87 177.74 4.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.258 -0.902 . . . . 0.0 110.085 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 8' ' ' THR . 23.6 t -141.11 -43.43 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.275 -0.89 . . . . 0.0 110.261 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.82 99.46 1.94 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.423 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 46.2 Cg_endo -73.38 -44.74 0.5 Allowed 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 124.021 1.537 . . . . 0.0 110.419 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 13' ' ' VAL . 1.9 p -64.8 -71.24 0.19 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.236 -0.915 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.417 ' C ' ' O ' ' A' ' 12' ' ' SER . 65.2 t -42.64 -30.96 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.325 -0.859 . . . . 0.0 110.142 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.498 ' CZ3' HD21 ' A' ' 17' ' ' LEU . 46.4 t-105 -64.78 -56.7 11.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.181 -0.95 . . . . 0.0 110.106 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.34 -28.55 43.52 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.211 -0.93 . . . . 0.0 109.904 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -69.45 -47.33 64.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.922 . . . . 0.0 109.842 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.498 HD21 ' CZ3' ' A' ' 14' ' ' TRP . 0.1 OUTLIER -65.73 -21.68 66.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.688 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -78.23 -51.47 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 109.952 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.69 -39.98 82.27 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.311 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -66.76 -52.91 38.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.27 -0.894 . . . . 0.0 110.28 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.422 HG23 ' CD1' ' A' ' 17' ' ' LEU . 81.9 t -60.91 -21.47 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 110.34 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.34 -53.59 8.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -53.75 -40.25 66.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.197 -1.178 . . . . 0.0 110.241 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.69 -33.47 72.58 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.34 -17.24 60.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.313 -0.867 . . . . 0.0 110.167 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.8 t -98.48 -14.4 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.305 -0.872 . . . . 0.0 110.179 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m -94.18 -25.63 17.01 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 110.125 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.93 -23.95 44.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.216 -0.927 . . . . 0.0 110.217 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -74.71 111.74 10.21 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 110.241 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.16 -179.946 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo . . . . . 0 N--CA 1.496 1.673 0 N-CA-C 110.218 -0.724 . . . . 0.0 110.218 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.05 62.83 7.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.21 -0.931 . . . . 0.0 110.059 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.41 ' HA ' HD11 ' A' ' 3' ' ' ILE . 34.3 mm -103.38 -56.7 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.311 -0.868 . . . . 0.0 110.565 -179.879 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -92.42 23.52 3.91 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-O 122.012 0.911 . . . . 0.0 110.239 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 13.9 mt -107.72 26.81 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 CA-C-O 121.843 0.83 . . . . 0.0 110.195 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -170.5 42.6 0.2 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -140.38 27.44 2.1 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.301 -1.117 . . . . 0.0 110.087 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.7 t -67.19 -167.9 0.06 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.885 . . . . 0.0 110.236 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 22.5 t -102.14 -63.28 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.384 -0.823 . . . . 0.0 110.071 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 131.66 74.48 0.11 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.83 -59.3 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.93 1.489 . . . . 0.0 110.608 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 88.3 p -62.98 -49.28 75.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 110.251 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.2 t -51.97 -42.23 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.192 -0.943 . . . . 0.0 110.095 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 27.5 t-105 -66.7 -32.55 73.93 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 110.122 179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.64 -33.61 71.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.284 -0.885 . . . . 0.0 110.234 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -76.4 -30.11 57.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.259 -0.901 . . . . 0.0 110.307 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -76.24 -29.82 57.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.162 -0.961 . . . . 0.0 109.67 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 69.0 t -79.57 -45.97 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.454 -0.778 . . . . 0.0 110.081 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.17 -48.58 81.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.327 -0.858 . . . . 0.0 110.126 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 43.0 mt -62.08 -49.37 76.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.258 -0.901 . . . . 0.0 110.262 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.0 t -73.29 -8.24 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 110.391 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.72 -33.24 13.33 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.64 -37.3 70.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -1.208 . . . . 0.0 110.427 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.46 -16.86 47.32 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.224 -0.923 . . . . 0.0 110.462 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.66 4.43 24.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.229 -0.92 . . . . 0.0 110.406 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 96.1 t -100.26 -15.92 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.12 -0.987 . . . . 0.0 110.253 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.5 t -108.61 -20.98 12.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 110.293 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.75 -26.59 40.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.241 -0.912 . . . . 0.0 110.305 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -105.55 74.21 1.07 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.291 -0.881 . . . . 0.0 110.169 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.137 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.426 ' HB2' HG13 ' A' ' 3' ' ' ILE . 48.4 Cg_endo . . . . . 0 N--CA 1.482 0.836 0 N-CA-C 110.409 -0.65 . . . . 0.0 110.409 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.463 ' HA ' HG13 ' A' ' 5' ' ' ILE . . . -116.87 50.37 1.08 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.174 -0.954 . . . . 0.0 110.229 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.426 HG13 ' HB2' ' A' ' 1' ' ' PRO . 17.9 mt -97.1 -47.22 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 110.219 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -96.99 22.47 8.37 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.198 -0.939 . . . . 0.0 110.024 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.463 HG13 ' HA ' ' A' ' 2' ' ' ALA . 17.7 mm -97.44 27.27 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.162 0 CA-C-O 121.955 0.883 . . . . 0.0 110.08 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 114.64 10.39 12.94 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -108.88 26.31 10.74 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.32 -1.106 . . . . 0.0 110.177 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.03 156.93 16.11 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.22 -0.925 . . . . 0.0 110.173 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.462 ' O ' ' HD3' ' A' ' 11' ' ' PRO . 20.1 t -71.69 -77.46 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.259 -0.9 . . . . 0.0 110.366 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.43 ' N ' HG11 ' A' ' 9' ' ' VAL . . . -41.54 101.33 0.02 OUTLIER Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 9' ' ' VAL . 48.4 Cg_endo -75.82 -52.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 124.017 1.535 . . . . 0.0 110.435 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -61.92 -58.07 9.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.328 -0.857 . . . . 0.0 110.32 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 77.2 t -46.48 -34.37 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.905 . . . . 0.0 110.35 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.43 ' O ' HG23 ' A' ' 18' ' ' VAL . 23.2 t-105 -68.5 -58.4 4.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.19 -0.944 . . . . 0.0 110.229 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.67 -23.44 28.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.904 . . . . 0.0 110.376 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.33 -41.57 33.19 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 0.0 110.311 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.462 ' O ' HD11 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -70.61 -25.87 63.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.915 . . . . 0.0 109.693 179.903 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 14' ' ' TRP . 21.4 t -83.35 -37.05 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 110.088 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.04 -22.66 60.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.992 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 mt -87.9 -53.48 4.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.385 -0.822 . . . . 0.0 110.279 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.1 t -62.07 -16.77 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.309 -0.87 . . . . 0.0 110.362 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.52 -29.78 63.24 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.31 -20.53 63.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.255 -1.144 . . . . 0.0 110.249 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.45 ' O ' HG23 ' A' ' 27' ' ' THR . . . -87.33 -17.94 31.25 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.887 . . . . 0.0 110.171 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.3 -1.05 21.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.216 -0.927 . . . . 0.0 110.194 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.63 -11.54 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.297 -0.877 . . . . 0.0 110.172 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.506 HG22 ' N ' ' A' ' 28' ' ' ALA . 8.9 t -101.12 -27.25 13.35 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.327 -0.858 . . . . 0.0 110.327 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.506 ' N ' HG22 ' A' ' 27' ' ' THR . . . -91.17 20.34 5.12 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.171 -0.956 . . . . 0.0 110.297 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -108.0 -173.34 2.26 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.264 -0.897 . . . . 0.0 110.186 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.223 -179.982 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo . . . . . 0 N--CA 1.496 1.662 0 N-CA-C 110.212 -0.726 . . . . 0.0 110.212 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 178.35 67.17 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.235 -0.915 . . . . 0.0 110.242 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.414 HG21 ' N ' ' A' ' 4' ' ' TYR . 81.1 mt -60.96 -88.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.126 -0.984 . . . . 0.0 109.994 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.414 ' N ' HG21 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -95.56 22.98 6.45 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.145 -0.972 . . . . 0.0 109.944 179.85 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 16.8 mm -101.76 27.4 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 CA-C-O 121.962 0.887 . . . . 0.0 110.264 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.451 ' O ' ' HB2' ' A' ' 7' ' ' ALA . . . -140.81 64.13 0.52 Allowed Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.451 ' HB2' ' O ' ' A' ' 6' ' ' GLY . . . 175.11 100.64 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.398 -1.06 . . . . 0.0 110.21 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -68.63 -151.04 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.21 -0.932 . . . . 0.0 110.169 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 74.4 t -108.9 -41.05 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.227 -0.921 . . . . 0.0 110.199 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.454 ' O ' ' HB3' ' A' ' 14' ' ' TRP . . . 178.42 88.88 0.07 OUTLIER Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.349 -1.501 . . . . 0.0 109.349 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.416 ' O ' ' HB2' ' A' ' 15' ' ' ALA . 46.2 Cg_endo -73.41 -52.76 0.14 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 124.023 1.538 . . . . 0.0 110.571 -179.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.52 -48.6 60.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.231 -0.918 . . . . 0.0 110.515 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.561 ' CG1' ' N ' ' A' ' 14' ' ' TRP . 2.9 p -59.64 -45.41 94.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.159 -0.963 . . . . 0.0 110.38 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.561 ' N ' ' CG1' ' A' ' 13' ' ' VAL . 49.3 t-105 -63.17 -36.88 85.09 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.116 -0.99 . . . . 0.0 110.013 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.416 ' HB2' ' O ' ' A' ' 11' ' ' PRO . . . -69.48 -23.48 63.64 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.332 -0.855 . . . . 0.0 110.089 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -78.13 -36.57 47.66 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.228 -0.92 . . . . 0.0 110.185 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.508 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.06 -26.1 56.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.209 -0.932 . . . . 0.0 109.583 179.802 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -81.52 -39.1 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.452 -0.78 . . . . 0.0 110.212 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.9 -38.15 67.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.225 -0.922 . . . . 0.0 110.139 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.2 mt -72.24 -39.18 68.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.935 . . . . 0.0 110.173 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.6 t -88.28 -4.77 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.307 -0.871 . . . . 0.0 110.195 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.26 -19.94 31.61 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -78.53 -29.78 46.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.226 -1.161 . . . . 0.0 110.244 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.445 ' O ' HG22 ' A' ' 27' ' ' THR . . . -81.54 -19.92 41.06 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.251 -0.906 . . . . 0.0 110.214 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.36 -15.8 60.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.284 -0.885 . . . . 0.0 110.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.5 t -83.7 -13.95 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 110.109 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.445 HG22 ' O ' ' A' ' 24' ' ' ALA . 10.1 t -113.57 -19.2 11.72 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 110.058 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.16 -22.25 36.17 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.276 -0.89 . . . . 0.0 110.217 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.99 13.17 11.55 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.307 -0.871 . . . . 0.0 110.228 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.1 t30 . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.231 179.977 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 110.199 -0.731 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.83 31.2 0.79 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.154 -0.966 . . . . 0.0 110.206 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.5 mm -80.52 -68.03 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 110.152 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -118.62 22.92 11.79 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.178 -0.951 . . . . 0.0 110.053 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.43 ' O ' HG21 ' A' ' 5' ' ' ILE . 9.8 mt -115.77 26.77 3.65 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.177 0 CA-C-O 121.809 0.814 . . . . 0.0 110.401 -179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -135.8 10.03 4.25 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -116.46 30.02 7.59 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.251 -1.146 . . . . 0.0 110.067 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.1 m -83.62 162.9 20.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 110.301 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.456 ' O ' ' C ' ' A' ' 10' ' ' GLY . 68.0 t 44.27 31.8 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.211 -0.931 . . . . 0.0 110.394 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 9' ' ' VAL . . . -39.68 106.12 0.05 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.41 -41.72 3.25 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 O-C-N 124.013 1.533 . . . . 0.0 110.461 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 t -68.72 -56.08 9.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 110.137 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.72 -29.11 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.339 -0.851 . . . . 0.0 110.138 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.461 ' O ' ' CG2' ' A' ' 18' ' ' VAL . 44.0 t-105 -64.12 -42.5 96.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.253 -0.904 . . . . 0.0 110.142 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.405 ' O ' ' HB2' ' A' ' 19' ' ' ALA . . . -66.82 -25.41 66.43 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.182 -0.949 . . . . 0.0 110.103 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -73.95 -42.52 60.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 110.193 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.407 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.15 -27.88 59.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.641 179.863 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.461 ' CG2' ' O ' ' A' ' 14' ' ' TRP . 68.9 t -76.64 -36.3 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.284 -0.885 . . . . 0.0 109.999 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.405 ' HB2' ' O ' ' A' ' 15' ' ' ALA . . . -73.69 -32.49 63.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 110.014 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.1 mt -70.09 -51.21 33.57 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.294 -0.878 . . . . 0.0 110.225 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 49.0 t -64.32 -47.1 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -0.915 . . . . 0.0 110.258 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.52 -45.35 67.23 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.52 -22.39 60.12 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.286 -1.126 . . . . 0.0 110.205 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.13 -14.68 53.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.301 -0.874 . . . . 0.0 110.254 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.05 -12.34 58.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.924 . . . . 0.0 110.307 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.9 t -89.29 -13.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -0.9 . . . . 0.0 110.157 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 99.6 m -77.29 -19.14 56.87 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.184 -0.947 . . . . 0.0 110.164 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.45 -23.92 32.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 110.236 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -89.19 159.0 17.68 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 110.18 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 22.2 t-20 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.3 179.986 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 N--CA 1.495 1.573 0 N-CA-C 110.194 -0.733 . . . . 0.0 110.194 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.46 46.05 0.43 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.195 -0.94 . . . . 0.0 110.107 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.471 HD12 HG21 ' A' ' 3' ' ' ILE . 34.7 mm -58.17 -87.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 110.193 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.436 ' N ' HG22 ' A' ' 3' ' ' ILE . 0.2 OUTLIER -104.26 23.04 13.72 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 122.144 0.973 . . . . 0.0 110.039 179.881 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.461 ' CG2' ' O ' ' A' ' 5' ' ' ILE . 29.8 mt -92.9 26.65 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 CA-C-O 121.926 0.87 . . . . 0.0 110.101 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -176.75 54.66 0.11 Allowed Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.531 ' O ' ' CG2' ' A' ' 8' ' ' THR . . . -126.78 33.23 4.99 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.255 -1.144 . . . . 0.0 110.184 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.531 ' CG2' ' O ' ' A' ' 7' ' ' ALA . 6.5 t 39.63 -155.31 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.591 -0.693 . . . . 0.0 110.349 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.475 ' CG2' HG22 ' A' ' 8' ' ' THR . 87.3 t 45.48 28.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.18 -0.95 . . . . 0.0 110.314 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -121.38 60.68 0.54 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.417 ' HD3' ' C ' ' A' ' 9' ' ' VAL . 45.9 Cg_endo -72.98 -47.7 0.31 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.944 1.497 . . . . 0.0 110.397 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 0.3 OUTLIER -67.05 -60.68 2.42 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -0.915 . . . . 0.0 110.191 -179.988 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.413 ' C ' ' O ' ' A' ' 12' ' ' SER . 54.3 t -43.21 -47.81 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 110.122 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.416 ' O ' HG21 ' A' ' 18' ' ' VAL . 21.4 t-105 -55.83 -56.2 23.45 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.927 . . . . 0.0 109.912 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -53.93 -23.92 14.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -0.938 . . . . 0.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -75.0 -38.61 61.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.2 -0.937 . . . . 0.0 110.351 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.445 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -73.89 -25.6 60.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.835 179.939 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.416 HG21 ' O ' ' A' ' 14' ' ' TRP . 5.9 t -86.24 -28.33 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.319 -0.863 . . . . 0.0 110.097 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.56 -35.93 60.52 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.261 -0.899 . . . . 0.0 110.054 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.9 mt -83.15 -40.07 20.23 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.283 -0.886 . . . . 0.0 110.177 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.438 HG22 ' O ' ' A' ' 17' ' ' LEU . 90.7 t -79.25 -17.6 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.224 -0.923 . . . . 0.0 110.196 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.53 -30.18 64.74 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.57 -26.6 68.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.152 . . . . 0.0 110.201 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -66.01 -40.3 90.99 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.204 -0.935 . . . . 0.0 110.203 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.4 -11.89 60.62 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 110.25 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.423 ' O ' ' HB2' ' A' ' 30' ' ' ASN . 38.1 t -84.95 -17.37 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.175 -0.953 . . . . 0.0 110.241 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.7 t -99.23 -8.54 24.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 110.097 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.53 -30.38 16.44 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.255 -0.903 . . . . 0.0 110.055 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -101.69 -7.28 22.78 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.274 -0.891 . . . . 0.0 110.018 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.423 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 35.3 t-20 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.26 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo . . . . . 0 N--CA 1.497 1.683 0 N-CA-C 110.209 -0.727 . . . . 0.0 110.209 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -160.81 36.95 0.15 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.201 -0.937 . . . . 0.0 110.398 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 1.8 mp -69.07 -56.48 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.121 -0.987 . . . . 0.0 110.06 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -141.44 23.3 2.15 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 122.159 0.981 . . . . 0.0 109.902 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.412 ' O ' ' CG2' ' A' ' 5' ' ' ILE . 42.3 mt -95.76 26.46 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-O 121.85 0.833 . . . . 0.0 110.201 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 136.52 -10.95 4.05 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 44.8 87.57 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -1.109 . . . . 0.0 110.337 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.42 -171.95 2.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.533 -0.729 . . . . 0.0 110.097 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 37.5 t -68.31 -13.73 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.245 -0.91 . . . . 0.0 110.192 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 45.96 62.13 3.55 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.93 -47.57 0.44 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.989 1.521 . . . . 0.0 110.295 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 m -61.47 -55.69 28.44 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.904 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 t -54.04 -37.57 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 109.87 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 46.4 t-105 -59.07 -52.18 66.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.215 -0.928 . . . . 0.0 109.922 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.2 -19.73 65.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.757 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -75.8 -40.25 55.4 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 110.095 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.45 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.7 -29.64 56.36 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.596 179.811 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.3 t -75.36 -29.65 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.393 -0.817 . . . . 0.0 109.87 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -77.05 -40.16 47.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.912 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.3 -36.4 81.44 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 110.042 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.405 HG23 HD11 ' A' ' 17' ' ' LEU . 84.8 t -77.51 -35.3 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.16 -0.963 . . . . 0.0 110.223 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.13 -12.32 68.49 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.43 -28.83 37.66 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -1.153 . . . . 0.0 110.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.99 -22.98 31.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.2 -0.938 . . . . 0.0 110.307 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.88 -0.91 17.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -0.889 . . . . 0.0 110.236 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 41.6 t -99.62 -2.34 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.267 -0.896 . . . . 0.0 110.113 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.18 -13.36 14.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.151 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.01 -22.49 36.49 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.251 -0.905 . . . . 0.0 110.33 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -96.56 -56.45 2.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.279 -0.888 . . . . 0.0 110.27 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.1 t-20 . . . . . 0 N--CA 1.489 1.508 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.27 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo . . . . . 0 N--CA 1.497 1.715 0 N-CA-C 110.276 -0.702 . . . . 0.0 110.276 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -162.45 39.71 0.12 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.296 -0.878 . . . . 0.0 110.244 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.9 mm -86.13 -66.45 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 110.438 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -111.02 25.79 11.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.195 -0.941 . . . . 0.0 110.303 -179.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.463 ' CG2' ' O ' ' A' ' 5' ' ' ILE . 42.1 mt -90.88 25.76 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 CA-C-O 121.826 0.822 . . . . 0.0 110.266 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.52 59.69 0.6 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -107.03 25.37 11.44 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.285 -1.127 . . . . 0.0 110.228 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.17 5.87 18.74 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.227 -0.921 . . . . 0.0 110.276 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.466 ' O ' ' HD3' ' A' ' 11' ' ' PRO . 65.0 t -127.48 -70.42 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.356 -0.84 . . . . 0.0 110.173 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 9' ' ' VAL . . . -42.93 102.74 0.03 OUTLIER Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 9' ' ' VAL . 45.8 Cg_endo -73.37 -42.69 0.85 Allowed 'Trans proline' 0 C--N 1.305 -1.728 0 O-C-N 123.992 1.522 . . . . 0.0 110.234 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.0 m -67.51 -55.62 12.79 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.22 -0.925 . . . . 0.0 110.186 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.7 t -53.99 -45.02 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.971 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.449 ' CE3' HD22 ' A' ' 17' ' ' LEU . 26.5 t-105 -58.33 -47.17 84.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.802 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.07 -23.73 21.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.323 -0.861 . . . . 0.0 109.979 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.531 ' CE1' HD13 ' A' ' 20' ' ' LEU . 0.2 OUTLIER -76.83 -51.17 11.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 110.006 179.916 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.453 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -59.53 -22.86 62.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.757 179.904 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.9 t -85.36 -44.12 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -0.905 . . . . 0.0 110.078 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.72 -24.73 67.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.333 -0.854 . . . . 0.0 110.084 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.531 HD13 ' CE1' ' A' ' 16' ' ' TYR . 0.9 OUTLIER -88.02 -39.29 14.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.23 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -72.12 -21.44 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.232 -0.918 . . . . 0.0 110.158 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.06 -18.32 69.89 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.61 -18.45 60.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -1.168 . . . . 0.0 110.22 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -88.75 -29.27 19.92 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.929 . . . . 0.0 110.31 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.61 -4.13 32.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.206 -0.934 . . . . 0.0 110.213 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 47.4 t -84.43 -20.17 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.249 -0.907 . . . . 0.0 110.22 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.8 -35.86 62.48 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 110.161 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.84 -31.86 20.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.214 -0.929 . . . . 0.0 110.165 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -103.56 134.91 46.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.216 -0.928 . . . . 0.0 110.178 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.216 179.995 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.482 0.796 0 N-CA-C 110.241 -0.715 . . . . 0.0 110.241 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.442 ' HA ' HG13 ' A' ' 5' ' ' ILE . . . -144.95 45.67 1.35 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.173 -0.954 . . . . 0.0 110.097 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.421 HG22 HD12 ' A' ' 3' ' ' ILE . 32.5 mm -96.82 -51.26 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.35 -0.844 . . . . 0.0 110.275 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -95.44 22.07 7.4 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 122.113 0.958 . . . . 0.0 110.107 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.513 ' CG2' ' O ' ' A' ' 5' ' ' ILE . 14.8 mm -94.27 26.37 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.077 0 CA-C-O 121.856 0.836 . . . . 0.0 110.061 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 96.15 -43.15 2.16 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 55.63 30.76 16.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.257 -1.143 . . . . 0.0 110.362 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -85.28 156.23 21.03 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.288 -0.882 . . . . 0.0 110.323 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 94.2 t -118.81 -22.68 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 110.163 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.523 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . 52.64 51.73 42.31 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.523 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 44.3 Cg_endo -72.65 -58.66 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.025 1.539 . . . . 0.0 110.63 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.415 ' O ' ' C ' ' A' ' 13' ' ' VAL . 5.4 t -55.71 -63.68 1.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -0.918 . . . . 0.0 110.195 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.415 ' C ' ' O ' ' A' ' 12' ' ' SER . 60.6 t -42.88 -51.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.344 -0.847 . . . . 0.0 110.245 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.46 ' O ' HG23 ' A' ' 18' ' ' VAL . 40.9 t-105 -48.43 -47.13 38.19 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.232 -0.918 . . . . 0.0 110.276 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.52 -34.77 74.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.262 -0.899 . . . . 0.0 110.424 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.8 t80 -67.14 -48.35 68.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.235 -0.915 . . . . 0.0 110.417 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.435 HD21 ' CE3' ' A' ' 14' ' ' TRP . 0.1 OUTLIER -64.96 -24.26 67.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.114 -0.991 . . . . 0.0 109.982 -179.901 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 14' ' ' TRP . 29.9 t -73.52 -62.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.337 -0.852 . . . . 0.0 110.248 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.55 -28.96 34.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.27 -0.894 . . . . 0.0 110.213 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.454 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 5.0 mt -67.87 -49.52 61.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 110.217 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.5 t -55.56 -48.48 77.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.216 -0.927 . . . . 0.0 110.204 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -62.73 -32.93 85.29 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.454 ' HB1' ' O ' ' A' ' 20' ' ' LEU . . . -62.04 -30.12 70.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.185 -1.185 . . . . 0.0 110.39 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.46 -34.89 18.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 110.265 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.92 -13.17 14.11 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.208 -0.932 . . . . 0.0 110.25 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 65.6 t -93.77 -23.59 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 110.26 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 m -72.41 -40.4 67.18 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.257 -0.902 . . . . 0.0 109.962 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.63 -47.15 33.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.399 -0.813 . . . . 0.0 110.082 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 30' ' ' ASN . . . -93.3 92.38 7.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.238 -0.914 . . . . 0.0 110.062 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.446 ' HB2' ' O ' ' A' ' 29' ' ' ALA . 13.7 m-80 . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.103 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.495 1.612 0 N-CA-C 110.188 -0.735 . . . . 0.0 110.188 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -175.09 56.25 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.314 -0.867 . . . . 0.0 110.142 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.4 mt -52.5 -52.9 22.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -0.917 . . . . 0.0 110.064 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.438 ' O ' ' N ' ' A' ' 6' ' ' GLY . 0.2 OUTLIER -111.74 23.28 14.04 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-O 122.111 0.958 . . . . 0.0 109.741 179.788 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.537 ' CG2' ' O ' ' A' ' 5' ' ' ILE . 38.9 mt 40.86 29.08 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.067 0 CA-C-O 121.967 0.889 . . . . 0.0 110.055 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 4' ' ' TYR . . . -177.3 43.06 0.1 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -152.28 28.4 0.58 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.38 -1.071 . . . . 0.0 110.183 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -82.06 6.42 16.31 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -0.86 . . . . 0.0 110.314 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.431 HG12 ' HD3' ' A' ' 11' ' ' PRO . 73.7 t -97.38 -67.62 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.337 -0.852 . . . . 0.0 109.978 179.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 71.52 65.49 2.4 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.431 ' HD3' HG12 ' A' ' 9' ' ' VAL . 45.8 Cg_endo -73.46 -40.24 1.65 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.963 1.507 . . . . 0.0 110.24 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.6 t -73.37 -59.19 2.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.434 -0.791 . . . . 0.0 110.302 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 53.1 t -53.36 -40.42 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.256 -0.903 . . . . 0.0 110.317 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.471 ' CE2' HG21 ' A' ' 18' ' ' VAL . 36.2 t-105 -58.65 -36.95 74.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.353 -0.842 . . . . 0.0 110.119 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.88 -32.41 69.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.931 . . . . 0.0 110.257 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.442 ' O ' HD12 ' A' ' 20' ' ' LEU . 0.3 OUTLIER -70.74 -41.02 72.38 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.136 -0.978 . . . . 0.0 110.064 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -72.43 -30.64 64.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.213 -0.93 . . . . 0.0 109.469 179.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.471 HG21 ' CE2' ' A' ' 14' ' ' TRP . 72.9 t -77.92 -27.78 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.435 -0.79 . . . . 0.0 109.891 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.72 -45.13 38.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 110.138 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.442 HD12 ' O ' ' A' ' 16' ' ' TYR . 0.3 OUTLIER -66.1 -52.12 51.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.866 . . . . 0.0 110.211 179.901 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.442 ' O ' ' HB3' ' A' ' 25' ' ' ALA . 45.5 t -69.21 -12.28 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 110.262 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.414 ' O ' HG21 ' A' ' 26' ' ' VAL . . . -75.18 -41.45 31.52 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.74 -33.57 68.61 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.25 -1.147 . . . . 0.0 110.149 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.22 -23.87 24.61 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.268 -0.895 . . . . 0.0 110.275 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.442 ' HB3' ' O ' ' A' ' 21' ' ' VAL . . . -77.5 -1.46 30.56 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.931 . . . . 0.0 110.192 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.459 HG11 ' O ' ' A' ' 26' ' ' VAL . 86.4 t -113.66 -6.83 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.231 -0.918 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.8 t -116.41 -23.23 8.41 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.131 -0.981 . . . . 0.0 110.193 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.57 6.23 15.58 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.284 -0.885 . . . . 0.0 110.126 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.92 112.01 13.08 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.344 -0.848 . . . . 0.0 110.233 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 14.6 p-10 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.231 179.987 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo . . . . . 0 N--CA 1.497 1.696 0 N-CA-C 110.272 -0.703 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 53.7 31.55 13.03 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.266 -0.896 . . . . 0.0 110.229 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.427 HG22 HD11 ' A' ' 3' ' ' ILE . 55.5 mt -95.7 -46.55 13.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.238 -0.914 . . . . 0.0 109.973 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -110.46 23.33 14.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.244 -0.91 . . . . 0.0 110.005 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.441 HD13 HG23 ' A' ' 5' ' ' ILE . 16.9 mt -101.57 27.01 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.16 0 CA-C-O 121.872 0.844 . . . . 0.0 110.15 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 103.7 -44.7 1.43 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 59.48 28.05 17.34 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -1.123 . . . . 0.0 110.38 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.4 t -84.65 -177.93 6.74 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.19 -0.944 . . . . 0.0 110.211 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 10.3 t -94.2 -37.43 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.25 -0.906 . . . . 0.0 109.94 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.86 87.08 1.68 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.1 -48.05 0.29 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.045 1.55 . . . . 0.0 110.373 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.51 -59.37 2.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.327 -0.858 . . . . 0.0 110.127 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.5 t -48.22 -29.49 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 110.161 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.0 t-105 -73.64 -59.47 2.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 110.158 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -57.76 -16.42 11.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.263 -0.898 . . . . 0.0 109.947 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.435 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.3 t80 -82.38 -42.3 18.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 110.104 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.477 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.2 -23.0 57.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.34 -0.85 . . . . 0.0 109.676 179.861 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -79.31 -56.69 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.48 -0.762 . . . . 0.0 109.941 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.76 -33.93 70.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.319 -0.863 . . . . 0.0 110.062 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 7.3 mt -67.86 -47.71 68.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.101 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 26.4 t -64.05 -16.28 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 110.175 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.29 -53.08 9.33 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -19.81 62.09 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -1.151 . . . . 0.0 110.209 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.62 -9.06 59.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.908 . . . . 0.0 110.134 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.29 3.85 26.01 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.36 -0.838 . . . . 0.0 110.122 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 20.8 t -101.58 -16.59 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 110.084 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.428 ' O ' ' OD1' ' A' ' 30' ' ' ASN . 15.1 t -90.29 -16.79 28.59 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.38 -28.78 67.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.259 -0.901 . . . . 0.0 110.218 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.447 ' O ' ' HB2' ' A' ' 30' ' ' ASN . . . -88.84 -23.39 22.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.261 -0.9 . . . . 0.0 110.198 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.447 ' HB2' ' O ' ' A' ' 29' ' ' ALA . 2.6 m120 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 117.903 -1.046 . . . . 0.0 110.289 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo . . . . . 0 N--CA 1.497 1.731 0 N-CA-C 110.328 -0.681 . . . . 0.0 110.328 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.526 ' HA ' ' CD1' ' A' ' 5' ' ' ILE . . . 179.26 39.55 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.262 -0.899 . . . . 0.0 110.344 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 23.3 mm -90.89 -26.9 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.252 -0.905 . . . . 0.0 110.235 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -121.0 23.55 10.6 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 122.125 0.964 . . . . 0.0 110.014 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.526 ' CD1' ' HA ' ' A' ' 2' ' ' ALA . 14.8 mt -96.48 26.5 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.114 0 CA-C-O 121.889 0.852 . . . . 0.0 109.999 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 130.02 -17.27 5.44 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 45.38 86.71 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.326 -1.102 . . . . 0.0 110.048 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.452 ' O ' HG22 ' A' ' 8' ' ' THR . 18.0 m -105.73 8.93 33.17 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.414 -0.804 . . . . 0.0 110.207 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 6.5 t -101.71 6.36 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.404 -0.81 . . . . 0.0 110.081 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.477 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . -162.59 53.83 0.3 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.477 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 46.1 Cg_endo -73.25 -47.5 0.3 Allowed 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 123.973 1.512 . . . . 0.0 110.337 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 4.4 m -62.45 -66.93 0.47 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 110.086 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.413 ' C ' ' O ' ' A' ' 12' ' ' SER . 21.8 t -44.03 -39.09 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 109.984 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.51 ' CZ3' HD22 ' A' ' 17' ' ' LEU . 30.6 t-105 -56.35 -52.22 65.37 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -56.83 -25.62 56.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.167 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 7.3 t80 -74.56 -34.22 62.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 110.198 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.51 HD22 ' CZ3' ' A' ' 14' ' ' TRP . 0.1 OUTLIER -73.03 -34.61 66.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.335 -0.853 . . . . 0.0 109.734 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.62 -35.26 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.408 -0.807 . . . . 0.0 110.082 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.04 -47.37 74.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.956 . . . . 0.0 110.119 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 17.1 mt -62.37 -54.82 34.8 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.277 -0.89 . . . . 0.0 110.085 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.446 HG13 ' O ' ' A' ' 21' ' ' VAL . 58.4 t -64.71 -15.11 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 110.154 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.31 -36.74 49.53 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.27 -29.67 61.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 110.153 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.57 -34.07 73.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 110.233 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.67 -17.76 61.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.244 -0.91 . . . . 0.0 110.035 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 39.8 t -83.34 -6.73 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.378 -0.826 . . . . 0.0 109.959 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m -98.42 -50.0 4.46 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 110.057 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -92.89 63.46 3.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.158 -0.964 . . . . 0.0 110.148 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.422 ' O ' ' O ' ' A' ' 30' ' ' ASN . . . -81.62 -73.19 0.39 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.311 -0.868 . . . . 0.0 110.245 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.422 ' O ' ' O ' ' A' ' 29' ' ' ALA . 12.0 m-80 . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.205 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo . . . . . 0 N--CA 1.494 1.546 0 N-CA-C 110.173 -0.741 . . . . 0.0 110.173 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -173.75 96.53 0.11 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.218 -0.926 . . . . 0.0 110.097 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.6 mm -94.83 -59.46 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.194 -0.941 . . . . 0.0 110.136 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -102.6 23.88 11.3 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.217 -0.927 . . . . 0.0 110.022 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.463 ' CG2' ' O ' ' A' ' 5' ' ' ILE . 22.8 mt -92.58 26.74 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.092 0 CA-C-O 121.851 0.834 . . . . 0.0 110.158 -179.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 96.76 -18.58 57.25 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 58.17 26.1 13.34 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.33 -1.1 . . . . 0.0 110.224 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.457 ' O ' ' CG2' ' A' ' 8' ' ' THR . 17.9 m -81.71 7.29 12.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.259 -0.9 . . . . 0.0 110.285 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.457 ' O ' ' HD3' ' A' ' 11' ' ' PRO . 8.7 p -125.04 -23.95 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.411 -0.805 . . . . 0.0 110.375 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 9' ' ' VAL . . . -42.91 102.35 0.03 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.457 ' HD3' ' O ' ' A' ' 9' ' ' VAL . 46.1 Cg_endo -72.99 -42.01 1.16 Allowed 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.974 1.512 . . . . 0.0 110.467 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.5 m -61.73 -61.75 2.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.905 . . . . 0.0 110.212 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.7 t -46.22 -39.13 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.28 -0.887 . . . . 0.0 110.256 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.488 ' CZ3' HD21 ' A' ' 17' ' ' LEU . 34.5 t-105 -63.09 -51.41 66.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.339 -0.851 . . . . 0.0 110.329 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.72 -26.99 67.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.122 -0.986 . . . . 0.0 110.254 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -69.91 -47.75 61.24 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.02 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.488 HD21 ' CZ3' ' A' ' 14' ' ' TRP . 0.1 OUTLIER -67.2 -30.22 70.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.204 -0.935 . . . . 0.0 109.742 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.402 ' O ' HG12 ' A' ' 18' ' ' VAL . 39.2 t -79.11 -27.07 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.447 -0.783 . . . . 0.0 110.107 179.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.98 -42.44 60.44 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.309 -0.87 . . . . 0.0 110.141 179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.2 mt -71.29 -48.03 53.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.174 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.0 t -71.77 -21.6 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 110.079 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -23.07 78.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.58 -29.67 41.31 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.16 -1.2 . . . . 0.0 110.15 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.32 -20.94 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 110.176 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.24 -17.02 64.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 110.15 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.41 ' O ' HG12 ' A' ' 26' ' ' VAL . 77.6 t -85.71 -19.24 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 110.097 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 67.1 m -104.61 -5.77 21.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.353 -0.842 . . . . 0.0 110.033 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.72 -28.23 19.54 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.292 -0.88 . . . . 0.0 110.228 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.4 ' O ' ' HB2' ' A' ' 30' ' ' ASN . . . -79.68 134.75 36.42 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.283 -0.886 . . . . 0.0 110.186 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.4 ' HB2' ' O ' ' A' ' 29' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.075 -0.965 . . . . 0.0 110.241 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo . . . . . 0 N--CA 1.495 1.608 0 N-CA-C 110.213 -0.726 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -179.0 74.91 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.28 -0.887 . . . . 0.0 110.271 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.407 HG21 ' N ' ' A' ' 4' ' ' TYR . 35.8 mt -48.55 -91.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.225 -0.922 . . . . 0.0 110.01 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.407 ' N ' HG21 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -106.09 23.68 13.65 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.138 0.97 . . . . 0.0 109.843 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.504 HD11 HG22 ' A' ' 5' ' ' ILE . 21.9 mt -92.01 26.17 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 CA-C-O 121.882 0.849 . . . . 0.0 110.107 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -132.29 49.2 0.93 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -118.49 24.97 10.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.353 -1.087 . . . . 0.0 110.084 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 37.0 m -98.01 174.02 6.76 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.253 -0.904 . . . . 0.0 110.211 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 91.7 t -118.63 -70.73 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.169 -0.957 . . . . 0.0 110.202 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.465 ' O ' ' HB2' ' A' ' 14' ' ' TRP . . . 162.77 95.02 0.1 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.57 -47.56 0.14 Allowed 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.002 1.527 . . . . 0.0 110.457 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 p -70.39 -63.22 1.13 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.296 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 91.2 t -47.8 -32.36 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 110.166 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.465 ' HB2' ' O ' ' A' ' 10' ' ' GLY . 63.6 t-105 -70.13 -41.8 73.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.928 . . . . 0.0 109.96 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.9 -23.35 65.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.471 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.7 t80 -77.53 -47.14 20.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.33 -0.856 . . . . 0.0 110.043 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.44 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -68.69 -21.5 64.42 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.292 -0.88 . . . . 0.0 109.709 179.885 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -82.6 -53.62 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -0.844 . . . . 0.0 110.207 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.47 -35.56 76.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.315 -0.866 . . . . 0.0 110.078 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 0.2 OUTLIER -72.1 -46.6 56.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.938 . . . . 0.0 110.171 179.935 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.416 HG22 ' CD1' ' A' ' 17' ' ' LEU . 37.2 t -66.95 -21.3 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.961 . . . . 0.0 109.902 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.16 -29.32 60.62 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.1 -22.98 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -1.078 . . . . 0.0 110.08 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.86 -35.98 75.15 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 110.207 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.51 -5.2 43.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 110.095 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.8 t -99.39 -13.54 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.207 -0.933 . . . . 0.0 110.223 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.486 HG22 ' N ' ' A' ' 28' ' ' ALA . 7.1 t -110.18 -25.74 10.01 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.205 -0.934 . . . . 0.0 110.239 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.486 ' N ' HG22 ' A' ' 27' ' ' THR . . . -92.64 44.08 1.15 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.251 -0.906 . . . . 0.0 110.091 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -90.34 2.27 55.72 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.301 -0.875 . . . . 0.0 110.254 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.9 m120 . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.142 179.944 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo . . . . . 0 N--CA 1.496 1.666 0 N-CA-C 110.189 -0.735 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -149.58 41.55 0.87 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.231 -0.918 . . . . 0.0 110.21 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 58.9 mt -72.82 -64.64 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.214 -0.929 . . . . 0.0 110.132 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -116.77 22.99 12.28 Favored 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 122.152 0.977 . . . . 0.0 110.037 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.502 ' CG2' ' O ' ' A' ' 5' ' ' ILE . 12.4 mm -96.8 26.51 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 CA-C-O 121.766 0.793 . . . . 0.0 110.167 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.46 -14.02 1.61 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -101.31 30.57 4.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.306 -1.114 . . . . 0.0 110.193 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.8 t -52.59 -177.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.311 -0.868 . . . . 0.0 110.377 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 85.7 t -95.24 -81.32 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.377 -0.827 . . . . 0.0 110.214 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -160.82 70.47 0.23 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.6 -54.57 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.047 1.551 . . . . 0.0 110.4 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -64.16 -51.26 64.68 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 110.146 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 38.5 t -57.48 -39.13 67.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.299 -0.876 . . . . 0.0 110.186 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 48.5 t-105 -64.88 -39.97 94.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.165 -0.959 . . . . 0.0 110.146 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.63 -25.66 64.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.181 -0.949 . . . . 0.0 110.196 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -75.79 -42.77 49.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 0.0 110.045 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -69.41 -29.85 67.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.321 -0.862 . . . . 0.0 109.827 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 32.3 t -77.26 -44.87 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.336 -0.852 . . . . 0.0 110.12 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -61.19 -36.76 80.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 110.1 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.4 mt -67.75 -48.22 67.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 110.044 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 64.0 t -77.43 -1.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.263 -0.898 . . . . 0.0 110.034 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.46 -21.51 31.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.17 -37.94 66.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.22 -1.165 . . . . 0.0 110.068 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 -7.05 58.4 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -78.3 -17.27 56.83 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.419 -0.8 . . . . 0.0 110.183 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.6 t -87.49 -16.29 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.371 -0.83 . . . . 0.0 110.031 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.88 -11.24 42.46 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.311 -0.868 . . . . 0.0 110.102 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.03 -31.33 18.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.256 -0.903 . . . . 0.0 110.152 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -108.67 177.03 4.9 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.265 -0.897 . . . . 0.0 110.157 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.207 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo . . . . . 0 N--CA 1.496 1.635 0 N-CA-C 110.333 -0.679 . . . . 0.0 110.333 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 174.89 40.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 110.279 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 46.7 mt -93.55 -73.3 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.182 -0.949 . . . . 0.0 110.147 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -116.78 22.76 12.44 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.104 -0.997 . . . . 0.0 109.987 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.488 ' CG2' ' O ' ' A' ' 5' ' ' ILE . 16.8 mm -94.98 26.9 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.108 0 CA-C-O 121.783 0.801 . . . . 0.0 110.107 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.472 ' O ' ' CB ' ' A' ' 7' ' ' ALA . . . 123.25 -19.68 7.63 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.472 ' CB ' ' O ' ' A' ' 6' ' ' GLY . . . 67.73 33.09 5.06 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.188 -1.184 . . . . 0.0 110.119 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.49 174.92 10.98 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.88 . . . . 0.0 110.378 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 69.2 t -99.57 -22.46 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.346 -0.846 . . . . 0.0 110.166 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 107.17 67.59 0.65 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.03 -52.47 0.23 Allowed 'Trans proline' 0 C--N 1.307 -1.605 0 O-C-N 124.019 1.536 . . . . 0.0 110.394 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 p -65.71 -56.97 9.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.936 . . . . 0.0 110.132 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 67.0 t -49.32 -46.71 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.27 -0.894 . . . . 0.0 110.021 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.533 ' CE3' HD21 ' A' ' 17' ' ' LEU . 48.7 t-105 -56.02 -52.55 63.83 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 109.991 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.47 -22.65 55.5 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 109.878 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -70.75 -46.91 62.11 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.368 -0.833 . . . . 0.0 110.021 179.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.533 HD21 ' CE3' ' A' ' 14' ' ' TRP . 0.1 OUTLIER -65.43 -29.47 70.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.893 179.944 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.9 t -74.11 -63.41 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.89 . . . . 0.0 110.149 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.51 -23.27 9.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 110.36 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 10.5 mt -75.51 -46.06 34.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.144 -0.972 . . . . 0.0 110.187 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 92.9 t -67.8 -11.26 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.311 -0.868 . . . . 0.0 110.138 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.38 -26.52 27.76 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.88 -22.03 61.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 110.232 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.53 -24.54 17.22 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 110.136 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -76.37 -10.8 59.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.218 -0.926 . . . . 0.0 110.277 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 54.2 t -97.99 -1.85 10.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.256 -0.902 . . . . 0.0 110.319 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 25.2 m -106.87 -31.06 8.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.093 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.96 40.23 1.04 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.29 -0.881 . . . . 0.0 110.173 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.83 95.14 8.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.329 -0.857 . . . . 0.0 110.145 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.202 179.983 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 N--CA 1.496 1.64 0 N-CA-C 110.129 -0.758 . . . . 0.0 110.129 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -135.88 69.49 1.43 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.196 -0.94 . . . . 0.0 110.299 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.433 HG21 ' N ' ' A' ' 4' ' ' TYR . 82.0 mt -58.24 -93.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.229 -0.92 . . . . 0.0 110.014 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.433 ' N ' HG21 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -108.46 23.92 13.8 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.15 0.976 . . . . 0.0 109.768 179.763 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.491 ' CG2' ' O ' ' A' ' 5' ' ' ILE . 18.4 mm -91.73 26.12 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 CA-C-O 121.805 0.812 . . . . 0.0 110.115 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -122.24 -12.03 5.42 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.403 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -92.8 26.5 2.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.266 -1.137 . . . . 0.0 110.229 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 7' ' ' ALA . 1.0 OUTLIER -45.22 150.47 0.42 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 109.985 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.2 t -83.04 -66.8 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.122 -0.986 . . . . 0.0 110.246 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -158.13 93.42 0.13 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 44.9 Cg_endo -72.97 -54.58 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.951 1.501 . . . . 0.0 110.22 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -58.53 -58.86 6.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.268 -0.895 . . . . 0.0 110.01 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 t -47.88 -41.39 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.874 . . . . 0.0 110.108 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.44 ' O ' HG23 ' A' ' 18' ' ' VAL . 32.9 t-105 -57.08 -53.34 59.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.252 -0.905 . . . . 0.0 110.03 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.87 -22.55 65.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 110.293 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.41 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.4 t80 -75.27 -36.2 61.26 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.285 -0.885 . . . . 0.0 110.197 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.452 ' O ' ' CD1' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -81.55 -28.53 33.85 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.165 -0.959 . . . . 0.0 109.805 179.964 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 14' ' ' TRP . 38.1 t -74.68 -32.48 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.37 -0.831 . . . . 0.0 109.979 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.1 -32.22 26.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.985 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 1.4 mt -68.4 -39.81 81.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.852 . . . . 0.0 110.159 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.5 t -64.58 -49.25 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -48.2 -40.54 21.84 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.72 -45.99 58.83 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -1.135 . . . . 0.0 110.176 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -66.0 -40.72 91.38 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.235 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.97 -8.01 40.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.169 -0.957 . . . . 0.0 110.205 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 99.4 t -96.6 0.28 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.299 -0.876 . . . . 0.0 110.248 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 m -105.18 -26.07 12.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.217 -0.927 . . . . 0.0 110.258 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.97 -28.6 65.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.31 -0.869 . . . . 0.0 110.237 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 177.74 8.0 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.191 -0.943 . . . . 0.0 110.151 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.251 -179.988 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo . . . . . 0 N--CA 1.496 1.668 0 N-CA-C 110.15 -0.75 . . . . 0.0 110.15 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.3 42.69 0.28 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.169 -0.957 . . . . 0.0 110.128 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 21.2 mm -92.17 -64.41 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -0.9 . . . . 0.0 110.39 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -130.54 23.46 5.09 Favored 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 122.049 0.928 . . . . 0.0 110.267 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.463 ' O ' HG21 ' A' ' 5' ' ' ILE . 9.9 mt -110.76 26.17 2.99 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-O 121.896 0.855 . . . . 0.0 110.162 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 165.72 36.9 0.02 OUTLIER Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -161.6 23.19 0.12 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -1.142 . . . . 0.0 109.983 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 t -140.15 -176.06 4.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.341 -0.849 . . . . 0.0 110.293 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.5 t -65.51 -25.61 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.226 -0.921 . . . . 0.0 110.171 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.82 65.63 1.34 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -73.67 -42.43 0.85 Allowed 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 124.098 1.578 . . . . 0.0 110.388 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -69.42 -59.29 3.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.323 -0.861 . . . . 0.0 110.168 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.1 t -53.26 -30.12 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.85 . . . . 0.0 110.076 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 36.0 t-105 -64.8 -38.35 90.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 110.035 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.42 -29.06 65.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 110.111 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -73.12 -34.62 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.442 ' CD1' HG22 ' A' ' 21' ' ' VAL . 0.1 OUTLIER -77.24 -30.89 54.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.249 -0.907 . . . . 0.0 109.728 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -42.06 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.345 -0.847 . . . . 0.0 109.967 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.43 -49.67 68.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.28 -0.887 . . . . 0.0 109.854 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.1 mt -60.05 -54.93 40.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.907 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.442 HG22 ' CD1' ' A' ' 17' ' ' LEU . 53.6 t -63.6 -19.11 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.391 -0.818 . . . . 0.0 110.047 179.838 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.64 -30.48 36.0 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -75.73 -33.23 60.27 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.358 -1.084 . . . . 0.0 110.199 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.424 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -84.93 -13.11 51.8 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.191 -0.943 . . . . 0.0 110.254 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.15 -3.87 32.32 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 110.141 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 41.3 t -107.45 -7.7 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 110.243 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.433 HG21 ' N ' ' A' ' 28' ' ' ALA . 11.0 t -113.47 -20.86 11.13 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.288 -0.882 . . . . 0.0 110.144 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.433 ' N ' HG21 ' A' ' 27' ' ' THR . . . -85.11 -11.94 54.04 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.226 -0.921 . . . . 0.0 110.205 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.44 ' O ' ' OXT' ' A' ' 30' ' ' ASN . . . -100.54 -25.9 14.02 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.182 -0.949 . . . . 0.0 110.287 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.44 ' OXT' ' O ' ' A' ' 29' ' ' ALA . 8.4 m-80 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.304 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo . . . . . 0 N--CA 1.496 1.648 0 N-CA-C 110.167 -0.743 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.464 ' HA ' HG13 ' A' ' 5' ' ' ILE . . . -136.92 44.47 2.32 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.262 -0.899 . . . . 0.0 110.08 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.3 mt -67.45 -39.24 82.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.248 -0.908 . . . . 0.0 110.314 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -111.96 22.12 15.21 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 122.013 0.911 . . . . 0.0 110.115 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.464 HG13 ' HA ' ' A' ' 2' ' ' ALA . 14.6 mm -104.28 27.11 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 CA-C-O 121.788 0.804 . . . . 0.0 110.347 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -124.41 22.52 6.59 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -131.7 29.44 4.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -1.165 . . . . 0.0 110.02 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.408 ' C ' HG23 ' A' ' 9' ' ' VAL . 3.7 m -98.83 170.17 8.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.347 -0.845 . . . . 0.0 110.419 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.481 ' HA ' ' CG1' ' A' ' 13' ' ' VAL . 43.6 t -138.3 27.11 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.356 -0.84 . . . . 0.0 109.944 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.9 -143.67 0.03 OUTLIER Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.5 -52.42 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.095 1.577 . . . . 0.0 110.426 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -48.52 -43.34 35.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.265 -0.897 . . . . 0.0 110.272 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.481 ' CG1' ' HA ' ' A' ' 9' ' ' VAL . 75.8 t -63.17 -37.53 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.225 -0.922 . . . . 0.0 110.174 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 28.3 t-105 -65.13 -42.52 93.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.4 -0.813 . . . . 0.0 110.092 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.74 -27.11 66.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.267 -0.896 . . . . 0.0 110.228 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.45 ' CE2' HD13 ' A' ' 20' ' ' LEU . 2.0 t80 -76.14 -30.55 58.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.942 . . . . 0.0 110.168 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.441 ' O ' HG21 ' A' ' 21' ' ' VAL . 0.1 OUTLIER -80.98 -29.47 35.28 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.952 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.1 t -79.03 -38.5 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.369 -0.832 . . . . 0.0 109.899 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.59 -49.72 44.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 109.985 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.45 HD13 ' CE2' ' A' ' 16' ' ' TYR . 13.7 mt -59.31 -50.72 72.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 110.224 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.441 HG21 ' O ' ' A' ' 17' ' ' LEU . 40.3 t -73.4 -17.51 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.286 -0.884 . . . . 0.0 110.174 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -77.37 -25.82 62.74 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -76.42 -39.91 52.23 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -1.12 . . . . 0.0 110.154 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -78.93 -28.97 43.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.353 -0.842 . . . . 0.0 110.168 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -69.73 -13.45 62.29 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.323 -0.861 . . . . 0.0 110.177 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 71.2 t -77.68 -15.68 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.255 -0.903 . . . . 0.0 110.161 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 86.2 m -108.25 -46.79 3.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 0.0 110.182 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.01 69.9 10.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 110.233 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -105.61 18.65 21.86 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.197 -0.94 . . . . 0.0 110.254 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 118.063 -0.97 . . . . 0.0 110.228 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo . . . . . 0 N--CA 1.498 1.761 0 N-CA-C 110.175 -0.74 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.93 45.61 2.13 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.281 -0.887 . . . . 0.0 110.157 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.491 HG22 HD11 ' A' ' 3' ' ' ILE . 46.3 mm -89.58 -80.15 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.149 -0.969 . . . . 0.0 110.11 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -131.98 24.94 4.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.133 -0.979 . . . . 0.0 110.041 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.475 HG22 HD12 ' A' ' 5' ' ' ILE . 25.4 mm -91.83 26.87 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.107 0 CA-C-O 121.85 0.833 . . . . 0.0 110.376 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -137.63 13.0 3.7 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.507 ' O ' ' CG2' ' A' ' 8' ' ' THR . . . -149.09 27.79 0.84 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.199 -1.177 . . . . 0.0 110.386 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.507 ' CG2' ' O ' ' A' ' 7' ' ' ALA . 6.6 t 39.0 -160.93 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.566 -0.709 . . . . 0.0 110.528 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.5 t -127.54 -32.4 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.179 -0.951 . . . . 0.0 110.267 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.93 82.11 1.35 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.12 -60.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.001 1.527 . . . . 0.0 110.653 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -58.8 -47.2 85.59 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 110.327 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.76 -40.24 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 110.222 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.556 ' CE2' HG23 ' A' ' 18' ' ' VAL . 36.8 t-105 -64.75 -42.42 95.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 110.158 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.48 -29.64 70.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 110.24 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -74.72 -56.74 4.48 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.264 -0.898 . . . . 0.0 110.104 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.45 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -58.42 -22.3 53.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.198 -0.939 . . . . 0.0 109.954 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.556 HG23 ' CE2' ' A' ' 14' ' ' TRP . 55.9 t -83.22 -42.77 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.287 -0.883 . . . . 0.0 110.27 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.95 -23.57 67.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.338 -0.851 . . . . 0.0 110.262 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.88 -61.28 1.75 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.263 -0.898 . . . . 0.0 110.258 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.4 t -54.01 -30.07 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -0.967 . . . . 0.0 110.181 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.11 -44.34 67.29 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.09 -28.09 69.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -1.125 . . . . 0.0 110.194 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.82 -19.22 31.0 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.267 -0.896 . . . . 0.0 110.19 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.99 -9.53 59.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.221 -0.924 . . . . 0.0 110.149 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -105.83 -6.63 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.93 . . . . 0.0 110.253 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.6 t -116.52 -18.15 10.45 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.269 -0.895 . . . . 0.0 110.194 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.73 -20.64 62.62 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.228 -0.92 . . . . 0.0 110.195 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -80.74 -7.91 59.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.136 -0.978 . . . . 0.0 110.134 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 27.0 m120 . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.276 -179.98 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.425 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 46.2 Cg_endo -73.38 -44.74 0.5 Allowed 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 124.021 1.537 . . . . 0.0 110.419 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 13' ' ' VAL . 1.9 p -64.8 -71.24 0.19 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.236 -0.915 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.417 ' C ' ' O ' ' A' ' 12' ' ' SER . 65.2 t -42.64 -30.96 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.325 -0.859 . . . . 0.0 110.142 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.425 ' HB3' ' O ' ' A' ' 11' ' ' PRO . 46.4 t-105 -64.78 -56.7 11.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.181 -0.95 . . . . 0.0 110.106 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.34 -28.55 43.52 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.211 -0.93 . . . . 0.0 109.904 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -69.45 -47.33 64.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.922 . . . . 0.0 109.842 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.753 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -65.73 -21.68 66.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.688 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -78.23 -51.47 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 109.952 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.69 -39.98 82.27 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.311 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -66.76 -52.91 38.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.27 -0.894 . . . . 0.0 110.28 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 17' ' ' LEU . 81.9 t -60.91 -21.47 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 110.34 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.665 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -72.34 -53.59 8.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -53.75 -40.25 66.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.197 -1.178 . . . . 0.0 110.241 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.69 -33.47 72.58 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.34 -17.24 60.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.313 -0.867 . . . . 0.0 110.167 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.665 HG23 ' O ' ' A' ' 22' ' ' GLY . 23.8 t -98.48 -14.4 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.305 -0.872 . . . . 0.0 110.179 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 110.125 179.925 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.83 -59.3 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.93 1.489 . . . . 0.0 110.608 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 88.3 p -62.98 -49.28 75.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 110.251 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.2 t -51.97 -42.23 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.192 -0.943 . . . . 0.0 110.095 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.508 ' O ' HG23 ' A' ' 18' ' ' VAL . 27.5 t-105 -66.7 -32.55 73.93 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 110.122 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.64 -33.61 71.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.284 -0.885 . . . . 0.0 110.234 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -76.4 -30.11 57.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.259 -0.901 . . . . 0.0 110.307 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.709 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.24 -29.82 57.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.162 -0.961 . . . . 0.0 109.67 179.917 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 14' ' ' TRP . 69.0 t -79.57 -45.97 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.454 -0.778 . . . . 0.0 110.081 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.17 -48.58 81.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.327 -0.858 . . . . 0.0 110.126 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.448 ' HA ' HD23 ' A' ' 20' ' ' LEU . 43.0 mt -62.08 -49.37 76.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.258 -0.901 . . . . 0.0 110.262 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 21' ' ' VAL . 53.0 t -73.29 -8.24 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 110.391 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.51 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -86.72 -33.24 13.33 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.64 -37.3 70.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -1.208 . . . . 0.0 110.427 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.46 -16.86 47.32 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.224 -0.923 . . . . 0.0 110.462 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.66 4.43 24.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.229 -0.92 . . . . 0.0 110.406 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 22' ' ' GLY . 96.1 t -100.26 -15.92 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.12 -0.987 . . . . 0.0 110.253 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 110.293 179.983 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -75.82 -52.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 124.017 1.535 . . . . 0.0 110.435 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -61.92 -58.07 9.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.328 -0.857 . . . . 0.0 110.32 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 77.2 t -46.48 -34.37 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.905 . . . . 0.0 110.35 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.629 ' O ' HG23 ' A' ' 18' ' ' VAL . 23.2 t-105 -68.5 -58.4 4.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.19 -0.944 . . . . 0.0 110.229 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.67 -23.44 28.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.904 . . . . 0.0 110.376 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.33 -41.57 33.19 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 0.0 110.311 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.901 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -70.61 -25.87 63.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.915 . . . . 0.0 109.693 179.903 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 14' ' ' TRP . 21.4 t -83.35 -37.05 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 110.088 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.04 -22.66 60.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.992 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 mt -87.9 -53.48 4.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.385 -0.822 . . . . 0.0 110.279 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.1 t -62.07 -16.77 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.309 -0.87 . . . . 0.0 110.362 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.52 -29.78 63.24 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.31 -20.53 63.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.255 -1.144 . . . . 0.0 110.249 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.602 ' O ' HG22 ' A' ' 27' ' ' THR . . . -87.33 -17.94 31.25 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.887 . . . . 0.0 110.171 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.3 -1.05 21.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.216 -0.927 . . . . 0.0 110.194 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.63 -11.54 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.297 -0.877 . . . . 0.0 110.172 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.602 HG22 ' O ' ' A' ' 24' ' ' ALA . 8.9 t . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.327 -0.858 . . . . 0.0 110.327 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.479 ' O ' ' HB3' ' A' ' 14' ' ' TRP . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.349 -1.501 . . . . 0.0 109.349 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.41 -52.76 0.14 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 124.023 1.538 . . . . 0.0 110.571 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.52 -48.6 60.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.231 -0.918 . . . . 0.0 110.515 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.561 ' CG1' ' N ' ' A' ' 14' ' ' TRP . 2.9 p -59.64 -45.41 94.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.159 -0.963 . . . . 0.0 110.38 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.704 ' O ' HG23 ' A' ' 18' ' ' VAL . 49.3 t-105 -63.17 -36.88 85.09 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.116 -0.99 . . . . 0.0 110.013 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.48 -23.48 63.64 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.332 -0.855 . . . . 0.0 110.089 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.558 ' HD1' HD12 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -78.13 -36.57 47.66 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.228 -0.92 . . . . 0.0 110.185 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.965 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.06 -26.1 56.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.209 -0.932 . . . . 0.0 109.583 179.802 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.704 HG23 ' O ' ' A' ' 14' ' ' TRP . 61.0 t -81.52 -39.1 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.452 -0.78 . . . . 0.0 110.212 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.9 -38.15 67.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.225 -0.922 . . . . 0.0 110.139 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.558 HD12 ' HD1' ' A' ' 16' ' ' TYR . 1.2 mt -72.24 -39.18 68.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.935 . . . . 0.0 110.173 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.6 t -88.28 -4.77 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.307 -0.871 . . . . 0.0 110.195 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.26 -19.94 31.61 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -78.53 -29.78 46.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.226 -1.161 . . . . 0.0 110.244 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.45 ' O ' HG22 ' A' ' 27' ' ' THR . . . -81.54 -19.92 41.06 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.251 -0.906 . . . . 0.0 110.214 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.36 -15.8 60.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.284 -0.885 . . . . 0.0 110.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.5 t -83.7 -13.95 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 110.109 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.45 HG22 ' O ' ' A' ' 24' ' ' ALA . 10.1 t . . . . . 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 110.058 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.424 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.41 -41.72 3.25 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 O-C-N 124.013 1.533 . . . . 0.0 110.461 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 t -68.72 -56.08 9.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 110.137 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.72 -29.11 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.339 -0.851 . . . . 0.0 110.138 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.808 ' O ' HG23 ' A' ' 18' ' ' VAL . 44.0 t-105 -64.12 -42.5 96.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.253 -0.904 . . . . 0.0 110.142 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.82 -25.41 66.43 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.182 -0.949 . . . . 0.0 110.103 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -73.95 -42.52 60.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 110.193 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.859 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.15 -27.88 59.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.641 179.863 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.808 HG23 ' O ' ' A' ' 14' ' ' TRP . 68.9 t -76.64 -36.3 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.284 -0.885 . . . . 0.0 109.999 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.69 -32.49 63.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 110.014 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.1 mt -70.09 -51.21 33.57 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.294 -0.878 . . . . 0.0 110.225 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 49.0 t -64.32 -47.1 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -0.915 . . . . 0.0 110.258 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.52 -45.35 67.23 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.52 -22.39 60.12 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.286 -1.126 . . . . 0.0 110.205 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.13 -14.68 53.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.301 -0.874 . . . . 0.0 110.254 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.05 -12.34 58.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.924 . . . . 0.0 110.307 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.9 t -89.29 -13.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -0.9 . . . . 0.0 110.157 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 99.6 m . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.184 -0.947 . . . . 0.0 110.164 179.851 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.98 -47.7 0.31 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.944 1.497 . . . . 0.0 110.397 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 0.3 OUTLIER -67.05 -60.68 2.42 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -0.915 . . . . 0.0 110.191 -179.988 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.413 ' C ' ' O ' ' A' ' 12' ' ' SER . 54.3 t -43.21 -47.81 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 110.122 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.604 ' O ' HG23 ' A' ' 18' ' ' VAL . 21.4 t-105 -55.83 -56.2 23.45 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.927 . . . . 0.0 109.912 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -53.93 -23.92 14.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -0.938 . . . . 0.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -75.0 -38.61 61.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.2 -0.937 . . . . 0.0 110.351 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.883 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -73.89 -25.6 60.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.835 179.939 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.604 HG23 ' O ' ' A' ' 14' ' ' TRP . 5.9 t -86.24 -28.33 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.319 -0.863 . . . . 0.0 110.097 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.56 -35.93 60.52 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.261 -0.899 . . . . 0.0 110.054 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.9 mt -83.15 -40.07 20.23 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.283 -0.886 . . . . 0.0 110.177 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 90.7 t -79.25 -17.6 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.224 -0.923 . . . . 0.0 110.196 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.53 -30.18 64.74 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.57 -26.6 68.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.152 . . . . 0.0 110.201 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.734 ' O ' HG22 ' A' ' 27' ' ' THR . . . -66.01 -40.3 90.99 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.204 -0.935 . . . . 0.0 110.203 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.4 -11.89 60.62 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 110.25 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.1 t -84.95 -17.37 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.175 -0.953 . . . . 0.0 110.241 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.734 HG22 ' O ' ' A' ' 24' ' ' ALA . 11.7 t . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 110.097 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.2 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.93 -47.57 0.44 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.989 1.521 . . . . 0.0 110.295 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 m -61.47 -55.69 28.44 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.904 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 t -54.04 -37.57 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 109.87 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.441 ' O ' HG23 ' A' ' 18' ' ' VAL . 46.4 t-105 -59.07 -52.18 66.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.215 -0.928 . . . . 0.0 109.922 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.2 -19.73 65.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.757 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -75.8 -40.25 55.4 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 110.095 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.919 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.7 -29.64 56.36 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.596 179.811 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 14' ' ' TRP . 95.3 t -75.36 -29.65 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.393 -0.817 . . . . 0.0 109.87 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -77.05 -40.16 47.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.912 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.3 -36.4 81.44 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 110.042 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 17' ' ' LEU . 84.8 t -77.51 -35.3 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.16 -0.963 . . . . 0.0 110.223 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.13 -12.32 68.49 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.43 -28.83 37.66 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -1.153 . . . . 0.0 110.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.99 -22.98 31.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.2 -0.938 . . . . 0.0 110.307 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.88 -0.91 17.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -0.889 . . . . 0.0 110.236 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.481 ' O ' HG12 ' A' ' 26' ' ' VAL . 41.6 t -99.62 -2.34 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.267 -0.896 . . . . 0.0 110.113 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.151 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.37 -42.69 0.85 Allowed 'Trans proline' 0 C--N 1.305 -1.728 0 O-C-N 123.992 1.522 . . . . 0.0 110.234 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.0 m -67.51 -55.62 12.79 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.22 -0.925 . . . . 0.0 110.186 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.446 HG23 ' H ' ' A' ' 13' ' ' VAL . 17.7 t -53.99 -45.02 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.971 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.636 ' O ' HG23 ' A' ' 18' ' ' VAL . 26.5 t-105 -58.33 -47.17 84.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.802 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.07 -23.73 21.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.323 -0.861 . . . . 0.0 109.979 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.475 ' CD1' HD12 ' A' ' 20' ' ' LEU . 0.2 OUTLIER -76.83 -51.17 11.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 110.006 179.916 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.735 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -59.53 -22.86 62.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.757 179.904 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.636 HG23 ' O ' ' A' ' 14' ' ' TRP . 33.9 t -85.36 -44.12 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -0.905 . . . . 0.0 110.078 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.72 -24.73 67.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.333 -0.854 . . . . 0.0 110.084 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.475 HD12 ' CD1' ' A' ' 16' ' ' TYR . 0.9 OUTLIER -88.02 -39.29 14.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.23 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -72.12 -21.44 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.232 -0.918 . . . . 0.0 110.158 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.5 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -81.06 -18.32 69.89 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.61 -18.45 60.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -1.168 . . . . 0.0 110.22 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -88.75 -29.27 19.92 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.929 . . . . 0.0 110.31 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.61 -4.13 32.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.206 -0.934 . . . . 0.0 110.213 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 22' ' ' GLY . 47.4 t -84.43 -20.17 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.249 -0.907 . . . . 0.0 110.22 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 110.161 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.523 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.523 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 44.3 Cg_endo -72.65 -58.66 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.025 1.539 . . . . 0.0 110.63 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.415 ' O ' ' C ' ' A' ' 13' ' ' VAL . 5.4 t -55.71 -63.68 1.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -0.918 . . . . 0.0 110.195 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.415 ' C ' ' O ' ' A' ' 12' ' ' SER . 60.6 t -42.88 -51.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.344 -0.847 . . . . 0.0 110.245 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.47 ' O ' HG23 ' A' ' 18' ' ' VAL . 40.9 t-105 -48.43 -47.13 38.19 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.232 -0.918 . . . . 0.0 110.276 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.52 -34.77 74.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.262 -0.899 . . . . 0.0 110.424 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.8 t80 -67.14 -48.35 68.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.235 -0.915 . . . . 0.0 110.417 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.755 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -64.96 -24.26 67.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.114 -0.991 . . . . 0.0 109.982 -179.901 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 14' ' ' TRP . 29.9 t -73.52 -62.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.337 -0.852 . . . . 0.0 110.248 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.55 -28.96 34.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.27 -0.894 . . . . 0.0 110.213 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.0 mt -67.87 -49.52 61.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 110.217 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.5 t -55.56 -48.48 77.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.216 -0.927 . . . . 0.0 110.204 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.486 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -62.73 -32.93 85.29 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.04 -30.12 70.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.185 -1.185 . . . . 0.0 110.39 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.46 -34.89 18.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 110.265 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.92 -13.17 14.11 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.208 -0.932 . . . . 0.0 110.25 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 22' ' ' GLY . 65.6 t -93.77 -23.59 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 110.26 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 m . . . . . 0 N--CA 1.492 1.64 0 O-C-N 121.257 -0.902 . . . . 0.0 109.962 179.822 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.46 -40.24 1.65 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.963 1.507 . . . . 0.0 110.24 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.6 t -73.37 -59.19 2.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.434 -0.791 . . . . 0.0 110.302 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 53.1 t -53.36 -40.42 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.256 -0.903 . . . . 0.0 110.317 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.642 ' O ' HG23 ' A' ' 18' ' ' VAL . 36.2 t-105 -58.65 -36.95 74.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.353 -0.842 . . . . 0.0 110.119 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.88 -32.41 69.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.931 . . . . 0.0 110.257 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -70.74 -41.02 72.38 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.136 -0.978 . . . . 0.0 110.064 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.776 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -72.43 -30.64 64.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.213 -0.93 . . . . 0.0 109.469 179.708 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 14' ' ' TRP . 72.9 t -77.92 -27.78 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.435 -0.79 . . . . 0.0 109.891 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.72 -45.13 38.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 110.138 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -66.1 -52.12 51.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.866 . . . . 0.0 110.211 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 45.5 t -69.21 -12.28 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 110.262 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.18 -41.45 31.52 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.74 -33.57 68.61 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.25 -1.147 . . . . 0.0 110.149 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.433 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -87.22 -23.87 24.61 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.268 -0.895 . . . . 0.0 110.275 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.5 -1.46 30.56 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.931 . . . . 0.0 110.192 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.412 ' O ' HG12 ' A' ' 26' ' ' VAL . 86.4 t -113.66 -6.83 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.231 -0.918 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.433 HG22 ' HA ' ' A' ' 24' ' ' ALA . 13.8 t . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.131 -0.981 . . . . 0.0 110.193 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.1 -48.05 0.29 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.045 1.55 . . . . 0.0 110.373 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.51 -59.37 2.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.327 -0.858 . . . . 0.0 110.127 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.5 t -48.22 -29.49 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 110.161 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.0 t-105 -73.64 -59.47 2.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 110.158 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -57.76 -16.42 11.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.263 -0.898 . . . . 0.0 109.947 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.428 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.3 t80 -82.38 -42.3 18.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 110.104 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.919 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.2 -23.0 57.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.34 -0.85 . . . . 0.0 109.676 179.861 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -79.31 -56.69 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.48 -0.762 . . . . 0.0 109.941 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.76 -33.93 70.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.319 -0.863 . . . . 0.0 110.062 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.519 HD23 ' HA ' ' A' ' 20' ' ' LEU . 7.3 mt -67.86 -47.71 68.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.101 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 26.4 t -64.05 -16.28 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 110.175 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.29 -53.08 9.33 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -19.81 62.09 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -1.151 . . . . 0.0 110.209 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.59 ' O ' HG22 ' A' ' 27' ' ' THR . . . -83.62 -9.06 59.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.908 . . . . 0.0 110.134 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.29 3.85 26.01 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.36 -0.838 . . . . 0.0 110.122 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 20.8 t -101.58 -16.59 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 110.084 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.59 HG22 ' O ' ' A' ' 24' ' ' ALA . 15.1 t . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.477 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.477 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 46.1 Cg_endo -73.25 -47.5 0.3 Allowed 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 123.973 1.512 . . . . 0.0 110.337 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 4.4 m -62.45 -66.93 0.47 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 110.086 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.426 ' H ' HG23 ' A' ' 13' ' ' VAL . 21.8 t -44.03 -39.09 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 109.984 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.43 ' HB3' ' O ' ' A' ' 11' ' ' PRO . 30.6 t-105 -56.35 -52.22 65.37 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -56.83 -25.62 56.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.167 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 7.3 t80 -74.56 -34.22 62.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 110.198 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.644 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -73.03 -34.61 66.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.335 -0.853 . . . . 0.0 109.734 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.62 -35.26 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.408 -0.807 . . . . 0.0 110.082 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.04 -47.37 74.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.956 . . . . 0.0 110.119 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 17.1 mt -62.37 -54.82 34.8 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.277 -0.89 . . . . 0.0 110.085 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -64.71 -15.11 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 110.154 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.427 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -74.31 -36.74 49.53 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.27 -29.67 61.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 110.153 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.57 -34.07 73.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 110.233 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.67 -17.76 61.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.244 -0.91 . . . . 0.0 110.035 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 22' ' ' GLY . 39.8 t -83.34 -6.73 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.378 -0.826 . . . . 0.0 109.959 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 110.057 179.874 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.99 -42.01 1.16 Allowed 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.974 1.512 . . . . 0.0 110.467 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.5 m -61.73 -61.75 2.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.905 . . . . 0.0 110.212 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.7 t -46.22 -39.13 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.28 -0.887 . . . . 0.0 110.256 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 34.5 t-105 -63.09 -51.41 66.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.339 -0.851 . . . . 0.0 110.329 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.72 -26.99 67.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.122 -0.986 . . . . 0.0 110.254 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -69.91 -47.75 61.24 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.02 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.799 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -67.2 -30.22 70.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.204 -0.935 . . . . 0.0 109.742 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.2 t -79.11 -27.07 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.447 -0.783 . . . . 0.0 110.107 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.98 -42.44 60.44 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.309 -0.87 . . . . 0.0 110.141 179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.2 mt -71.29 -48.03 53.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.174 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.0 t -71.77 -21.6 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 110.079 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -23.07 78.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.58 -29.67 41.31 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.16 -1.2 . . . . 0.0 110.15 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.32 -20.94 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 110.176 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.24 -17.02 64.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 110.15 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 77.6 t -85.71 -19.24 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 110.097 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.4 ' O ' HG22 ' A' ' 27' ' ' THR . 67.1 m . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.353 -0.842 . . . . 0.0 110.033 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.491 ' O ' ' HB2' ' A' ' 14' ' ' TRP . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.57 -47.56 0.14 Allowed 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.002 1.527 . . . . 0.0 110.457 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 p -70.39 -63.22 1.13 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.296 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 91.2 t -47.8 -32.36 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 110.166 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.54 ' O ' HG23 ' A' ' 18' ' ' VAL . 63.6 t-105 -70.13 -41.8 73.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.928 . . . . 0.0 109.96 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.9 -23.35 65.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.47 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.7 t80 -77.53 -47.14 20.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.33 -0.856 . . . . 0.0 110.043 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.884 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -68.69 -21.5 64.42 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.292 -0.88 . . . . 0.0 109.709 179.885 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.54 HG23 ' O ' ' A' ' 14' ' ' TRP . 55.6 t -82.6 -53.62 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -0.844 . . . . 0.0 110.207 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.47 -35.56 76.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.315 -0.866 . . . . 0.0 110.078 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 0.2 OUTLIER -72.1 -46.6 56.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.938 . . . . 0.0 110.171 179.935 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.2 t -66.95 -21.3 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.961 . . . . 0.0 109.902 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.16 -29.32 60.62 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.1 -22.98 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -1.078 . . . . 0.0 110.08 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.86 -35.98 75.15 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 110.207 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.51 -5.2 43.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 110.095 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.8 t -99.39 -13.54 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.207 -0.933 . . . . 0.0 110.223 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.1 t . . . . . 0 N--CA 1.492 1.63 0 O-C-N 121.205 -0.934 . . . . 0.0 110.239 -179.983 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.355 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.6 -54.57 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.047 1.551 . . . . 0.0 110.4 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -64.16 -51.26 64.68 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 110.146 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 38.5 t -57.48 -39.13 67.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.299 -0.876 . . . . 0.0 110.186 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 48.5 t-105 -64.88 -39.97 94.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.165 -0.959 . . . . 0.0 110.146 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.63 -25.66 64.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.181 -0.949 . . . . 0.0 110.196 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -75.79 -42.77 49.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 0.0 110.045 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.688 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -69.41 -29.85 67.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.321 -0.862 . . . . 0.0 109.827 -179.989 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 32.3 t -77.26 -44.87 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.336 -0.852 . . . . 0.0 110.12 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -61.19 -36.76 80.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 110.1 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.4 mt -67.75 -48.22 67.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 110.044 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.446 ' O ' HG12 ' A' ' 21' ' ' VAL . 64.0 t -77.43 -1.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.263 -0.898 . . . . 0.0 110.034 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.46 -21.51 31.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.17 -37.94 66.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.22 -1.165 . . . . 0.0 110.068 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 -7.05 58.4 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -78.3 -17.27 56.83 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.419 -0.8 . . . . 0.0 110.183 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.6 t -87.49 -16.29 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.371 -0.83 . . . . 0.0 110.031 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.311 -0.868 . . . . 0.0 110.102 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.03 -52.47 0.23 Allowed 'Trans proline' 0 C--N 1.307 -1.605 0 O-C-N 124.019 1.536 . . . . 0.0 110.394 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 p -65.71 -56.97 9.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.936 . . . . 0.0 110.132 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 67.0 t -49.32 -46.71 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.27 -0.894 . . . . 0.0 110.021 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.46 ' O ' HG23 ' A' ' 18' ' ' VAL . 48.7 t-105 -56.02 -52.55 63.83 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 109.991 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.47 -22.65 55.5 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 109.878 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.418 ' O ' HD12 ' A' ' 20' ' ' LEU . 0.6 OUTLIER -70.75 -46.91 62.11 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.368 -0.833 . . . . 0.0 110.021 179.844 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.671 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -65.43 -29.47 70.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.893 179.944 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 14' ' ' TRP . 47.9 t -74.11 -63.41 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.89 . . . . 0.0 110.149 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.51 -23.27 9.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 110.36 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.418 HD12 ' O ' ' A' ' 16' ' ' TYR . 10.5 mt -75.51 -46.06 34.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.144 -0.972 . . . . 0.0 110.187 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 17' ' ' LEU . 92.9 t -67.8 -11.26 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.311 -0.868 . . . . 0.0 110.138 179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.38 -26.52 27.76 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.88 -22.03 61.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 110.232 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.53 -24.54 17.22 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 110.136 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -76.37 -10.8 59.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.218 -0.926 . . . . 0.0 110.277 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.502 ' O ' HG12 ' A' ' 26' ' ' VAL . 54.2 t -97.99 -1.85 10.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.256 -0.902 . . . . 0.0 110.319 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 25.2 m . . . . . 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.093 -179.982 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.431 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 44.9 Cg_endo -72.97 -54.58 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.951 1.501 . . . . 0.0 110.22 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -58.53 -58.86 6.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.268 -0.895 . . . . 0.0 110.01 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 t -47.88 -41.39 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.874 . . . . 0.0 110.108 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.765 ' O ' HG23 ' A' ' 18' ' ' VAL . 32.9 t-105 -57.08 -53.34 59.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.252 -0.905 . . . . 0.0 110.03 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.87 -22.55 65.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 110.293 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.412 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.4 t80 -75.27 -36.2 61.26 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.285 -0.885 . . . . 0.0 110.197 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.893 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -81.55 -28.53 33.85 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.165 -0.959 . . . . 0.0 109.805 179.964 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 14' ' ' TRP . 38.1 t -74.68 -32.48 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.37 -0.831 . . . . 0.0 109.979 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.1 -32.22 26.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.985 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.501 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.4 mt -68.4 -39.81 81.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.852 . . . . 0.0 110.159 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.5 t -64.58 -49.25 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.736 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -48.2 -40.54 21.84 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.72 -45.99 58.83 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -1.135 . . . . 0.0 110.176 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -66.0 -40.72 91.38 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.235 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.97 -8.01 40.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.169 -0.957 . . . . 0.0 110.205 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 22' ' ' GLY . 99.4 t -96.6 0.28 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.299 -0.876 . . . . 0.0 110.248 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.217 -0.927 . . . . 0.0 110.258 -179.962 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -73.67 -42.43 0.85 Allowed 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 124.098 1.578 . . . . 0.0 110.388 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -69.42 -59.29 3.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.323 -0.861 . . . . 0.0 110.168 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.1 t -53.26 -30.12 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.85 . . . . 0.0 110.076 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 36.0 t-105 -64.8 -38.35 90.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 110.035 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.42 -29.06 65.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 110.111 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -73.12 -34.62 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.79 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -77.24 -30.89 54.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.249 -0.907 . . . . 0.0 109.728 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -42.06 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.345 -0.847 . . . . 0.0 109.967 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.43 -49.67 68.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.28 -0.887 . . . . 0.0 109.854 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.482 HD23 ' HA ' ' A' ' 20' ' ' LEU . 2.1 mt -60.05 -54.93 40.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.907 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.6 t -63.6 -19.11 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.391 -0.818 . . . . 0.0 110.047 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.64 -30.48 36.0 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -75.73 -33.23 60.27 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.358 -1.084 . . . . 0.0 110.199 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.402 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -84.93 -13.11 51.8 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.191 -0.943 . . . . 0.0 110.254 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.15 -3.87 32.32 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 110.141 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.414 ' O ' HG12 ' A' ' 26' ' ' VAL . 41.3 t -107.45 -7.7 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 110.243 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.402 HG22 ' HA ' ' A' ' 24' ' ' ALA . 11.0 t . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.288 -0.882 . . . . 0.0 110.144 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.5 -52.42 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.095 1.577 . . . . 0.0 110.426 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -48.52 -43.34 35.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.265 -0.897 . . . . 0.0 110.272 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.17 -37.53 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.225 -0.922 . . . . 0.0 110.174 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 28.3 t-105 -65.13 -42.52 93.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.4 -0.813 . . . . 0.0 110.092 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.74 -27.11 66.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.267 -0.896 . . . . 0.0 110.228 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -76.14 -30.55 58.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.942 . . . . 0.0 110.168 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.764 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -80.98 -29.47 35.28 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.952 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.1 t -79.03 -38.5 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.369 -0.832 . . . . 0.0 109.899 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.59 -49.72 44.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 109.985 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 13.7 mt -59.31 -50.72 72.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 110.224 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.3 t -73.4 -17.51 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.286 -0.884 . . . . 0.0 110.174 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.733 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -77.37 -25.82 62.74 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -76.42 -39.91 52.23 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -1.12 . . . . 0.0 110.154 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -78.93 -28.97 43.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.353 -0.842 . . . . 0.0 110.168 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -69.73 -13.45 62.29 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.323 -0.861 . . . . 0.0 110.177 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 22' ' ' GLY . 71.2 t -77.68 -15.68 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.255 -0.903 . . . . 0.0 110.161 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 86.2 m . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 0.0 110.182 -179.923 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.218 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.12 -60.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.001 1.527 . . . . 0.0 110.653 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -58.8 -47.2 85.59 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 110.327 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.76 -40.24 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 110.222 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.609 ' O ' HG23 ' A' ' 18' ' ' VAL . 36.8 t-105 -64.75 -42.42 95.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 110.158 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.48 -29.64 70.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 110.24 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -74.72 -56.74 4.48 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.264 -0.898 . . . . 0.0 110.104 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.674 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -58.42 -22.3 53.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.198 -0.939 . . . . 0.0 109.954 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.609 HG23 ' O ' ' A' ' 14' ' ' TRP . 55.9 t -83.22 -42.77 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.287 -0.883 . . . . 0.0 110.27 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.95 -23.57 67.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.338 -0.851 . . . . 0.0 110.262 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.88 -61.28 1.75 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.263 -0.898 . . . . 0.0 110.258 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.4 t -54.01 -30.07 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -0.967 . . . . 0.0 110.181 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.11 -44.34 67.29 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.09 -28.09 69.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -1.125 . . . . 0.0 110.194 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.454 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -85.82 -19.22 31.0 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.267 -0.896 . . . . 0.0 110.19 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.99 -9.53 59.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.221 -0.924 . . . . 0.0 110.149 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.433 ' O ' HG12 ' A' ' 26' ' ' VAL . 50.9 t -105.83 -6.63 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.93 . . . . 0.0 110.253 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.454 HG22 ' HA ' ' A' ' 24' ' ' ALA . 14.6 t . . . . . 0 N--CA 1.492 1.66 0 O-C-N 121.269 -0.895 . . . . 0.0 110.194 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.497 ' HG2' HG13 ' A' ' 5' ' ' ILE . 48.1 Cg_endo . . . . . 0 N--CA 1.496 1.651 0 N-CA-C 110.277 -0.701 . . . . 0.0 110.277 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -130.25 50.26 2.21 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.254 -0.904 . . . . 0.0 110.164 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.5 mt -106.84 -67.59 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.201 -0.937 . . . . 0.0 110.178 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -135.29 23.0 3.47 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-O 122.027 0.918 . . . . 0.0 110.013 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.577 ' O ' HG22 ' A' ' 5' ' ' ILE . 43.2 mm -92.12 27.15 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 CA-C-O 121.899 0.857 . . . . 0.0 110.329 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.74 45.5 0.4 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -87.52 21.98 2.35 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.276 -1.132 . . . . 0.0 110.315 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.1 t -114.87 177.74 4.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.258 -0.902 . . . . 0.0 110.085 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.6 t -141.11 -43.43 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.275 -0.89 . . . . 0.0 110.261 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.82 99.46 1.94 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.425 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 46.2 Cg_endo -73.38 -44.74 0.5 Allowed 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 124.021 1.537 . . . . 0.0 110.419 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 13' ' ' VAL . 1.9 p -64.8 -71.24 0.19 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.236 -0.915 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.417 ' C ' ' O ' ' A' ' 12' ' ' SER . 65.2 t -42.64 -30.96 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.325 -0.859 . . . . 0.0 110.142 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.425 ' HB3' ' O ' ' A' ' 11' ' ' PRO . 46.4 t-105 -64.78 -56.7 11.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.181 -0.95 . . . . 0.0 110.106 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.34 -28.55 43.52 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.211 -0.93 . . . . 0.0 109.904 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -69.45 -47.33 64.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.922 . . . . 0.0 109.842 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.753 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -65.73 -21.68 66.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.688 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -78.23 -51.47 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 109.952 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.69 -39.98 82.27 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.311 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -66.76 -52.91 38.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.27 -0.894 . . . . 0.0 110.28 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 17' ' ' LEU . 81.9 t -60.91 -21.47 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 110.34 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.665 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -72.34 -53.59 8.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -53.75 -40.25 66.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.197 -1.178 . . . . 0.0 110.241 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.69 -33.47 72.58 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.34 -17.24 60.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.313 -0.867 . . . . 0.0 110.167 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.665 HG23 ' O ' ' A' ' 22' ' ' GLY . 23.8 t -98.48 -14.4 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.305 -0.872 . . . . 0.0 110.179 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m -94.18 -25.63 17.01 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 110.125 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.93 -23.95 44.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.216 -0.927 . . . . 0.0 110.217 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -74.71 111.74 10.21 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 110.241 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.16 -179.946 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo . . . . . 0 N--CA 1.496 1.673 0 N-CA-C 110.218 -0.724 . . . . 0.0 110.218 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.05 62.83 7.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.21 -0.931 . . . . 0.0 110.059 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 34.3 mm -103.38 -56.7 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.311 -0.868 . . . . 0.0 110.565 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -92.42 23.52 3.91 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-O 122.012 0.911 . . . . 0.0 110.239 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.643 ' O ' HG22 ' A' ' 5' ' ' ILE . 13.9 mt -107.72 26.81 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 CA-C-O 121.843 0.83 . . . . 0.0 110.195 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -170.5 42.6 0.2 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -140.38 27.44 2.1 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.301 -1.117 . . . . 0.0 110.087 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.7 t -67.19 -167.9 0.06 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.885 . . . . 0.0 110.236 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 22.5 t -102.14 -63.28 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.384 -0.823 . . . . 0.0 110.071 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 131.66 74.48 0.11 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.83 -59.3 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.93 1.489 . . . . 0.0 110.608 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 88.3 p -62.98 -49.28 75.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 110.251 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.2 t -51.97 -42.23 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.192 -0.943 . . . . 0.0 110.095 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.508 ' O ' HG23 ' A' ' 18' ' ' VAL . 27.5 t-105 -66.7 -32.55 73.93 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 110.122 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.64 -33.61 71.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.284 -0.885 . . . . 0.0 110.234 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -76.4 -30.11 57.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.259 -0.901 . . . . 0.0 110.307 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.709 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.24 -29.82 57.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.162 -0.961 . . . . 0.0 109.67 179.917 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 14' ' ' TRP . 69.0 t -79.57 -45.97 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.454 -0.778 . . . . 0.0 110.081 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.17 -48.58 81.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.327 -0.858 . . . . 0.0 110.126 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.448 ' HA ' HD23 ' A' ' 20' ' ' LEU . 43.0 mt -62.08 -49.37 76.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.258 -0.901 . . . . 0.0 110.262 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 21' ' ' VAL . 53.0 t -73.29 -8.24 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 110.391 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.51 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -86.72 -33.24 13.33 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.64 -37.3 70.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -1.208 . . . . 0.0 110.427 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.46 -16.86 47.32 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.224 -0.923 . . . . 0.0 110.462 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.66 4.43 24.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.229 -0.92 . . . . 0.0 110.406 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 22' ' ' GLY . 96.1 t -100.26 -15.92 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.12 -0.987 . . . . 0.0 110.253 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.5 t -108.61 -20.98 12.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 110.293 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.75 -26.59 40.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.241 -0.912 . . . . 0.0 110.305 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -105.55 74.21 1.07 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.291 -0.881 . . . . 0.0 110.169 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.137 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.436 ' HB2' HG13 ' A' ' 3' ' ' ILE . 48.4 Cg_endo . . . . . 0 N--CA 1.482 0.836 0 N-CA-C 110.409 -0.65 . . . . 0.0 110.409 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.499 ' HA ' HG13 ' A' ' 5' ' ' ILE . . . -116.87 50.37 1.08 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.174 -0.954 . . . . 0.0 110.229 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.505 ' O ' ' HB3' ' A' ' 7' ' ' ALA . 17.9 mt -97.1 -47.22 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 110.219 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -96.99 22.47 8.37 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.198 -0.939 . . . . 0.0 110.024 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.717 ' O ' HG22 ' A' ' 5' ' ' ILE . 17.7 mm -97.44 27.27 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.162 0 CA-C-O 121.955 0.883 . . . . 0.0 110.08 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 114.64 10.39 12.94 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.505 ' HB3' ' O ' ' A' ' 3' ' ' ILE . . . -108.88 26.31 10.74 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.32 -1.106 . . . . 0.0 110.177 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.03 156.93 16.11 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.22 -0.925 . . . . 0.0 110.173 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.568 HG12 ' N ' ' A' ' 10' ' ' GLY . 20.1 t -71.69 -77.46 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.259 -0.9 . . . . 0.0 110.366 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.568 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -41.54 101.33 0.02 OUTLIER Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 9' ' ' VAL . 48.4 Cg_endo -75.82 -52.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 124.017 1.535 . . . . 0.0 110.435 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -61.92 -58.07 9.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.328 -0.857 . . . . 0.0 110.32 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 77.2 t -46.48 -34.37 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.905 . . . . 0.0 110.35 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.629 ' O ' HG23 ' A' ' 18' ' ' VAL . 23.2 t-105 -68.5 -58.4 4.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.19 -0.944 . . . . 0.0 110.229 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.67 -23.44 28.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.904 . . . . 0.0 110.376 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.33 -41.57 33.19 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 0.0 110.311 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.901 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -70.61 -25.87 63.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.915 . . . . 0.0 109.693 179.903 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 14' ' ' TRP . 21.4 t -83.35 -37.05 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 110.088 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.04 -22.66 60.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.992 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 mt -87.9 -53.48 4.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.385 -0.822 . . . . 0.0 110.279 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.1 t -62.07 -16.77 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.309 -0.87 . . . . 0.0 110.362 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.52 -29.78 63.24 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.31 -20.53 63.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.255 -1.144 . . . . 0.0 110.249 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.602 ' O ' HG22 ' A' ' 27' ' ' THR . . . -87.33 -17.94 31.25 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.887 . . . . 0.0 110.171 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.3 -1.05 21.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.216 -0.927 . . . . 0.0 110.194 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.63 -11.54 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.297 -0.877 . . . . 0.0 110.172 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.602 HG22 ' O ' ' A' ' 24' ' ' ALA . 8.9 t -101.12 -27.25 13.35 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.327 -0.858 . . . . 0.0 110.327 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.17 20.34 5.12 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.171 -0.956 . . . . 0.0 110.297 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -108.0 -173.34 2.26 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.264 -0.897 . . . . 0.0 110.186 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.223 -179.982 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.532 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 47.8 Cg_endo . . . . . 0 N--CA 1.496 1.662 0 N-CA-C 110.212 -0.726 . . . . 0.0 110.212 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.532 ' HB2' ' O ' ' A' ' 1' ' ' PRO . . . 178.35 67.17 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.235 -0.915 . . . . 0.0 110.242 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.471 HG22 ' N ' ' A' ' 4' ' ' TYR . 81.1 mt -60.96 -88.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.126 -0.984 . . . . 0.0 109.994 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.471 ' N ' HG22 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -95.56 22.98 6.45 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.145 -0.972 . . . . 0.0 109.944 179.85 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.639 ' O ' HG22 ' A' ' 5' ' ' ILE . 16.8 mm -101.76 27.4 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 CA-C-O 121.962 0.887 . . . . 0.0 110.264 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.605 ' O ' ' HB2' ' A' ' 7' ' ' ALA . . . -140.81 64.13 0.52 Allowed Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.605 ' HB2' ' O ' ' A' ' 6' ' ' GLY . . . 175.11 100.64 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.398 -1.06 . . . . 0.0 110.21 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.502 HG22 ' H ' ' A' ' 9' ' ' VAL . 0.4 OUTLIER -68.63 -151.04 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.21 -0.932 . . . . 0.0 110.169 179.981 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.502 ' H ' HG22 ' A' ' 8' ' ' THR . 74.4 t -108.9 -41.05 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.227 -0.921 . . . . 0.0 110.199 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.479 ' O ' ' HB3' ' A' ' 14' ' ' TRP . . . 178.42 88.88 0.07 OUTLIER Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.349 -1.501 . . . . 0.0 109.349 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.41 -52.76 0.14 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 124.023 1.538 . . . . 0.0 110.571 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.52 -48.6 60.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.231 -0.918 . . . . 0.0 110.515 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.561 ' CG1' ' N ' ' A' ' 14' ' ' TRP . 2.9 p -59.64 -45.41 94.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.159 -0.963 . . . . 0.0 110.38 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.704 ' O ' HG23 ' A' ' 18' ' ' VAL . 49.3 t-105 -63.17 -36.88 85.09 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.116 -0.99 . . . . 0.0 110.013 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.48 -23.48 63.64 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.332 -0.855 . . . . 0.0 110.089 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.558 ' HD1' HD12 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -78.13 -36.57 47.66 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.228 -0.92 . . . . 0.0 110.185 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.965 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.06 -26.1 56.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.209 -0.932 . . . . 0.0 109.583 179.802 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.704 HG23 ' O ' ' A' ' 14' ' ' TRP . 61.0 t -81.52 -39.1 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.452 -0.78 . . . . 0.0 110.212 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.9 -38.15 67.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.225 -0.922 . . . . 0.0 110.139 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.558 HD12 ' HD1' ' A' ' 16' ' ' TYR . 1.2 mt -72.24 -39.18 68.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.935 . . . . 0.0 110.173 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.6 t -88.28 -4.77 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.307 -0.871 . . . . 0.0 110.195 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.26 -19.94 31.61 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -78.53 -29.78 46.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.226 -1.161 . . . . 0.0 110.244 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.45 ' O ' HG22 ' A' ' 27' ' ' THR . . . -81.54 -19.92 41.06 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.251 -0.906 . . . . 0.0 110.214 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.36 -15.8 60.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.284 -0.885 . . . . 0.0 110.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.5 t -83.7 -13.95 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 110.109 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.45 HG22 ' O ' ' A' ' 24' ' ' ALA . 10.1 t -113.57 -19.2 11.72 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 110.058 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.16 -22.25 36.17 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.276 -0.89 . . . . 0.0 110.217 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.99 13.17 11.55 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.307 -0.871 . . . . 0.0 110.228 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.1 t30 . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.231 179.977 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.691 ' HG2' HD12 ' A' ' 5' ' ' ILE . 49.4 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 110.199 -0.731 . . . . 0.0 110.199 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.83 31.2 0.79 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.154 -0.966 . . . . 0.0 110.206 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.5 mm -80.52 -68.03 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 110.152 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -118.62 22.92 11.79 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.178 -0.951 . . . . 0.0 110.053 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.691 HD12 ' HG2' ' A' ' 1' ' ' PRO . 9.8 mt -115.77 26.77 3.65 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.177 0 CA-C-O 121.809 0.814 . . . . 0.0 110.401 -179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -135.8 10.03 4.25 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -116.46 30.02 7.59 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.251 -1.146 . . . . 0.0 110.067 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.1 m -83.62 162.9 20.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 110.301 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.71 ' O ' HG12 ' A' ' 9' ' ' VAL . 68.0 t 44.27 31.8 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.211 -0.931 . . . . 0.0 110.394 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 9' ' ' VAL . . . -39.68 106.12 0.05 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.41 -41.72 3.25 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 O-C-N 124.013 1.533 . . . . 0.0 110.461 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 t -68.72 -56.08 9.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 110.137 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.72 -29.11 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.339 -0.851 . . . . 0.0 110.138 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.808 ' O ' HG23 ' A' ' 18' ' ' VAL . 44.0 t-105 -64.12 -42.5 96.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.253 -0.904 . . . . 0.0 110.142 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.82 -25.41 66.43 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.182 -0.949 . . . . 0.0 110.103 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -73.95 -42.52 60.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 110.193 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.859 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.15 -27.88 59.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.641 179.863 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.808 HG23 ' O ' ' A' ' 14' ' ' TRP . 68.9 t -76.64 -36.3 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.284 -0.885 . . . . 0.0 109.999 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.69 -32.49 63.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 110.014 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.1 mt -70.09 -51.21 33.57 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.294 -0.878 . . . . 0.0 110.225 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 49.0 t -64.32 -47.1 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -0.915 . . . . 0.0 110.258 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.52 -45.35 67.23 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.52 -22.39 60.12 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.286 -1.126 . . . . 0.0 110.205 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.13 -14.68 53.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.301 -0.874 . . . . 0.0 110.254 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.05 -12.34 58.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.924 . . . . 0.0 110.307 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.9 t -89.29 -13.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -0.9 . . . . 0.0 110.157 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 99.6 m -77.29 -19.14 56.87 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.184 -0.947 . . . . 0.0 110.164 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.45 -23.92 32.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 110.236 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -89.19 159.0 17.68 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 110.18 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 22.2 t-20 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.3 179.986 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 N--CA 1.495 1.573 0 N-CA-C 110.194 -0.733 . . . . 0.0 110.194 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.46 46.05 0.43 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.195 -0.94 . . . . 0.0 110.107 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.438 HG22 ' N ' ' A' ' 4' ' ' TYR . 34.7 mm -58.17 -87.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 110.193 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.438 ' N ' HG22 ' A' ' 3' ' ' ILE . 0.2 OUTLIER -104.26 23.04 13.72 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 122.144 0.973 . . . . 0.0 110.039 179.881 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.725 ' O ' HG22 ' A' ' 5' ' ' ILE . 29.8 mt -92.9 26.65 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 CA-C-O 121.926 0.87 . . . . 0.0 110.101 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -176.75 54.66 0.11 Allowed Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.726 ' O ' HG22 ' A' ' 8' ' ' THR . . . -126.78 33.23 4.99 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.255 -1.144 . . . . 0.0 110.184 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . 1.046 HG23 HG23 ' A' ' 9' ' ' VAL . 6.5 t 39.63 -155.31 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.591 -0.693 . . . . 0.0 110.349 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 1.046 HG23 HG23 ' A' ' 8' ' ' THR . 87.3 t 45.48 28.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.18 -0.95 . . . . 0.0 110.314 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -121.38 60.68 0.54 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.446 ' HD3' ' C ' ' A' ' 9' ' ' VAL . 45.9 Cg_endo -72.98 -47.7 0.31 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.944 1.497 . . . . 0.0 110.397 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 0.3 OUTLIER -67.05 -60.68 2.42 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -0.915 . . . . 0.0 110.191 -179.988 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.413 ' C ' ' O ' ' A' ' 12' ' ' SER . 54.3 t -43.21 -47.81 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 110.122 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.604 ' O ' HG23 ' A' ' 18' ' ' VAL . 21.4 t-105 -55.83 -56.2 23.45 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.927 . . . . 0.0 109.912 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -53.93 -23.92 14.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -0.938 . . . . 0.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -75.0 -38.61 61.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.2 -0.937 . . . . 0.0 110.351 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.883 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -73.89 -25.6 60.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.835 179.939 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.604 HG23 ' O ' ' A' ' 14' ' ' TRP . 5.9 t -86.24 -28.33 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.319 -0.863 . . . . 0.0 110.097 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.56 -35.93 60.52 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.261 -0.899 . . . . 0.0 110.054 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.9 mt -83.15 -40.07 20.23 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.283 -0.886 . . . . 0.0 110.177 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 90.7 t -79.25 -17.6 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.224 -0.923 . . . . 0.0 110.196 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.53 -30.18 64.74 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.57 -26.6 68.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.152 . . . . 0.0 110.201 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.734 ' O ' HG22 ' A' ' 27' ' ' THR . . . -66.01 -40.3 90.99 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.204 -0.935 . . . . 0.0 110.203 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.4 -11.89 60.62 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 110.25 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.434 ' O ' ' HB2' ' A' ' 30' ' ' ASN . 38.1 t -84.95 -17.37 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.175 -0.953 . . . . 0.0 110.241 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.734 HG22 ' O ' ' A' ' 24' ' ' ALA . 11.7 t -99.23 -8.54 24.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 110.097 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.53 -30.38 16.44 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.255 -0.903 . . . . 0.0 110.055 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -101.69 -7.28 22.78 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.274 -0.891 . . . . 0.0 110.018 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.434 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 35.3 t-20 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.26 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo . . . . . 0 N--CA 1.497 1.683 0 N-CA-C 110.209 -0.727 . . . . 0.0 110.209 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -160.81 36.95 0.15 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.201 -0.937 . . . . 0.0 110.398 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 1.8 mp -69.07 -56.48 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.121 -0.987 . . . . 0.0 110.06 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -141.44 23.3 2.15 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 122.159 0.981 . . . . 0.0 109.902 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.661 ' O ' HG22 ' A' ' 5' ' ' ILE . 42.3 mt -95.76 26.46 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-O 121.85 0.833 . . . . 0.0 110.201 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 136.52 -10.95 4.05 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 44.8 87.57 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -1.109 . . . . 0.0 110.337 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.477 HG22 ' H ' ' A' ' 9' ' ' VAL . 0.2 OUTLIER -121.42 -171.95 2.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.533 -0.729 . . . . 0.0 110.097 179.858 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.477 ' H ' HG22 ' A' ' 8' ' ' THR . 37.5 t -68.31 -13.73 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.245 -0.91 . . . . 0.0 110.192 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 45.96 62.13 3.55 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.93 -47.57 0.44 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.989 1.521 . . . . 0.0 110.295 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 m -61.47 -55.69 28.44 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.904 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 t -54.04 -37.57 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 109.87 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.441 ' O ' HG23 ' A' ' 18' ' ' VAL . 46.4 t-105 -59.07 -52.18 66.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.215 -0.928 . . . . 0.0 109.922 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.2 -19.73 65.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.757 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -75.8 -40.25 55.4 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 110.095 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.919 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.7 -29.64 56.36 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.596 179.811 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 14' ' ' TRP . 95.3 t -75.36 -29.65 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.393 -0.817 . . . . 0.0 109.87 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -77.05 -40.16 47.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.912 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.3 -36.4 81.44 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 110.042 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 17' ' ' LEU . 84.8 t -77.51 -35.3 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.16 -0.963 . . . . 0.0 110.223 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.13 -12.32 68.49 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.43 -28.83 37.66 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -1.153 . . . . 0.0 110.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.99 -22.98 31.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.2 -0.938 . . . . 0.0 110.307 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.88 -0.91 17.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -0.889 . . . . 0.0 110.236 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.481 ' O ' HG12 ' A' ' 26' ' ' VAL . 41.6 t -99.62 -2.34 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.267 -0.896 . . . . 0.0 110.113 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.18 -13.36 14.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.151 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.01 -22.49 36.49 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.251 -0.905 . . . . 0.0 110.33 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -96.56 -56.45 2.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.279 -0.888 . . . . 0.0 110.27 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.1 t-20 . . . . . 0 N--CA 1.489 1.508 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.27 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.411 ' O ' HD12 ' A' ' 5' ' ' ILE . 47.2 Cg_endo . . . . . 0 N--CA 1.497 1.715 0 N-CA-C 110.276 -0.702 . . . . 0.0 110.276 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -162.45 39.71 0.12 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.296 -0.878 . . . . 0.0 110.244 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.404 HG23 HD12 ' A' ' 3' ' ' ILE . 18.9 mm -86.13 -66.45 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 110.438 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -111.02 25.79 11.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.195 -0.941 . . . . 0.0 110.303 -179.693 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.723 ' O ' HG22 ' A' ' 5' ' ' ILE . 42.1 mt -90.88 25.76 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 CA-C-O 121.826 0.822 . . . . 0.0 110.266 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.52 59.69 0.6 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -107.03 25.37 11.44 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.285 -1.127 . . . . 0.0 110.228 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.17 5.87 18.74 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.227 -0.921 . . . . 0.0 110.276 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.447 ' O ' ' HD3' ' A' ' 11' ' ' PRO . 65.0 t -127.48 -70.42 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.356 -0.84 . . . . 0.0 110.173 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 9' ' ' VAL . . . -42.93 102.74 0.03 OUTLIER Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.447 ' HD3' ' O ' ' A' ' 9' ' ' VAL . 45.8 Cg_endo -73.37 -42.69 0.85 Allowed 'Trans proline' 0 C--N 1.305 -1.728 0 O-C-N 123.992 1.522 . . . . 0.0 110.234 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.0 m -67.51 -55.62 12.79 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.22 -0.925 . . . . 0.0 110.186 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.446 HG23 ' H ' ' A' ' 13' ' ' VAL . 17.7 t -53.99 -45.02 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.971 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.636 ' O ' HG23 ' A' ' 18' ' ' VAL . 26.5 t-105 -58.33 -47.17 84.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.802 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.07 -23.73 21.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.323 -0.861 . . . . 0.0 109.979 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.475 ' CD1' HD12 ' A' ' 20' ' ' LEU . 0.2 OUTLIER -76.83 -51.17 11.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 110.006 179.916 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.735 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -59.53 -22.86 62.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.757 179.904 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.636 HG23 ' O ' ' A' ' 14' ' ' TRP . 33.9 t -85.36 -44.12 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -0.905 . . . . 0.0 110.078 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.72 -24.73 67.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.333 -0.854 . . . . 0.0 110.084 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.475 HD12 ' CD1' ' A' ' 16' ' ' TYR . 0.9 OUTLIER -88.02 -39.29 14.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.23 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -72.12 -21.44 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.232 -0.918 . . . . 0.0 110.158 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.5 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -81.06 -18.32 69.89 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.61 -18.45 60.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -1.168 . . . . 0.0 110.22 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -88.75 -29.27 19.92 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.929 . . . . 0.0 110.31 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.61 -4.13 32.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.206 -0.934 . . . . 0.0 110.213 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 22' ' ' GLY . 47.4 t -84.43 -20.17 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.249 -0.907 . . . . 0.0 110.22 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.8 -35.86 62.48 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 110.161 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.84 -31.86 20.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.214 -0.929 . . . . 0.0 110.165 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -103.56 134.91 46.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.216 -0.928 . . . . 0.0 110.178 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.216 179.995 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.482 0.796 0 N-CA-C 110.241 -0.715 . . . . 0.0 110.241 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.479 ' HA ' HG13 ' A' ' 5' ' ' ILE . . . -144.95 45.67 1.35 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.173 -0.954 . . . . 0.0 110.097 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.5 mm -96.82 -51.26 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.35 -0.844 . . . . 0.0 110.275 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -95.44 22.07 7.4 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 122.113 0.958 . . . . 0.0 110.107 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.764 ' O ' HG22 ' A' ' 5' ' ' ILE . 14.8 mm -94.27 26.37 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.077 0 CA-C-O 121.856 0.836 . . . . 0.0 110.061 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' ' HB3' ' A' ' 7' ' ' ALA . . . 96.15 -43.15 2.16 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 6' ' ' GLY . . . 55.63 30.76 16.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.257 -1.143 . . . . 0.0 110.362 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -85.28 156.23 21.03 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.288 -0.882 . . . . 0.0 110.323 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 94.2 t -118.81 -22.68 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 110.163 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.523 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . 52.64 51.73 42.31 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.523 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 44.3 Cg_endo -72.65 -58.66 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.025 1.539 . . . . 0.0 110.63 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.415 ' O ' ' C ' ' A' ' 13' ' ' VAL . 5.4 t -55.71 -63.68 1.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -0.918 . . . . 0.0 110.195 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.415 ' C ' ' O ' ' A' ' 12' ' ' SER . 60.6 t -42.88 -51.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.344 -0.847 . . . . 0.0 110.245 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.47 ' O ' HG23 ' A' ' 18' ' ' VAL . 40.9 t-105 -48.43 -47.13 38.19 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.232 -0.918 . . . . 0.0 110.276 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.52 -34.77 74.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.262 -0.899 . . . . 0.0 110.424 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.8 t80 -67.14 -48.35 68.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.235 -0.915 . . . . 0.0 110.417 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.755 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -64.96 -24.26 67.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.114 -0.991 . . . . 0.0 109.982 -179.901 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 14' ' ' TRP . 29.9 t -73.52 -62.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.337 -0.852 . . . . 0.0 110.248 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.55 -28.96 34.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.27 -0.894 . . . . 0.0 110.213 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.0 mt -67.87 -49.52 61.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 110.217 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.5 t -55.56 -48.48 77.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.216 -0.927 . . . . 0.0 110.204 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.486 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -62.73 -32.93 85.29 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.04 -30.12 70.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.185 -1.185 . . . . 0.0 110.39 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.46 -34.89 18.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 110.265 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.92 -13.17 14.11 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.208 -0.932 . . . . 0.0 110.25 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 22' ' ' GLY . 65.6 t -93.77 -23.59 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 110.26 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 m -72.41 -40.4 67.18 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.257 -0.902 . . . . 0.0 109.962 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.63 -47.15 33.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.399 -0.813 . . . . 0.0 110.082 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 30' ' ' ASN . . . -93.3 92.38 7.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.238 -0.914 . . . . 0.0 110.062 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.427 ' HB2' ' O ' ' A' ' 29' ' ' ALA . 9.6 m120 . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.103 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.495 1.612 0 N-CA-C 110.188 -0.735 . . . . 0.0 110.188 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -175.09 56.25 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.314 -0.867 . . . . 0.0 110.142 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.4 mt -52.5 -52.9 22.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -0.917 . . . . 0.0 110.064 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.438 ' O ' ' N ' ' A' ' 6' ' ' GLY . 0.2 OUTLIER -111.74 23.28 14.04 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-O 122.111 0.958 . . . . 0.0 109.741 179.788 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.757 ' O ' HG22 ' A' ' 5' ' ' ILE . 38.9 mt 40.86 29.08 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.067 0 CA-C-O 121.967 0.889 . . . . 0.0 110.055 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 4' ' ' TYR . . . -177.3 43.06 0.1 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -152.28 28.4 0.58 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.38 -1.071 . . . . 0.0 110.183 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -82.06 6.42 16.31 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -0.86 . . . . 0.0 110.314 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.7 t -97.38 -67.62 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.337 -0.852 . . . . 0.0 109.978 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 71.52 65.49 2.4 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.46 -40.24 1.65 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.963 1.507 . . . . 0.0 110.24 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.6 t -73.37 -59.19 2.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.434 -0.791 . . . . 0.0 110.302 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 53.1 t -53.36 -40.42 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.256 -0.903 . . . . 0.0 110.317 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.642 ' O ' HG23 ' A' ' 18' ' ' VAL . 36.2 t-105 -58.65 -36.95 74.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.353 -0.842 . . . . 0.0 110.119 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.88 -32.41 69.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.931 . . . . 0.0 110.257 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -70.74 -41.02 72.38 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.136 -0.978 . . . . 0.0 110.064 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.776 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -72.43 -30.64 64.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.213 -0.93 . . . . 0.0 109.469 179.708 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 14' ' ' TRP . 72.9 t -77.92 -27.78 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.435 -0.79 . . . . 0.0 109.891 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.72 -45.13 38.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 110.138 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -66.1 -52.12 51.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.866 . . . . 0.0 110.211 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 45.5 t -69.21 -12.28 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 110.262 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.18 -41.45 31.52 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.74 -33.57 68.61 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.25 -1.147 . . . . 0.0 110.149 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.433 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -87.22 -23.87 24.61 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.268 -0.895 . . . . 0.0 110.275 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.5 -1.46 30.56 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.931 . . . . 0.0 110.192 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.412 ' O ' HG12 ' A' ' 26' ' ' VAL . 86.4 t -113.66 -6.83 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.231 -0.918 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.433 HG22 ' HA ' ' A' ' 24' ' ' ALA . 13.8 t -116.41 -23.23 8.41 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.131 -0.981 . . . . 0.0 110.193 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.57 6.23 15.58 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.284 -0.885 . . . . 0.0 110.126 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.92 112.01 13.08 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.344 -0.848 . . . . 0.0 110.233 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 14.6 p-10 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.231 179.987 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo . . . . . 0 N--CA 1.497 1.696 0 N-CA-C 110.272 -0.703 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 53.7 31.55 13.03 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.266 -0.896 . . . . 0.0 110.229 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 55.5 mt -95.7 -46.55 13.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.238 -0.914 . . . . 0.0 109.973 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -110.46 23.33 14.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.244 -0.91 . . . . 0.0 110.005 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.693 ' O ' HG22 ' A' ' 5' ' ' ILE . 16.9 mt -101.57 27.01 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.16 0 CA-C-O 121.872 0.844 . . . . 0.0 110.15 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.524 ' O ' ' HB3' ' A' ' 7' ' ' ALA . . . 103.7 -44.7 1.43 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.524 ' HB3' ' O ' ' A' ' 6' ' ' GLY . . . 59.48 28.05 17.34 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -1.123 . . . . 0.0 110.38 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.4 t -84.65 -177.93 6.74 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.19 -0.944 . . . . 0.0 110.211 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 10.3 t -94.2 -37.43 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.25 -0.906 . . . . 0.0 109.94 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.86 87.08 1.68 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.1 -48.05 0.29 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.045 1.55 . . . . 0.0 110.373 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.51 -59.37 2.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.327 -0.858 . . . . 0.0 110.127 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.5 t -48.22 -29.49 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 110.161 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.0 t-105 -73.64 -59.47 2.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 110.158 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -57.76 -16.42 11.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.263 -0.898 . . . . 0.0 109.947 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.428 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.3 t80 -82.38 -42.3 18.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 110.104 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.919 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.2 -23.0 57.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.34 -0.85 . . . . 0.0 109.676 179.861 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -79.31 -56.69 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.48 -0.762 . . . . 0.0 109.941 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.76 -33.93 70.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.319 -0.863 . . . . 0.0 110.062 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.519 HD23 ' HA ' ' A' ' 20' ' ' LEU . 7.3 mt -67.86 -47.71 68.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.101 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 26.4 t -64.05 -16.28 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 110.175 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.29 -53.08 9.33 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -19.81 62.09 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -1.151 . . . . 0.0 110.209 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.59 ' O ' HG22 ' A' ' 27' ' ' THR . . . -83.62 -9.06 59.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.908 . . . . 0.0 110.134 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.29 3.85 26.01 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.36 -0.838 . . . . 0.0 110.122 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 20.8 t -101.58 -16.59 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 110.084 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.59 HG22 ' O ' ' A' ' 24' ' ' ALA . 15.1 t -90.29 -16.79 28.59 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.38 -28.78 67.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.259 -0.901 . . . . 0.0 110.218 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.447 ' O ' ' HB2' ' A' ' 30' ' ' ASN . . . -88.84 -23.39 22.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.261 -0.9 . . . . 0.0 110.198 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.447 ' HB2' ' O ' ' A' ' 29' ' ' ALA . 2.6 m120 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 117.903 -1.046 . . . . 0.0 110.289 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.502 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 46.9 Cg_endo . . . . . 0 N--CA 1.497 1.731 0 N-CA-C 110.328 -0.681 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.6 ' HA ' HD12 ' A' ' 5' ' ' ILE . . . 179.26 39.55 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.262 -0.899 . . . . 0.0 110.344 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 23.3 mm -90.89 -26.9 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.252 -0.905 . . . . 0.0 110.235 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -121.0 23.55 10.6 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 122.125 0.964 . . . . 0.0 110.014 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.718 ' O ' HG22 ' A' ' 5' ' ' ILE . 14.8 mt -96.48 26.5 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.114 0 CA-C-O 121.889 0.852 . . . . 0.0 109.999 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 130.02 -17.27 5.44 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 45.38 86.71 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.326 -1.102 . . . . 0.0 110.048 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 18.0 m -105.73 8.93 33.17 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.414 -0.804 . . . . 0.0 110.207 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 6.5 t -101.71 6.36 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.404 -0.81 . . . . 0.0 110.081 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.477 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . -162.59 53.83 0.3 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.477 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 46.1 Cg_endo -73.25 -47.5 0.3 Allowed 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 123.973 1.512 . . . . 0.0 110.337 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 4.4 m -62.45 -66.93 0.47 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 110.086 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.426 ' H ' HG23 ' A' ' 13' ' ' VAL . 21.8 t -44.03 -39.09 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 109.984 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.43 ' HB3' ' O ' ' A' ' 11' ' ' PRO . 30.6 t-105 -56.35 -52.22 65.37 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -56.83 -25.62 56.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.167 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 7.3 t80 -74.56 -34.22 62.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 110.198 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.644 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -73.03 -34.61 66.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.335 -0.853 . . . . 0.0 109.734 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.62 -35.26 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.408 -0.807 . . . . 0.0 110.082 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.04 -47.37 74.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.956 . . . . 0.0 110.119 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 17.1 mt -62.37 -54.82 34.8 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.277 -0.89 . . . . 0.0 110.085 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -64.71 -15.11 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 110.154 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.427 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -74.31 -36.74 49.53 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.27 -29.67 61.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 110.153 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.57 -34.07 73.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 110.233 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.67 -17.76 61.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.244 -0.91 . . . . 0.0 110.035 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 22' ' ' GLY . 39.8 t -83.34 -6.73 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.378 -0.826 . . . . 0.0 109.959 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m -98.42 -50.0 4.46 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 110.057 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -92.89 63.46 3.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.158 -0.964 . . . . 0.0 110.148 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.422 ' O ' ' O ' ' A' ' 30' ' ' ASN . . . -81.62 -73.19 0.39 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.311 -0.868 . . . . 0.0 110.245 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.422 ' O ' ' O ' ' A' ' 29' ' ' ALA . 8.7 m120 . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.205 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo . . . . . 0 N--CA 1.494 1.546 0 N-CA-C 110.173 -0.741 . . . . 0.0 110.173 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.585 ' HA ' HD12 ' A' ' 5' ' ' ILE . . . -173.75 96.53 0.11 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.218 -0.926 . . . . 0.0 110.097 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.6 mm -94.83 -59.46 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.194 -0.941 . . . . 0.0 110.136 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -102.6 23.88 11.3 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.217 -0.927 . . . . 0.0 110.022 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.735 ' O ' HG22 ' A' ' 5' ' ' ILE . 22.8 mt -92.58 26.74 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.092 0 CA-C-O 121.851 0.834 . . . . 0.0 110.158 -179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.5 ' O ' ' HB3' ' A' ' 7' ' ' ALA . . . 96.76 -18.58 57.25 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 -179.83 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' A' ' 6' ' ' GLY . . . 58.17 26.1 13.34 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.33 -1.1 . . . . 0.0 110.224 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.628 ' O ' HG22 ' A' ' 8' ' ' THR . 17.9 m -81.71 7.29 12.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.259 -0.9 . . . . 0.0 110.285 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.443 ' O ' ' HD3' ' A' ' 11' ' ' PRO . 8.7 p -125.04 -23.95 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.411 -0.805 . . . . 0.0 110.375 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 9' ' ' VAL . . . -42.91 102.35 0.03 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 9' ' ' VAL . 46.1 Cg_endo -72.99 -42.01 1.16 Allowed 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.974 1.512 . . . . 0.0 110.467 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.5 m -61.73 -61.75 2.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.905 . . . . 0.0 110.212 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.7 t -46.22 -39.13 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.28 -0.887 . . . . 0.0 110.256 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 34.5 t-105 -63.09 -51.41 66.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.339 -0.851 . . . . 0.0 110.329 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.72 -26.99 67.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.122 -0.986 . . . . 0.0 110.254 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -69.91 -47.75 61.24 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.02 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.799 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -67.2 -30.22 70.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.204 -0.935 . . . . 0.0 109.742 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.2 t -79.11 -27.07 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.447 -0.783 . . . . 0.0 110.107 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.98 -42.44 60.44 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.309 -0.87 . . . . 0.0 110.141 179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.2 mt -71.29 -48.03 53.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.174 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.0 t -71.77 -21.6 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 110.079 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -23.07 78.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.58 -29.67 41.31 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.16 -1.2 . . . . 0.0 110.15 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.32 -20.94 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 110.176 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.24 -17.02 64.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 110.15 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 77.6 t -85.71 -19.24 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 110.097 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.4 ' O ' HG22 ' A' ' 27' ' ' THR . 67.1 m -104.61 -5.77 21.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.353 -0.842 . . . . 0.0 110.033 179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.72 -28.23 19.54 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.292 -0.88 . . . . 0.0 110.228 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.68 134.75 36.42 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.283 -0.886 . . . . 0.0 110.186 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.075 -0.965 . . . . 0.0 110.241 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.466 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 50.2 Cg_endo . . . . . 0 N--CA 1.495 1.608 0 N-CA-C 110.213 -0.726 . . . . 0.0 110.213 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 1' ' ' PRO . . . -179.0 74.91 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.28 -0.887 . . . . 0.0 110.271 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.587 HG22 ' N ' ' A' ' 4' ' ' TYR . 35.8 mt -48.55 -91.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.225 -0.922 . . . . 0.0 110.01 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.587 ' N ' HG22 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -106.09 23.68 13.65 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.138 0.97 . . . . 0.0 109.843 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.723 ' O ' HG22 ' A' ' 5' ' ' ILE . 21.9 mt -92.01 26.17 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 CA-C-O 121.882 0.849 . . . . 0.0 110.107 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -132.29 49.2 0.93 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -118.49 24.97 10.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.353 -1.087 . . . . 0.0 110.084 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.544 HG22 ' N ' ' A' ' 9' ' ' VAL . 37.0 m -98.01 174.02 6.76 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.253 -0.904 . . . . 0.0 110.211 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.544 ' N ' HG22 ' A' ' 8' ' ' THR . 91.7 t -118.63 -70.73 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.169 -0.957 . . . . 0.0 110.202 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.491 ' O ' ' HB2' ' A' ' 14' ' ' TRP . . . 162.77 95.02 0.1 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.57 -47.56 0.14 Allowed 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.002 1.527 . . . . 0.0 110.457 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 p -70.39 -63.22 1.13 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.296 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 91.2 t -47.8 -32.36 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 110.166 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.54 ' O ' HG23 ' A' ' 18' ' ' VAL . 63.6 t-105 -70.13 -41.8 73.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.928 . . . . 0.0 109.96 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.9 -23.35 65.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.47 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.7 t80 -77.53 -47.14 20.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.33 -0.856 . . . . 0.0 110.043 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.884 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -68.69 -21.5 64.42 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.292 -0.88 . . . . 0.0 109.709 179.885 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.54 HG23 ' O ' ' A' ' 14' ' ' TRP . 55.6 t -82.6 -53.62 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -0.844 . . . . 0.0 110.207 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.47 -35.56 76.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.315 -0.866 . . . . 0.0 110.078 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 0.2 OUTLIER -72.1 -46.6 56.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.938 . . . . 0.0 110.171 179.935 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.2 t -66.95 -21.3 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.961 . . . . 0.0 109.902 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.16 -29.32 60.62 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.1 -22.98 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -1.078 . . . . 0.0 110.08 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.86 -35.98 75.15 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 110.207 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.51 -5.2 43.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 110.095 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.8 t -99.39 -13.54 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.207 -0.933 . . . . 0.0 110.223 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.1 t -110.18 -25.74 10.01 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.205 -0.934 . . . . 0.0 110.239 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -92.64 44.08 1.15 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.251 -0.906 . . . . 0.0 110.091 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -90.34 2.27 55.72 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.301 -0.875 . . . . 0.0 110.254 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.9 m120 . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.142 179.944 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo . . . . . 0 N--CA 1.496 1.666 0 N-CA-C 110.189 -0.735 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -149.58 41.55 0.87 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.231 -0.918 . . . . 0.0 110.21 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.47 ' O ' ' HB3' ' A' ' 7' ' ' ALA . 58.9 mt -72.82 -64.64 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.214 -0.929 . . . . 0.0 110.132 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -116.77 22.99 12.28 Favored 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 122.152 0.977 . . . . 0.0 110.037 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.742 ' O ' HG22 ' A' ' 5' ' ' ILE . 12.4 mm -96.8 26.51 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 CA-C-O 121.766 0.793 . . . . 0.0 110.167 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.46 -14.02 1.61 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' A' ' 3' ' ' ILE . . . -101.31 30.57 4.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.306 -1.114 . . . . 0.0 110.193 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.8 t -52.59 -177.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.311 -0.868 . . . . 0.0 110.377 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 85.7 t -95.24 -81.32 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.377 -0.827 . . . . 0.0 110.214 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -160.82 70.47 0.23 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.6 -54.57 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.047 1.551 . . . . 0.0 110.4 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -64.16 -51.26 64.68 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 110.146 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 38.5 t -57.48 -39.13 67.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.299 -0.876 . . . . 0.0 110.186 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 48.5 t-105 -64.88 -39.97 94.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.165 -0.959 . . . . 0.0 110.146 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.63 -25.66 64.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.181 -0.949 . . . . 0.0 110.196 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -75.79 -42.77 49.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 0.0 110.045 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.688 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -69.41 -29.85 67.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.321 -0.862 . . . . 0.0 109.827 -179.989 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 32.3 t -77.26 -44.87 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.336 -0.852 . . . . 0.0 110.12 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -61.19 -36.76 80.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 110.1 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.4 mt -67.75 -48.22 67.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 110.044 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.446 ' O ' HG12 ' A' ' 21' ' ' VAL . 64.0 t -77.43 -1.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.263 -0.898 . . . . 0.0 110.034 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.46 -21.51 31.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.17 -37.94 66.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.22 -1.165 . . . . 0.0 110.068 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 -7.05 58.4 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -78.3 -17.27 56.83 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.419 -0.8 . . . . 0.0 110.183 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.6 t -87.49 -16.29 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.371 -0.83 . . . . 0.0 110.031 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.88 -11.24 42.46 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.311 -0.868 . . . . 0.0 110.102 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.03 -31.33 18.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.256 -0.903 . . . . 0.0 110.152 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -108.67 177.03 4.9 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.265 -0.897 . . . . 0.0 110.157 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.207 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.607 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 46.2 Cg_endo . . . . . 0 N--CA 1.496 1.635 0 N-CA-C 110.333 -0.679 . . . . 0.0 110.333 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.607 ' HB2' ' O ' ' A' ' 1' ' ' PRO . . . 174.89 40.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 110.279 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.404 HD13 HG21 ' A' ' 3' ' ' ILE . 46.7 mt -93.55 -73.3 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.182 -0.949 . . . . 0.0 110.147 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -116.78 22.76 12.44 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.104 -0.997 . . . . 0.0 109.987 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.734 ' O ' HG22 ' A' ' 5' ' ' ILE . 16.8 mm -94.98 26.9 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.108 0 CA-C-O 121.783 0.801 . . . . 0.0 110.107 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.696 ' O ' ' HB3' ' A' ' 7' ' ' ALA . . . 123.25 -19.68 7.63 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.696 ' HB3' ' O ' ' A' ' 6' ' ' GLY . . . 67.73 33.09 5.06 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.188 -1.184 . . . . 0.0 110.119 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.49 174.92 10.98 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.88 . . . . 0.0 110.378 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 69.2 t -99.57 -22.46 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.346 -0.846 . . . . 0.0 110.166 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 107.17 67.59 0.65 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.03 -52.47 0.23 Allowed 'Trans proline' 0 C--N 1.307 -1.605 0 O-C-N 124.019 1.536 . . . . 0.0 110.394 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 p -65.71 -56.97 9.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.936 . . . . 0.0 110.132 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 67.0 t -49.32 -46.71 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.27 -0.894 . . . . 0.0 110.021 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.46 ' O ' HG23 ' A' ' 18' ' ' VAL . 48.7 t-105 -56.02 -52.55 63.83 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 109.991 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.47 -22.65 55.5 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 109.878 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.418 ' O ' HD12 ' A' ' 20' ' ' LEU . 0.6 OUTLIER -70.75 -46.91 62.11 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.368 -0.833 . . . . 0.0 110.021 179.844 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.671 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -65.43 -29.47 70.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.893 179.944 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 14' ' ' TRP . 47.9 t -74.11 -63.41 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.89 . . . . 0.0 110.149 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.51 -23.27 9.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 110.36 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.418 HD12 ' O ' ' A' ' 16' ' ' TYR . 10.5 mt -75.51 -46.06 34.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.144 -0.972 . . . . 0.0 110.187 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 17' ' ' LEU . 92.9 t -67.8 -11.26 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.311 -0.868 . . . . 0.0 110.138 179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.38 -26.52 27.76 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.88 -22.03 61.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 110.232 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.53 -24.54 17.22 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 110.136 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -76.37 -10.8 59.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.218 -0.926 . . . . 0.0 110.277 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.502 ' O ' HG12 ' A' ' 26' ' ' VAL . 54.2 t -97.99 -1.85 10.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.256 -0.902 . . . . 0.0 110.319 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 25.2 m -106.87 -31.06 8.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.093 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.96 40.23 1.04 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.29 -0.881 . . . . 0.0 110.173 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.83 95.14 8.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.329 -0.857 . . . . 0.0 110.145 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.202 179.983 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 N--CA 1.496 1.64 0 N-CA-C 110.129 -0.758 . . . . 0.0 110.129 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -135.88 69.49 1.43 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.196 -0.94 . . . . 0.0 110.299 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.434 HG22 ' N ' ' A' ' 4' ' ' TYR . 82.0 mt -58.24 -93.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.229 -0.92 . . . . 0.0 110.014 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.434 ' N ' HG22 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -108.46 23.92 13.8 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.15 0.976 . . . . 0.0 109.768 179.763 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.728 ' O ' HG22 ' A' ' 5' ' ' ILE . 18.4 mm -91.73 26.12 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 CA-C-O 121.805 0.812 . . . . 0.0 110.115 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -122.24 -12.03 5.42 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.403 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -92.8 26.5 2.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.266 -1.137 . . . . 0.0 110.229 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 7' ' ' ALA . 1.0 OUTLIER -45.22 150.47 0.42 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 109.985 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.2 t -83.04 -66.8 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.122 -0.986 . . . . 0.0 110.246 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -158.13 93.42 0.13 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.431 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 44.9 Cg_endo -72.97 -54.58 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.951 1.501 . . . . 0.0 110.22 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -58.53 -58.86 6.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.268 -0.895 . . . . 0.0 110.01 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 t -47.88 -41.39 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.874 . . . . 0.0 110.108 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.765 ' O ' HG23 ' A' ' 18' ' ' VAL . 32.9 t-105 -57.08 -53.34 59.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.252 -0.905 . . . . 0.0 110.03 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.87 -22.55 65.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 110.293 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.412 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.4 t80 -75.27 -36.2 61.26 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.285 -0.885 . . . . 0.0 110.197 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.893 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -81.55 -28.53 33.85 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.165 -0.959 . . . . 0.0 109.805 179.964 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 14' ' ' TRP . 38.1 t -74.68 -32.48 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.37 -0.831 . . . . 0.0 109.979 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.1 -32.22 26.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.985 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.501 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.4 mt -68.4 -39.81 81.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.852 . . . . 0.0 110.159 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.5 t -64.58 -49.25 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.736 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -48.2 -40.54 21.84 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.72 -45.99 58.83 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -1.135 . . . . 0.0 110.176 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -66.0 -40.72 91.38 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.235 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.97 -8.01 40.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.169 -0.957 . . . . 0.0 110.205 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 22' ' ' GLY . 99.4 t -96.6 0.28 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.299 -0.876 . . . . 0.0 110.248 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 m -105.18 -26.07 12.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.217 -0.927 . . . . 0.0 110.258 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.97 -28.6 65.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.31 -0.869 . . . . 0.0 110.237 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 177.74 8.0 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.191 -0.943 . . . . 0.0 110.151 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.251 -179.988 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.443 ' HG2' HD12 ' A' ' 5' ' ' ILE . 47.4 Cg_endo . . . . . 0 N--CA 1.496 1.668 0 N-CA-C 110.15 -0.75 . . . . 0.0 110.15 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.3 42.69 0.28 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.169 -0.957 . . . . 0.0 110.128 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.439 ' HA ' HD13 ' A' ' 3' ' ' ILE . 21.2 mm -92.17 -64.41 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -0.9 . . . . 0.0 110.39 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -130.54 23.46 5.09 Favored 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 122.049 0.928 . . . . 0.0 110.267 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.661 ' O ' HG22 ' A' ' 5' ' ' ILE . 9.9 mt -110.76 26.17 2.99 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-O 121.896 0.855 . . . . 0.0 110.162 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 165.72 36.9 0.02 OUTLIER Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -161.6 23.19 0.12 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -1.142 . . . . 0.0 109.983 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 t -140.15 -176.06 4.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.341 -0.849 . . . . 0.0 110.293 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.5 t -65.51 -25.61 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.226 -0.921 . . . . 0.0 110.171 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.82 65.63 1.34 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -73.67 -42.43 0.85 Allowed 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 124.098 1.578 . . . . 0.0 110.388 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -69.42 -59.29 3.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.323 -0.861 . . . . 0.0 110.168 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.1 t -53.26 -30.12 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.85 . . . . 0.0 110.076 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 36.0 t-105 -64.8 -38.35 90.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 110.035 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.42 -29.06 65.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 110.111 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -73.12 -34.62 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.79 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -77.24 -30.89 54.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.249 -0.907 . . . . 0.0 109.728 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -42.06 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.345 -0.847 . . . . 0.0 109.967 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.43 -49.67 68.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.28 -0.887 . . . . 0.0 109.854 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.482 HD23 ' HA ' ' A' ' 20' ' ' LEU . 2.1 mt -60.05 -54.93 40.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.907 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.6 t -63.6 -19.11 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.391 -0.818 . . . . 0.0 110.047 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.64 -30.48 36.0 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -75.73 -33.23 60.27 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.358 -1.084 . . . . 0.0 110.199 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.402 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -84.93 -13.11 51.8 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.191 -0.943 . . . . 0.0 110.254 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.15 -3.87 32.32 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 110.141 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.414 ' O ' HG12 ' A' ' 26' ' ' VAL . 41.3 t -107.45 -7.7 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 110.243 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.402 HG22 ' HA ' ' A' ' 24' ' ' ALA . 11.0 t -113.47 -20.86 11.13 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.288 -0.882 . . . . 0.0 110.144 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.11 -11.94 54.04 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.226 -0.921 . . . . 0.0 110.205 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.44 ' O ' ' OXT' ' A' ' 30' ' ' ASN . . . -100.54 -25.9 14.02 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.182 -0.949 . . . . 0.0 110.287 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.44 ' OXT' ' O ' ' A' ' 29' ' ' ALA . 8.4 m-80 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.304 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo . . . . . 0 N--CA 1.496 1.648 0 N-CA-C 110.167 -0.743 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.489 ' HA ' HG13 ' A' ' 5' ' ' ILE . . . -136.92 44.47 2.32 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.262 -0.899 . . . . 0.0 110.08 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.3 mt -67.45 -39.24 82.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.248 -0.908 . . . . 0.0 110.314 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -111.96 22.12 15.21 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 122.013 0.911 . . . . 0.0 110.115 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.672 ' O ' HG22 ' A' ' 5' ' ' ILE . 14.6 mm -104.28 27.11 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 CA-C-O 121.788 0.804 . . . . 0.0 110.347 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -124.41 22.52 6.59 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -131.7 29.44 4.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -1.165 . . . . 0.0 110.02 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.83 ' O ' HG21 ' A' ' 13' ' ' VAL . 3.7 m -98.83 170.17 8.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.347 -0.845 . . . . 0.0 110.419 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.692 ' HA ' HG11 ' A' ' 13' ' ' VAL . 43.6 t -138.3 27.11 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.356 -0.84 . . . . 0.0 109.944 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.9 -143.67 0.03 OUTLIER Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.5 -52.42 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.095 1.577 . . . . 0.0 110.426 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -48.52 -43.34 35.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.265 -0.897 . . . . 0.0 110.272 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.83 HG21 ' O ' ' A' ' 8' ' ' THR . 75.8 t -63.17 -37.53 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.225 -0.922 . . . . 0.0 110.174 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 28.3 t-105 -65.13 -42.52 93.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.4 -0.813 . . . . 0.0 110.092 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.74 -27.11 66.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.267 -0.896 . . . . 0.0 110.228 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -76.14 -30.55 58.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.942 . . . . 0.0 110.168 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.764 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -80.98 -29.47 35.28 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.952 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.1 t -79.03 -38.5 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.369 -0.832 . . . . 0.0 109.899 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.59 -49.72 44.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 109.985 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 13.7 mt -59.31 -50.72 72.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 110.224 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.3 t -73.4 -17.51 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.286 -0.884 . . . . 0.0 110.174 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.733 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -77.37 -25.82 62.74 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -76.42 -39.91 52.23 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -1.12 . . . . 0.0 110.154 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -78.93 -28.97 43.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.353 -0.842 . . . . 0.0 110.168 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -69.73 -13.45 62.29 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.323 -0.861 . . . . 0.0 110.177 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 22' ' ' GLY . 71.2 t -77.68 -15.68 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.255 -0.903 . . . . 0.0 110.161 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 86.2 m -108.25 -46.79 3.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 0.0 110.182 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.01 69.9 10.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 110.233 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -105.61 18.65 21.86 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.197 -0.94 . . . . 0.0 110.254 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 118.063 -0.97 . . . . 0.0 110.228 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo . . . . . 0 N--CA 1.498 1.761 0 N-CA-C 110.175 -0.74 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.93 45.61 2.13 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.281 -0.887 . . . . 0.0 110.157 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.412 HG23 HD12 ' A' ' 3' ' ' ILE . 46.3 mm -89.58 -80.15 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.149 -0.969 . . . . 0.0 110.11 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -131.98 24.94 4.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.133 -0.979 . . . . 0.0 110.041 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.712 ' O ' HG22 ' A' ' 5' ' ' ILE . 25.4 mm -91.83 26.87 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.107 0 CA-C-O 121.85 0.833 . . . . 0.0 110.376 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -137.63 13.0 3.7 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.693 ' O ' HG22 ' A' ' 8' ' ' THR . . . -149.09 27.79 0.84 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.199 -1.177 . . . . 0.0 110.386 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.693 HG22 ' O ' ' A' ' 7' ' ' ALA . 6.6 t 39.0 -160.93 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.566 -0.709 . . . . 0.0 110.528 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.5 t -127.54 -32.4 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.179 -0.951 . . . . 0.0 110.267 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.93 82.11 1.35 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.12 -60.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.001 1.527 . . . . 0.0 110.653 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -58.8 -47.2 85.59 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 110.327 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.76 -40.24 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 110.222 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.609 ' O ' HG23 ' A' ' 18' ' ' VAL . 36.8 t-105 -64.75 -42.42 95.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 110.158 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.48 -29.64 70.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 110.24 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -74.72 -56.74 4.48 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.264 -0.898 . . . . 0.0 110.104 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.674 HD12 ' O ' ' A' ' 17' ' ' LEU . 0.1 OUTLIER -58.42 -22.3 53.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.198 -0.939 . . . . 0.0 109.954 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.609 HG23 ' O ' ' A' ' 14' ' ' TRP . 55.9 t -83.22 -42.77 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.287 -0.883 . . . . 0.0 110.27 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.95 -23.57 67.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.338 -0.851 . . . . 0.0 110.262 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.88 -61.28 1.75 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.263 -0.898 . . . . 0.0 110.258 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.4 t -54.01 -30.07 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -0.967 . . . . 0.0 110.181 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.11 -44.34 67.29 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.09 -28.09 69.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -1.125 . . . . 0.0 110.194 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.454 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -85.82 -19.22 31.0 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.267 -0.896 . . . . 0.0 110.19 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.99 -9.53 59.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.221 -0.924 . . . . 0.0 110.149 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.433 ' O ' HG12 ' A' ' 26' ' ' VAL . 50.9 t -105.83 -6.63 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.93 . . . . 0.0 110.253 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.454 HG22 ' HA ' ' A' ' 24' ' ' ALA . 14.6 t -116.52 -18.15 10.45 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.269 -0.895 . . . . 0.0 110.194 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.73 -20.64 62.62 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.228 -0.92 . . . . 0.0 110.195 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -80.74 -7.91 59.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.136 -0.978 . . . . 0.0 110.134 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 27.0 m120 . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.276 -179.98 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.425 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 46.2 Cg_endo -73.38 -44.74 0.5 Allowed 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 124.021 1.537 . . . . 0.0 110.419 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 13' ' ' VAL . 1.9 p -64.8 -71.24 0.19 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.236 -0.915 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.417 ' C ' ' O ' ' A' ' 12' ' ' SER . 65.2 t -42.64 -30.96 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.325 -0.859 . . . . 0.0 110.142 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.425 ' HB3' ' O ' ' A' ' 11' ' ' PRO . 46.4 t-105 -64.78 -56.7 11.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.181 -0.95 . . . . 0.0 110.106 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.34 -28.55 43.52 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.211 -0.93 . . . . 0.0 109.904 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -69.45 -47.33 64.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.922 . . . . 0.0 109.842 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.753 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -65.73 -21.68 66.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.688 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -78.23 -51.47 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 109.952 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.69 -39.98 82.27 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.311 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -66.76 -52.91 38.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.27 -0.894 . . . . 0.0 110.28 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 17' ' ' LEU . 81.9 t -60.91 -21.47 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 110.34 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.665 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -72.34 -53.59 8.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -53.75 -40.25 66.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.197 -1.178 . . . . 0.0 110.241 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.69 -33.47 72.58 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.34 -17.24 60.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.313 -0.867 . . . . 0.0 110.167 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.665 HG23 ' O ' ' A' ' 22' ' ' GLY . 23.8 t -98.48 -14.4 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.305 -0.872 . . . . 0.0 110.179 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 110.125 179.925 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.83 -59.3 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.93 1.489 . . . . 0.0 110.608 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 88.3 p -62.98 -49.28 75.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 110.251 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.2 t -51.97 -42.23 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.192 -0.943 . . . . 0.0 110.095 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.508 ' O ' HG23 ' A' ' 18' ' ' VAL . 27.5 t-105 -66.7 -32.55 73.93 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 110.122 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.64 -33.61 71.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.284 -0.885 . . . . 0.0 110.234 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -76.4 -30.11 57.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.259 -0.901 . . . . 0.0 110.307 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.709 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.24 -29.82 57.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.162 -0.961 . . . . 0.0 109.67 179.917 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 14' ' ' TRP . 69.0 t -79.57 -45.97 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.454 -0.778 . . . . 0.0 110.081 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.17 -48.58 81.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.327 -0.858 . . . . 0.0 110.126 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.448 ' HA ' HD23 ' A' ' 20' ' ' LEU . 43.0 mt -62.08 -49.37 76.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.258 -0.901 . . . . 0.0 110.262 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 21' ' ' VAL . 53.0 t -73.29 -8.24 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 110.391 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.51 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -86.72 -33.24 13.33 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.64 -37.3 70.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -1.208 . . . . 0.0 110.427 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.46 -16.86 47.32 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.224 -0.923 . . . . 0.0 110.462 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.66 4.43 24.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.229 -0.92 . . . . 0.0 110.406 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 22' ' ' GLY . 96.1 t -100.26 -15.92 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.12 -0.987 . . . . 0.0 110.253 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 110.293 179.983 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -75.82 -52.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 124.017 1.535 . . . . 0.0 110.435 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -61.92 -58.07 9.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.328 -0.857 . . . . 0.0 110.32 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 77.2 t -46.48 -34.37 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.905 . . . . 0.0 110.35 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.629 ' O ' HG23 ' A' ' 18' ' ' VAL . 23.2 t-105 -68.5 -58.4 4.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.19 -0.944 . . . . 0.0 110.229 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.67 -23.44 28.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.904 . . . . 0.0 110.376 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.33 -41.57 33.19 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 0.0 110.311 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.901 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -70.61 -25.87 63.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.915 . . . . 0.0 109.693 179.903 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 14' ' ' TRP . 21.4 t -83.35 -37.05 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 110.088 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.04 -22.66 60.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.992 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 mt -87.9 -53.48 4.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.385 -0.822 . . . . 0.0 110.279 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.1 t -62.07 -16.77 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.309 -0.87 . . . . 0.0 110.362 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.52 -29.78 63.24 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.31 -20.53 63.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.255 -1.144 . . . . 0.0 110.249 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.602 ' O ' HG22 ' A' ' 27' ' ' THR . . . -87.33 -17.94 31.25 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.887 . . . . 0.0 110.171 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.3 -1.05 21.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.216 -0.927 . . . . 0.0 110.194 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.63 -11.54 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.297 -0.877 . . . . 0.0 110.172 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.602 HG22 ' O ' ' A' ' 24' ' ' ALA . 8.9 t . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.327 -0.858 . . . . 0.0 110.327 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.479 ' O ' ' HB3' ' A' ' 14' ' ' TRP . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.349 -1.501 . . . . 0.0 109.349 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.41 -52.76 0.14 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 124.023 1.538 . . . . 0.0 110.571 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.52 -48.6 60.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.231 -0.918 . . . . 0.0 110.515 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.561 ' CG1' ' N ' ' A' ' 14' ' ' TRP . 2.9 p -59.64 -45.41 94.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.159 -0.963 . . . . 0.0 110.38 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.704 ' O ' HG23 ' A' ' 18' ' ' VAL . 49.3 t-105 -63.17 -36.88 85.09 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.116 -0.99 . . . . 0.0 110.013 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.48 -23.48 63.64 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.332 -0.855 . . . . 0.0 110.089 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.558 ' HD1' HD12 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -78.13 -36.57 47.66 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.228 -0.92 . . . . 0.0 110.185 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.965 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.06 -26.1 56.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.209 -0.932 . . . . 0.0 109.583 179.802 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.704 HG23 ' O ' ' A' ' 14' ' ' TRP . 61.0 t -81.52 -39.1 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.452 -0.78 . . . . 0.0 110.212 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.9 -38.15 67.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.225 -0.922 . . . . 0.0 110.139 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.558 HD12 ' HD1' ' A' ' 16' ' ' TYR . 1.2 mt -72.24 -39.18 68.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.935 . . . . 0.0 110.173 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.6 t -88.28 -4.77 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.307 -0.871 . . . . 0.0 110.195 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.26 -19.94 31.61 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -78.53 -29.78 46.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.226 -1.161 . . . . 0.0 110.244 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.45 ' O ' HG22 ' A' ' 27' ' ' THR . . . -81.54 -19.92 41.06 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.251 -0.906 . . . . 0.0 110.214 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.36 -15.8 60.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.284 -0.885 . . . . 0.0 110.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.5 t -83.7 -13.95 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 110.109 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.45 HG22 ' O ' ' A' ' 24' ' ' ALA . 10.1 t . . . . . 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 110.058 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.424 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.41 -41.72 3.25 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 O-C-N 124.013 1.533 . . . . 0.0 110.461 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 t -68.72 -56.08 9.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 110.137 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.72 -29.11 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.339 -0.851 . . . . 0.0 110.138 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.808 ' O ' HG23 ' A' ' 18' ' ' VAL . 44.0 t-105 -64.12 -42.5 96.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.253 -0.904 . . . . 0.0 110.142 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.82 -25.41 66.43 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.182 -0.949 . . . . 0.0 110.103 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -73.95 -42.52 60.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 110.193 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.859 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.15 -27.88 59.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.641 179.863 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.808 HG23 ' O ' ' A' ' 14' ' ' TRP . 68.9 t -76.64 -36.3 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.284 -0.885 . . . . 0.0 109.999 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.69 -32.49 63.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 110.014 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.1 mt -70.09 -51.21 33.57 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.294 -0.878 . . . . 0.0 110.225 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 49.0 t -64.32 -47.1 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -0.915 . . . . 0.0 110.258 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.52 -45.35 67.23 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.52 -22.39 60.12 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.286 -1.126 . . . . 0.0 110.205 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.13 -14.68 53.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.301 -0.874 . . . . 0.0 110.254 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.05 -12.34 58.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.924 . . . . 0.0 110.307 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.9 t -89.29 -13.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -0.9 . . . . 0.0 110.157 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 99.6 m . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.184 -0.947 . . . . 0.0 110.164 179.851 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.98 -47.7 0.31 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.944 1.497 . . . . 0.0 110.397 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 0.3 OUTLIER -67.05 -60.68 2.42 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -0.915 . . . . 0.0 110.191 -179.988 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.413 ' C ' ' O ' ' A' ' 12' ' ' SER . 54.3 t -43.21 -47.81 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 110.122 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.604 ' O ' HG23 ' A' ' 18' ' ' VAL . 21.4 t-105 -55.83 -56.2 23.45 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.927 . . . . 0.0 109.912 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -53.93 -23.92 14.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -0.938 . . . . 0.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -75.0 -38.61 61.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.2 -0.937 . . . . 0.0 110.351 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.883 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -73.89 -25.6 60.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.835 179.939 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.604 HG23 ' O ' ' A' ' 14' ' ' TRP . 5.9 t -86.24 -28.33 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.319 -0.863 . . . . 0.0 110.097 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.56 -35.93 60.52 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.261 -0.899 . . . . 0.0 110.054 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.9 mt -83.15 -40.07 20.23 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.283 -0.886 . . . . 0.0 110.177 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 90.7 t -79.25 -17.6 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.224 -0.923 . . . . 0.0 110.196 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.53 -30.18 64.74 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.57 -26.6 68.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.152 . . . . 0.0 110.201 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.734 ' O ' HG22 ' A' ' 27' ' ' THR . . . -66.01 -40.3 90.99 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.204 -0.935 . . . . 0.0 110.203 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.4 -11.89 60.62 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 110.25 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.1 t -84.95 -17.37 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.175 -0.953 . . . . 0.0 110.241 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.734 HG22 ' O ' ' A' ' 24' ' ' ALA . 11.7 t . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 110.097 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.2 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.93 -47.57 0.44 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.989 1.521 . . . . 0.0 110.295 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 m -61.47 -55.69 28.44 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.904 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 t -54.04 -37.57 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 109.87 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.441 ' O ' HG23 ' A' ' 18' ' ' VAL . 46.4 t-105 -59.07 -52.18 66.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.215 -0.928 . . . . 0.0 109.922 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.2 -19.73 65.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.757 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -75.8 -40.25 55.4 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 110.095 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.919 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.7 -29.64 56.36 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.596 179.811 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 14' ' ' TRP . 95.3 t -75.36 -29.65 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.393 -0.817 . . . . 0.0 109.87 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -77.05 -40.16 47.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.912 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.3 -36.4 81.44 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 110.042 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 17' ' ' LEU . 84.8 t -77.51 -35.3 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.16 -0.963 . . . . 0.0 110.223 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.13 -12.32 68.49 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.43 -28.83 37.66 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -1.153 . . . . 0.0 110.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.99 -22.98 31.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.2 -0.938 . . . . 0.0 110.307 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.88 -0.91 17.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -0.889 . . . . 0.0 110.236 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.481 ' O ' HG12 ' A' ' 26' ' ' VAL . 41.6 t -99.62 -2.34 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.267 -0.896 . . . . 0.0 110.113 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.151 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.37 -42.69 0.85 Allowed 'Trans proline' 0 C--N 1.305 -1.728 0 O-C-N 123.992 1.522 . . . . 0.0 110.234 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.0 m -67.51 -55.62 12.79 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.22 -0.925 . . . . 0.0 110.186 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.446 HG23 ' H ' ' A' ' 13' ' ' VAL . 17.7 t -53.99 -45.02 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.971 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.636 ' O ' HG23 ' A' ' 18' ' ' VAL . 26.5 t-105 -58.33 -47.17 84.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.802 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.07 -23.73 21.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.323 -0.861 . . . . 0.0 109.979 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.475 ' CD1' HD12 ' A' ' 20' ' ' LEU . 0.2 OUTLIER -76.83 -51.17 11.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 110.006 179.916 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.735 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -59.53 -22.86 62.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.757 179.904 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.636 HG23 ' O ' ' A' ' 14' ' ' TRP . 33.9 t -85.36 -44.12 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -0.905 . . . . 0.0 110.078 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.72 -24.73 67.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.333 -0.854 . . . . 0.0 110.084 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.475 HD12 ' CD1' ' A' ' 16' ' ' TYR . 0.9 OUTLIER -88.02 -39.29 14.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.23 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -72.12 -21.44 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.232 -0.918 . . . . 0.0 110.158 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.5 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -81.06 -18.32 69.89 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.61 -18.45 60.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -1.168 . . . . 0.0 110.22 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -88.75 -29.27 19.92 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.929 . . . . 0.0 110.31 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.61 -4.13 32.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.206 -0.934 . . . . 0.0 110.213 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 22' ' ' GLY . 47.4 t -84.43 -20.17 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.249 -0.907 . . . . 0.0 110.22 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 110.161 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.523 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.523 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 44.3 Cg_endo -72.65 -58.66 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.025 1.539 . . . . 0.0 110.63 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.415 ' O ' ' C ' ' A' ' 13' ' ' VAL . 5.4 t -55.71 -63.68 1.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -0.918 . . . . 0.0 110.195 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.415 ' C ' ' O ' ' A' ' 12' ' ' SER . 60.6 t -42.88 -51.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.344 -0.847 . . . . 0.0 110.245 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.47 ' O ' HG23 ' A' ' 18' ' ' VAL . 40.9 t-105 -48.43 -47.13 38.19 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.232 -0.918 . . . . 0.0 110.276 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.52 -34.77 74.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.262 -0.899 . . . . 0.0 110.424 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.8 t80 -67.14 -48.35 68.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.235 -0.915 . . . . 0.0 110.417 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.755 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -64.96 -24.26 67.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.114 -0.991 . . . . 0.0 109.982 -179.901 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 14' ' ' TRP . 29.9 t -73.52 -62.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.337 -0.852 . . . . 0.0 110.248 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.55 -28.96 34.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.27 -0.894 . . . . 0.0 110.213 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.0 mt -67.87 -49.52 61.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 110.217 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.5 t -55.56 -48.48 77.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.216 -0.927 . . . . 0.0 110.204 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.486 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -62.73 -32.93 85.29 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.04 -30.12 70.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.185 -1.185 . . . . 0.0 110.39 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.46 -34.89 18.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 110.265 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.92 -13.17 14.11 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.208 -0.932 . . . . 0.0 110.25 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 22' ' ' GLY . 65.6 t -93.77 -23.59 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 110.26 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 m . . . . . 0 N--CA 1.492 1.64 0 O-C-N 121.257 -0.902 . . . . 0.0 109.962 179.822 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.46 -40.24 1.65 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.963 1.507 . . . . 0.0 110.24 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.6 t -73.37 -59.19 2.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.434 -0.791 . . . . 0.0 110.302 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 53.1 t -53.36 -40.42 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.256 -0.903 . . . . 0.0 110.317 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.642 ' O ' HG23 ' A' ' 18' ' ' VAL . 36.2 t-105 -58.65 -36.95 74.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.353 -0.842 . . . . 0.0 110.119 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.88 -32.41 69.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.931 . . . . 0.0 110.257 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -70.74 -41.02 72.38 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.136 -0.978 . . . . 0.0 110.064 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.776 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -72.43 -30.64 64.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.213 -0.93 . . . . 0.0 109.469 179.708 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 14' ' ' TRP . 72.9 t -77.92 -27.78 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.435 -0.79 . . . . 0.0 109.891 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.72 -45.13 38.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 110.138 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -66.1 -52.12 51.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.866 . . . . 0.0 110.211 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 45.5 t -69.21 -12.28 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 110.262 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.18 -41.45 31.52 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.74 -33.57 68.61 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.25 -1.147 . . . . 0.0 110.149 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.433 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -87.22 -23.87 24.61 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.268 -0.895 . . . . 0.0 110.275 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.5 -1.46 30.56 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.931 . . . . 0.0 110.192 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.412 ' O ' HG12 ' A' ' 26' ' ' VAL . 86.4 t -113.66 -6.83 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.231 -0.918 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.433 HG22 ' HA ' ' A' ' 24' ' ' ALA . 13.8 t . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.131 -0.981 . . . . 0.0 110.193 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.1 -48.05 0.29 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.045 1.55 . . . . 0.0 110.373 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.51 -59.37 2.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.327 -0.858 . . . . 0.0 110.127 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.5 t -48.22 -29.49 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 110.161 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.0 t-105 -73.64 -59.47 2.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 110.158 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -57.76 -16.42 11.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.263 -0.898 . . . . 0.0 109.947 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.428 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.3 t80 -82.38 -42.3 18.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 110.104 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.919 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.2 -23.0 57.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.34 -0.85 . . . . 0.0 109.676 179.861 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -79.31 -56.69 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.48 -0.762 . . . . 0.0 109.941 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.76 -33.93 70.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.319 -0.863 . . . . 0.0 110.062 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.519 HD23 ' HA ' ' A' ' 20' ' ' LEU . 7.3 mt -67.86 -47.71 68.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.101 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 26.4 t -64.05 -16.28 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 110.175 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.29 -53.08 9.33 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -19.81 62.09 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -1.151 . . . . 0.0 110.209 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.59 ' O ' HG22 ' A' ' 27' ' ' THR . . . -83.62 -9.06 59.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.908 . . . . 0.0 110.134 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.29 3.85 26.01 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.36 -0.838 . . . . 0.0 110.122 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 20.8 t -101.58 -16.59 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 110.084 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.59 HG22 ' O ' ' A' ' 24' ' ' ALA . 15.1 t . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.477 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.477 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 46.1 Cg_endo -73.25 -47.5 0.3 Allowed 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 123.973 1.512 . . . . 0.0 110.337 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 4.4 m -62.45 -66.93 0.47 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 110.086 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.426 ' H ' HG23 ' A' ' 13' ' ' VAL . 21.8 t -44.03 -39.09 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 109.984 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.43 ' HB3' ' O ' ' A' ' 11' ' ' PRO . 30.6 t-105 -56.35 -52.22 65.37 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -56.83 -25.62 56.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.167 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 7.3 t80 -74.56 -34.22 62.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 110.198 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.644 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -73.03 -34.61 66.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.335 -0.853 . . . . 0.0 109.734 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.62 -35.26 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.408 -0.807 . . . . 0.0 110.082 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.04 -47.37 74.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.956 . . . . 0.0 110.119 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 17.1 mt -62.37 -54.82 34.8 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.277 -0.89 . . . . 0.0 110.085 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -64.71 -15.11 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 110.154 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.427 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -74.31 -36.74 49.53 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.27 -29.67 61.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 110.153 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.57 -34.07 73.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 110.233 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.67 -17.76 61.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.244 -0.91 . . . . 0.0 110.035 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 22' ' ' GLY . 39.8 t -83.34 -6.73 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.378 -0.826 . . . . 0.0 109.959 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 110.057 179.874 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.99 -42.01 1.16 Allowed 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.974 1.512 . . . . 0.0 110.467 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.5 m -61.73 -61.75 2.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.905 . . . . 0.0 110.212 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.7 t -46.22 -39.13 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.28 -0.887 . . . . 0.0 110.256 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 34.5 t-105 -63.09 -51.41 66.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.339 -0.851 . . . . 0.0 110.329 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.72 -26.99 67.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.122 -0.986 . . . . 0.0 110.254 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -69.91 -47.75 61.24 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.02 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.799 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -67.2 -30.22 70.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.204 -0.935 . . . . 0.0 109.742 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.2 t -79.11 -27.07 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.447 -0.783 . . . . 0.0 110.107 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.98 -42.44 60.44 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.309 -0.87 . . . . 0.0 110.141 179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.2 mt -71.29 -48.03 53.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.174 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.0 t -71.77 -21.6 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 110.079 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -23.07 78.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.58 -29.67 41.31 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.16 -1.2 . . . . 0.0 110.15 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.32 -20.94 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 110.176 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.24 -17.02 64.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 110.15 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 77.6 t -85.71 -19.24 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 110.097 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.4 ' O ' HG22 ' A' ' 27' ' ' THR . 67.1 m . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.353 -0.842 . . . . 0.0 110.033 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.491 ' O ' ' HB2' ' A' ' 14' ' ' TRP . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.57 -47.56 0.14 Allowed 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.002 1.527 . . . . 0.0 110.457 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 p -70.39 -63.22 1.13 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.296 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 91.2 t -47.8 -32.36 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 110.166 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.54 ' O ' HG23 ' A' ' 18' ' ' VAL . 63.6 t-105 -70.13 -41.8 73.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.928 . . . . 0.0 109.96 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.9 -23.35 65.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.47 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.7 t80 -77.53 -47.14 20.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.33 -0.856 . . . . 0.0 110.043 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.884 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -68.69 -21.5 64.42 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.292 -0.88 . . . . 0.0 109.709 179.885 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.54 HG23 ' O ' ' A' ' 14' ' ' TRP . 55.6 t -82.6 -53.62 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -0.844 . . . . 0.0 110.207 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.47 -35.56 76.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.315 -0.866 . . . . 0.0 110.078 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 0.2 OUTLIER -72.1 -46.6 56.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.938 . . . . 0.0 110.171 179.935 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.2 t -66.95 -21.3 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.961 . . . . 0.0 109.902 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.16 -29.32 60.62 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.1 -22.98 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -1.078 . . . . 0.0 110.08 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.86 -35.98 75.15 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 110.207 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.51 -5.2 43.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 110.095 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.8 t -99.39 -13.54 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.207 -0.933 . . . . 0.0 110.223 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.1 t . . . . . 0 N--CA 1.492 1.63 0 O-C-N 121.205 -0.934 . . . . 0.0 110.239 -179.983 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.355 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.6 -54.57 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.047 1.551 . . . . 0.0 110.4 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -64.16 -51.26 64.68 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 110.146 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 38.5 t -57.48 -39.13 67.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.299 -0.876 . . . . 0.0 110.186 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 48.5 t-105 -64.88 -39.97 94.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.165 -0.959 . . . . 0.0 110.146 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.63 -25.66 64.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.181 -0.949 . . . . 0.0 110.196 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -75.79 -42.77 49.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 0.0 110.045 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.688 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -69.41 -29.85 67.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.321 -0.862 . . . . 0.0 109.827 -179.989 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 32.3 t -77.26 -44.87 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.336 -0.852 . . . . 0.0 110.12 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -61.19 -36.76 80.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 110.1 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.4 mt -67.75 -48.22 67.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 110.044 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.446 ' O ' HG12 ' A' ' 21' ' ' VAL . 64.0 t -77.43 -1.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.263 -0.898 . . . . 0.0 110.034 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.46 -21.51 31.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.17 -37.94 66.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.22 -1.165 . . . . 0.0 110.068 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 -7.05 58.4 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -78.3 -17.27 56.83 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.419 -0.8 . . . . 0.0 110.183 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.6 t -87.49 -16.29 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.371 -0.83 . . . . 0.0 110.031 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.311 -0.868 . . . . 0.0 110.102 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.03 -52.47 0.23 Allowed 'Trans proline' 0 C--N 1.307 -1.605 0 O-C-N 124.019 1.536 . . . . 0.0 110.394 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 p -65.71 -56.97 9.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.936 . . . . 0.0 110.132 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 67.0 t -49.32 -46.71 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.27 -0.894 . . . . 0.0 110.021 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.46 ' O ' HG23 ' A' ' 18' ' ' VAL . 48.7 t-105 -56.02 -52.55 63.83 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 109.991 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.47 -22.65 55.5 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 109.878 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.418 ' O ' HD12 ' A' ' 20' ' ' LEU . 0.6 OUTLIER -70.75 -46.91 62.11 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.368 -0.833 . . . . 0.0 110.021 179.844 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.671 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -65.43 -29.47 70.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.893 179.944 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 14' ' ' TRP . 47.9 t -74.11 -63.41 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.89 . . . . 0.0 110.149 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.51 -23.27 9.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 110.36 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.418 HD12 ' O ' ' A' ' 16' ' ' TYR . 10.5 mt -75.51 -46.06 34.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.144 -0.972 . . . . 0.0 110.187 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 17' ' ' LEU . 92.9 t -67.8 -11.26 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.311 -0.868 . . . . 0.0 110.138 179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.38 -26.52 27.76 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.88 -22.03 61.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 110.232 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.53 -24.54 17.22 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 110.136 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -76.37 -10.8 59.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.218 -0.926 . . . . 0.0 110.277 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.502 ' O ' HG12 ' A' ' 26' ' ' VAL . 54.2 t -97.99 -1.85 10.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.256 -0.902 . . . . 0.0 110.319 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 25.2 m . . . . . 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.093 -179.982 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.431 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 44.9 Cg_endo -72.97 -54.58 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.951 1.501 . . . . 0.0 110.22 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -58.53 -58.86 6.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.268 -0.895 . . . . 0.0 110.01 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 t -47.88 -41.39 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.874 . . . . 0.0 110.108 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.765 ' O ' HG23 ' A' ' 18' ' ' VAL . 32.9 t-105 -57.08 -53.34 59.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.252 -0.905 . . . . 0.0 110.03 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.87 -22.55 65.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 110.293 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.412 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.4 t80 -75.27 -36.2 61.26 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.285 -0.885 . . . . 0.0 110.197 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.893 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -81.55 -28.53 33.85 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.165 -0.959 . . . . 0.0 109.805 179.964 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 14' ' ' TRP . 38.1 t -74.68 -32.48 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.37 -0.831 . . . . 0.0 109.979 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.1 -32.22 26.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.985 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.501 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.4 mt -68.4 -39.81 81.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.852 . . . . 0.0 110.159 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.5 t -64.58 -49.25 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.736 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -48.2 -40.54 21.84 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.72 -45.99 58.83 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -1.135 . . . . 0.0 110.176 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -66.0 -40.72 91.38 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.235 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.97 -8.01 40.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.169 -0.957 . . . . 0.0 110.205 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 22' ' ' GLY . 99.4 t -96.6 0.28 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.299 -0.876 . . . . 0.0 110.248 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.217 -0.927 . . . . 0.0 110.258 -179.962 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -73.67 -42.43 0.85 Allowed 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 124.098 1.578 . . . . 0.0 110.388 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -69.42 -59.29 3.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.323 -0.861 . . . . 0.0 110.168 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.1 t -53.26 -30.12 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.85 . . . . 0.0 110.076 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 36.0 t-105 -64.8 -38.35 90.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 110.035 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.42 -29.06 65.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 110.111 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -73.12 -34.62 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.79 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -77.24 -30.89 54.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.249 -0.907 . . . . 0.0 109.728 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -42.06 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.345 -0.847 . . . . 0.0 109.967 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.43 -49.67 68.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.28 -0.887 . . . . 0.0 109.854 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.482 HD23 ' HA ' ' A' ' 20' ' ' LEU . 2.1 mt -60.05 -54.93 40.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.907 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.6 t -63.6 -19.11 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.391 -0.818 . . . . 0.0 110.047 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.64 -30.48 36.0 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -75.73 -33.23 60.27 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.358 -1.084 . . . . 0.0 110.199 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.402 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -84.93 -13.11 51.8 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.191 -0.943 . . . . 0.0 110.254 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.15 -3.87 32.32 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 110.141 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.414 ' O ' HG12 ' A' ' 26' ' ' VAL . 41.3 t -107.45 -7.7 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 110.243 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.402 HG22 ' HA ' ' A' ' 24' ' ' ALA . 11.0 t . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.288 -0.882 . . . . 0.0 110.144 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.5 -52.42 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.095 1.577 . . . . 0.0 110.426 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -48.52 -43.34 35.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.265 -0.897 . . . . 0.0 110.272 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.17 -37.53 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.225 -0.922 . . . . 0.0 110.174 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 28.3 t-105 -65.13 -42.52 93.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.4 -0.813 . . . . 0.0 110.092 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.74 -27.11 66.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.267 -0.896 . . . . 0.0 110.228 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -76.14 -30.55 58.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.942 . . . . 0.0 110.168 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.764 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -80.98 -29.47 35.28 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.952 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.1 t -79.03 -38.5 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.369 -0.832 . . . . 0.0 109.899 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.59 -49.72 44.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 109.985 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 13.7 mt -59.31 -50.72 72.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 110.224 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.3 t -73.4 -17.51 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.286 -0.884 . . . . 0.0 110.174 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.733 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -77.37 -25.82 62.74 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -76.42 -39.91 52.23 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -1.12 . . . . 0.0 110.154 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -78.93 -28.97 43.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.353 -0.842 . . . . 0.0 110.168 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -69.73 -13.45 62.29 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.323 -0.861 . . . . 0.0 110.177 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 22' ' ' GLY . 71.2 t -77.68 -15.68 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.255 -0.903 . . . . 0.0 110.161 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 86.2 m . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 0.0 110.182 -179.923 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.218 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.12 -60.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.001 1.527 . . . . 0.0 110.653 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -58.8 -47.2 85.59 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 110.327 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.76 -40.24 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 110.222 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.609 ' O ' HG23 ' A' ' 18' ' ' VAL . 36.8 t-105 -64.75 -42.42 95.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 110.158 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.48 -29.64 70.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 110.24 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -74.72 -56.74 4.48 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.264 -0.898 . . . . 0.0 110.104 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.674 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -58.42 -22.3 53.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.198 -0.939 . . . . 0.0 109.954 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.609 HG23 ' O ' ' A' ' 14' ' ' TRP . 55.9 t -83.22 -42.77 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.287 -0.883 . . . . 0.0 110.27 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.95 -23.57 67.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.338 -0.851 . . . . 0.0 110.262 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.88 -61.28 1.75 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.263 -0.898 . . . . 0.0 110.258 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.4 t -54.01 -30.07 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -0.967 . . . . 0.0 110.181 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.11 -44.34 67.29 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.09 -28.09 69.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -1.125 . . . . 0.0 110.194 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.454 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -85.82 -19.22 31.0 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.267 -0.896 . . . . 0.0 110.19 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.99 -9.53 59.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.221 -0.924 . . . . 0.0 110.149 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.433 ' O ' HG12 ' A' ' 26' ' ' VAL . 50.9 t -105.83 -6.63 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.93 . . . . 0.0 110.253 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.454 HG22 ' HA ' ' A' ' 24' ' ' ALA . 14.6 t . . . . . 0 N--CA 1.492 1.66 0 O-C-N 121.269 -0.895 . . . . 0.0 110.194 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.497 ' HG2' HG13 ' A' ' 5' ' ' ILE . 48.1 Cg_endo . . . . . 0 N--CA 1.496 1.651 0 N-CA-C 110.277 -0.701 . . . . 0.0 110.277 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -130.25 50.26 2.21 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.254 -0.904 . . . . 0.0 110.164 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.5 mt -106.84 -67.59 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.201 -0.937 . . . . 0.0 110.178 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -135.29 23.0 3.47 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-O 122.027 0.918 . . . . 0.0 110.013 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.577 HG22 ' O ' ' A' ' 5' ' ' ILE . 43.2 mm -92.12 27.15 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 CA-C-O 121.899 0.857 . . . . 0.0 110.329 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.74 45.5 0.4 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -87.52 21.98 2.35 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.276 -1.132 . . . . 0.0 110.315 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.1 t -114.87 177.74 4.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.258 -0.902 . . . . 0.0 110.085 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.6 t -141.11 -43.43 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.275 -0.89 . . . . 0.0 110.261 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.82 99.46 1.94 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.425 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 46.2 Cg_endo -73.38 -44.74 0.5 Allowed 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 124.021 1.537 . . . . 0.0 110.419 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 13' ' ' VAL . 1.9 p -64.8 -71.24 0.19 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.236 -0.915 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.417 ' C ' ' O ' ' A' ' 12' ' ' SER . 65.2 t -42.64 -30.96 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.325 -0.859 . . . . 0.0 110.142 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.425 ' HB3' ' O ' ' A' ' 11' ' ' PRO . 46.4 t-105 -64.78 -56.7 11.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.181 -0.95 . . . . 0.0 110.106 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -54.34 -28.55 43.52 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.211 -0.93 . . . . 0.0 109.904 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -69.45 -47.33 64.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.922 . . . . 0.0 109.842 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.753 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -65.73 -21.68 66.54 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.688 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -78.23 -51.47 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 109.952 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.69 -39.98 82.27 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.311 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -66.76 -52.91 38.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.27 -0.894 . . . . 0.0 110.28 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 17' ' ' LEU . 81.9 t -60.91 -21.47 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 110.34 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.665 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -72.34 -53.59 8.7 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -53.75 -40.25 66.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.197 -1.178 . . . . 0.0 110.241 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.69 -33.47 72.58 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.2 -0.938 . . . . 0.0 110.208 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.34 -17.24 60.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.313 -0.867 . . . . 0.0 110.167 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.665 HG23 ' O ' ' A' ' 22' ' ' GLY . 23.8 t -98.48 -14.4 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.305 -0.872 . . . . 0.0 110.179 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m -94.18 -25.63 17.01 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 110.125 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.93 -23.95 44.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.216 -0.927 . . . . 0.0 110.217 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -74.71 111.74 10.21 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 110.241 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.16 -179.946 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo . . . . . 0 N--CA 1.496 1.673 0 N-CA-C 110.218 -0.724 . . . . 0.0 110.218 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -88.05 62.83 7.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.21 -0.931 . . . . 0.0 110.059 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 34.3 mm -103.38 -56.7 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.311 -0.868 . . . . 0.0 110.565 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -92.42 23.52 3.91 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-O 122.012 0.911 . . . . 0.0 110.239 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.643 HG22 ' O ' ' A' ' 5' ' ' ILE . 13.9 mt -107.72 26.81 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 CA-C-O 121.843 0.83 . . . . 0.0 110.195 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -170.5 42.6 0.2 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -140.38 27.44 2.1 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.301 -1.117 . . . . 0.0 110.087 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.7 t -67.19 -167.9 0.06 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.885 . . . . 0.0 110.236 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 22.5 t -102.14 -63.28 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.384 -0.823 . . . . 0.0 110.071 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 131.66 74.48 0.11 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.83 -59.3 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.93 1.489 . . . . 0.0 110.608 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 88.3 p -62.98 -49.28 75.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.224 -0.922 . . . . 0.0 110.251 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.2 t -51.97 -42.23 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.192 -0.943 . . . . 0.0 110.095 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.508 ' O ' HG23 ' A' ' 18' ' ' VAL . 27.5 t-105 -66.7 -32.55 73.93 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 110.122 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.64 -33.61 71.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.284 -0.885 . . . . 0.0 110.234 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -76.4 -30.11 57.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.259 -0.901 . . . . 0.0 110.307 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.709 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.24 -29.82 57.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.162 -0.961 . . . . 0.0 109.67 179.917 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 14' ' ' TRP . 69.0 t -79.57 -45.97 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.454 -0.778 . . . . 0.0 110.081 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.17 -48.58 81.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.327 -0.858 . . . . 0.0 110.126 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.448 ' HA ' HD23 ' A' ' 20' ' ' LEU . 43.0 mt -62.08 -49.37 76.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.258 -0.901 . . . . 0.0 110.262 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 21' ' ' VAL . 53.0 t -73.29 -8.24 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 110.391 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.51 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -86.72 -33.24 13.33 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.64 -37.3 70.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -1.208 . . . . 0.0 110.427 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.46 -16.86 47.32 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.224 -0.923 . . . . 0.0 110.462 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.66 4.43 24.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.229 -0.92 . . . . 0.0 110.406 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 22' ' ' GLY . 96.1 t -100.26 -15.92 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.12 -0.987 . . . . 0.0 110.253 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.5 t -108.61 -20.98 12.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 110.293 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.75 -26.59 40.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.241 -0.912 . . . . 0.0 110.305 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -105.55 74.21 1.07 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.291 -0.881 . . . . 0.0 110.169 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.137 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.436 ' HB2' HG13 ' A' ' 3' ' ' ILE . 48.4 Cg_endo . . . . . 0 N--CA 1.482 0.836 0 N-CA-C 110.409 -0.65 . . . . 0.0 110.409 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.499 ' HA ' HG13 ' A' ' 5' ' ' ILE . . . -116.87 50.37 1.08 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.174 -0.954 . . . . 0.0 110.229 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.505 ' O ' ' HB3' ' A' ' 7' ' ' ALA . 17.9 mt -97.1 -47.22 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 110.219 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -96.99 22.47 8.37 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.198 -0.939 . . . . 0.0 110.024 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.717 HG22 ' O ' ' A' ' 5' ' ' ILE . 17.7 mm -97.44 27.27 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.162 0 CA-C-O 121.955 0.883 . . . . 0.0 110.08 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 114.64 10.39 12.94 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.505 ' HB3' ' O ' ' A' ' 3' ' ' ILE . . . -108.88 26.31 10.74 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.32 -1.106 . . . . 0.0 110.177 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.03 156.93 16.11 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.22 -0.925 . . . . 0.0 110.173 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.568 HG12 ' N ' ' A' ' 10' ' ' GLY . 20.1 t -71.69 -77.46 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.259 -0.9 . . . . 0.0 110.366 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.568 ' N ' HG12 ' A' ' 9' ' ' VAL . . . -41.54 101.33 0.02 OUTLIER Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 9' ' ' VAL . 48.4 Cg_endo -75.82 -52.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 124.017 1.535 . . . . 0.0 110.435 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -61.92 -58.07 9.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.328 -0.857 . . . . 0.0 110.32 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 77.2 t -46.48 -34.37 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.251 -0.905 . . . . 0.0 110.35 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.629 ' O ' HG23 ' A' ' 18' ' ' VAL . 23.2 t-105 -68.5 -58.4 4.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.19 -0.944 . . . . 0.0 110.229 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.67 -23.44 28.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.253 -0.904 . . . . 0.0 110.376 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.33 -41.57 33.19 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 0.0 110.311 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.901 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -70.61 -25.87 63.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.915 . . . . 0.0 109.693 179.903 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 14' ' ' TRP . 21.4 t -83.35 -37.05 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 110.088 179.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.04 -22.66 60.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.247 -0.908 . . . . 0.0 109.992 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.3 mt -87.9 -53.48 4.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.385 -0.822 . . . . 0.0 110.279 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.1 t -62.07 -16.77 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.309 -0.87 . . . . 0.0 110.362 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.52 -29.78 63.24 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.31 -20.53 63.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.255 -1.144 . . . . 0.0 110.249 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.602 ' O ' HG22 ' A' ' 27' ' ' THR . . . -87.33 -17.94 31.25 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.887 . . . . 0.0 110.171 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.3 -1.05 21.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.216 -0.927 . . . . 0.0 110.194 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 75.1 t -105.63 -11.54 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.297 -0.877 . . . . 0.0 110.172 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.602 HG22 ' O ' ' A' ' 24' ' ' ALA . 8.9 t -101.12 -27.25 13.35 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.327 -0.858 . . . . 0.0 110.327 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.17 20.34 5.12 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.171 -0.956 . . . . 0.0 110.297 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -108.0 -173.34 2.26 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.264 -0.897 . . . . 0.0 110.186 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.223 -179.982 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.532 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 47.8 Cg_endo . . . . . 0 N--CA 1.496 1.662 0 N-CA-C 110.212 -0.726 . . . . 0.0 110.212 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.532 ' HB2' ' O ' ' A' ' 1' ' ' PRO . . . 178.35 67.17 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.235 -0.915 . . . . 0.0 110.242 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.471 HG22 ' N ' ' A' ' 4' ' ' TYR . 81.1 mt -60.96 -88.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.126 -0.984 . . . . 0.0 109.994 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.471 ' N ' HG22 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -95.56 22.98 6.45 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.145 -0.972 . . . . 0.0 109.944 179.85 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.639 HG22 ' O ' ' A' ' 5' ' ' ILE . 16.8 mm -101.76 27.4 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 CA-C-O 121.962 0.887 . . . . 0.0 110.264 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.605 ' O ' ' HB2' ' A' ' 7' ' ' ALA . . . -140.81 64.13 0.52 Allowed Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.605 ' HB2' ' O ' ' A' ' 6' ' ' GLY . . . 175.11 100.64 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.398 -1.06 . . . . 0.0 110.21 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.502 HG22 ' H ' ' A' ' 9' ' ' VAL . 0.4 OUTLIER -68.63 -151.04 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.21 -0.932 . . . . 0.0 110.169 179.981 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.502 ' H ' HG22 ' A' ' 8' ' ' THR . 74.4 t -108.9 -41.05 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.227 -0.921 . . . . 0.0 110.199 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.479 ' O ' ' HB3' ' A' ' 14' ' ' TRP . . . 178.42 88.88 0.07 OUTLIER Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.349 -1.501 . . . . 0.0 109.349 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.41 -52.76 0.14 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 124.023 1.538 . . . . 0.0 110.571 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.52 -48.6 60.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.231 -0.918 . . . . 0.0 110.515 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.561 ' CG1' ' N ' ' A' ' 14' ' ' TRP . 2.9 p -59.64 -45.41 94.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.159 -0.963 . . . . 0.0 110.38 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.704 ' O ' HG23 ' A' ' 18' ' ' VAL . 49.3 t-105 -63.17 -36.88 85.09 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.116 -0.99 . . . . 0.0 110.013 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.48 -23.48 63.64 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.332 -0.855 . . . . 0.0 110.089 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.558 ' HD1' HD12 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -78.13 -36.57 47.66 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.228 -0.92 . . . . 0.0 110.185 179.952 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.965 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.06 -26.1 56.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.209 -0.932 . . . . 0.0 109.583 179.802 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.704 HG23 ' O ' ' A' ' 14' ' ' TRP . 61.0 t -81.52 -39.1 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.452 -0.78 . . . . 0.0 110.212 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.9 -38.15 67.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.225 -0.922 . . . . 0.0 110.139 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.558 HD12 ' HD1' ' A' ' 16' ' ' TYR . 1.2 mt -72.24 -39.18 68.65 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.935 . . . . 0.0 110.173 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.6 t -88.28 -4.77 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.307 -0.871 . . . . 0.0 110.195 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.26 -19.94 31.61 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -78.53 -29.78 46.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.226 -1.161 . . . . 0.0 110.244 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.45 ' O ' HG22 ' A' ' 27' ' ' THR . . . -81.54 -19.92 41.06 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.251 -0.906 . . . . 0.0 110.214 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.36 -15.8 60.44 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.284 -0.885 . . . . 0.0 110.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.5 t -83.7 -13.95 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 110.109 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.45 HG22 ' O ' ' A' ' 24' ' ' ALA . 10.1 t -113.57 -19.2 11.72 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 110.058 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.16 -22.25 36.17 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.276 -0.89 . . . . 0.0 110.217 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.99 13.17 11.55 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.307 -0.871 . . . . 0.0 110.228 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.1 t30 . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.231 179.977 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.691 ' HG2' HD12 ' A' ' 5' ' ' ILE . 49.4 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 110.199 -0.731 . . . . 0.0 110.199 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.83 31.2 0.79 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.154 -0.966 . . . . 0.0 110.206 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.5 mm -80.52 -68.03 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 110.152 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -118.62 22.92 11.79 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.178 -0.951 . . . . 0.0 110.053 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.691 HD12 ' HG2' ' A' ' 1' ' ' PRO . 9.8 mt -115.77 26.77 3.65 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.177 0 CA-C-O 121.809 0.814 . . . . 0.0 110.401 -179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -135.8 10.03 4.25 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -116.46 30.02 7.59 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.251 -1.146 . . . . 0.0 110.067 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.1 m -83.62 162.9 20.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 110.301 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.71 HG12 ' O ' ' A' ' 9' ' ' VAL . 68.0 t 44.27 31.8 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.211 -0.931 . . . . 0.0 110.394 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 9' ' ' VAL . . . -39.68 106.12 0.05 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.41 -41.72 3.25 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 O-C-N 124.013 1.533 . . . . 0.0 110.461 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 t -68.72 -56.08 9.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.302 -0.874 . . . . 0.0 110.137 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.72 -29.11 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.339 -0.851 . . . . 0.0 110.138 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.808 ' O ' HG23 ' A' ' 18' ' ' VAL . 44.0 t-105 -64.12 -42.5 96.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.253 -0.904 . . . . 0.0 110.142 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.82 -25.41 66.43 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.182 -0.949 . . . . 0.0 110.103 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -73.95 -42.52 60.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 110.193 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.859 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.15 -27.88 59.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.641 179.863 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.808 HG23 ' O ' ' A' ' 14' ' ' TRP . 68.9 t -76.64 -36.3 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.284 -0.885 . . . . 0.0 109.999 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.69 -32.49 63.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 110.014 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.1 mt -70.09 -51.21 33.57 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.294 -0.878 . . . . 0.0 110.225 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 49.0 t -64.32 -47.1 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.237 -0.915 . . . . 0.0 110.258 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.52 -45.35 67.23 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.52 -22.39 60.12 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.286 -1.126 . . . . 0.0 110.205 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.13 -14.68 53.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.301 -0.874 . . . . 0.0 110.254 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.05 -12.34 58.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.924 . . . . 0.0 110.307 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 95.9 t -89.29 -13.94 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -0.9 . . . . 0.0 110.157 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 99.6 m -77.29 -19.14 56.87 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.184 -0.947 . . . . 0.0 110.164 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.45 -23.92 32.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 110.236 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -89.19 159.0 17.68 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 110.18 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 22.2 t-20 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.3 179.986 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 N--CA 1.495 1.573 0 N-CA-C 110.194 -0.733 . . . . 0.0 110.194 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.46 46.05 0.43 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.195 -0.94 . . . . 0.0 110.107 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.438 HG22 ' N ' ' A' ' 4' ' ' TYR . 34.7 mm -58.17 -87.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 110.193 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.438 ' N ' HG22 ' A' ' 3' ' ' ILE . 0.2 OUTLIER -104.26 23.04 13.72 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-O 122.144 0.973 . . . . 0.0 110.039 179.881 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.725 HG22 ' O ' ' A' ' 5' ' ' ILE . 29.8 mt -92.9 26.65 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 CA-C-O 121.926 0.87 . . . . 0.0 110.101 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -176.75 54.66 0.11 Allowed Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.726 ' O ' HG22 ' A' ' 8' ' ' THR . . . -126.78 33.23 4.99 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.255 -1.144 . . . . 0.0 110.184 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 1.046 HG23 HG23 ' A' ' 9' ' ' VAL . 6.5 t 39.63 -155.31 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.591 -0.693 . . . . 0.0 110.349 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 1.046 HG23 HG23 ' A' ' 8' ' ' THR . 87.3 t 45.48 28.51 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.18 -0.95 . . . . 0.0 110.314 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -121.38 60.68 0.54 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.446 ' HD3' ' C ' ' A' ' 9' ' ' VAL . 45.9 Cg_endo -72.98 -47.7 0.31 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.944 1.497 . . . . 0.0 110.397 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 0.3 OUTLIER -67.05 -60.68 2.42 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -0.915 . . . . 0.0 110.191 -179.988 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.413 ' C ' ' O ' ' A' ' 12' ' ' SER . 54.3 t -43.21 -47.81 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 110.122 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.604 ' O ' HG23 ' A' ' 18' ' ' VAL . 21.4 t-105 -55.83 -56.2 23.45 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.927 . . . . 0.0 109.912 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -53.93 -23.92 14.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -0.938 . . . . 0.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -75.0 -38.61 61.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.2 -0.937 . . . . 0.0 110.351 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.883 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -73.89 -25.6 60.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.835 179.939 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.604 HG23 ' O ' ' A' ' 14' ' ' TRP . 5.9 t -86.24 -28.33 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.319 -0.863 . . . . 0.0 110.097 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.56 -35.93 60.52 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.261 -0.899 . . . . 0.0 110.054 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.9 mt -83.15 -40.07 20.23 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.283 -0.886 . . . . 0.0 110.177 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 90.7 t -79.25 -17.6 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.224 -0.923 . . . . 0.0 110.196 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.53 -30.18 64.74 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.57 -26.6 68.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.152 . . . . 0.0 110.201 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.734 ' O ' HG22 ' A' ' 27' ' ' THR . . . -66.01 -40.3 90.99 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.204 -0.935 . . . . 0.0 110.203 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.4 -11.89 60.62 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.178 -0.951 . . . . 0.0 110.25 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.434 ' O ' ' HB2' ' A' ' 30' ' ' ASN . 38.1 t -84.95 -17.37 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.175 -0.953 . . . . 0.0 110.241 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.734 HG22 ' O ' ' A' ' 24' ' ' ALA . 11.7 t -99.23 -8.54 24.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 110.097 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.53 -30.38 16.44 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.255 -0.903 . . . . 0.0 110.055 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -101.69 -7.28 22.78 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.274 -0.891 . . . . 0.0 110.018 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.434 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 35.3 t-20 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.26 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo . . . . . 0 N--CA 1.497 1.683 0 N-CA-C 110.209 -0.727 . . . . 0.0 110.209 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -160.81 36.95 0.15 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.201 -0.937 . . . . 0.0 110.398 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 1.8 mp -69.07 -56.48 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.121 -0.987 . . . . 0.0 110.06 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -141.44 23.3 2.15 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 122.159 0.981 . . . . 0.0 109.902 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.661 HG22 ' O ' ' A' ' 5' ' ' ILE . 42.3 mt -95.76 26.46 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-O 121.85 0.833 . . . . 0.0 110.201 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 136.52 -10.95 4.05 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 44.8 87.57 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -1.109 . . . . 0.0 110.337 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.477 HG22 ' H ' ' A' ' 9' ' ' VAL . 0.2 OUTLIER -121.42 -171.95 2.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.533 -0.729 . . . . 0.0 110.097 179.858 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.477 ' H ' HG22 ' A' ' 8' ' ' THR . 37.5 t -68.31 -13.73 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.245 -0.91 . . . . 0.0 110.192 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 45.96 62.13 3.55 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.93 -47.57 0.44 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.989 1.521 . . . . 0.0 110.295 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 m -61.47 -55.69 28.44 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.904 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 t -54.04 -37.57 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 109.87 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.441 ' O ' HG23 ' A' ' 18' ' ' VAL . 46.4 t-105 -59.07 -52.18 66.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.215 -0.928 . . . . 0.0 109.922 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.2 -19.73 65.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.757 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 3.8 t80 -75.8 -40.25 55.4 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 110.095 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.919 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -76.7 -29.64 56.36 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.596 179.811 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 14' ' ' TRP . 95.3 t -75.36 -29.65 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.393 -0.817 . . . . 0.0 109.87 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -77.05 -40.16 47.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.912 179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.3 -36.4 81.44 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 110.042 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 17' ' ' LEU . 84.8 t -77.51 -35.3 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.16 -0.963 . . . . 0.0 110.223 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.13 -12.32 68.49 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.43 -28.83 37.66 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -1.153 . . . . 0.0 110.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.99 -22.98 31.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.2 -0.938 . . . . 0.0 110.307 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.88 -0.91 17.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -0.889 . . . . 0.0 110.236 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.481 ' O ' HG12 ' A' ' 26' ' ' VAL . 41.6 t -99.62 -2.34 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.267 -0.896 . . . . 0.0 110.113 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.18 -13.36 14.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.151 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.01 -22.49 36.49 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.251 -0.905 . . . . 0.0 110.33 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -96.56 -56.45 2.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.279 -0.888 . . . . 0.0 110.27 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 18.1 t-20 . . . . . 0 N--CA 1.489 1.508 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.27 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.411 ' O ' HD12 ' A' ' 5' ' ' ILE . 47.2 Cg_endo . . . . . 0 N--CA 1.497 1.715 0 N-CA-C 110.276 -0.702 . . . . 0.0 110.276 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -162.45 39.71 0.12 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.296 -0.878 . . . . 0.0 110.244 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.404 HG23 HD12 ' A' ' 3' ' ' ILE . 18.9 mm -86.13 -66.45 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 110.438 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -111.02 25.79 11.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.195 -0.941 . . . . 0.0 110.303 -179.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.723 HG22 ' O ' ' A' ' 5' ' ' ILE . 42.1 mt -90.88 25.76 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 CA-C-O 121.826 0.822 . . . . 0.0 110.266 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.52 59.69 0.6 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -107.03 25.37 11.44 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.285 -1.127 . . . . 0.0 110.228 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.17 5.87 18.74 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.227 -0.921 . . . . 0.0 110.276 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.447 ' O ' ' HD3' ' A' ' 11' ' ' PRO . 65.0 t -127.48 -70.42 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.356 -0.84 . . . . 0.0 110.173 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 9' ' ' VAL . . . -42.93 102.74 0.03 OUTLIER Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.447 ' HD3' ' O ' ' A' ' 9' ' ' VAL . 45.8 Cg_endo -73.37 -42.69 0.85 Allowed 'Trans proline' 0 C--N 1.305 -1.728 0 O-C-N 123.992 1.522 . . . . 0.0 110.234 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.0 m -67.51 -55.62 12.79 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.22 -0.925 . . . . 0.0 110.186 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.446 HG23 ' H ' ' A' ' 13' ' ' VAL . 17.7 t -53.99 -45.02 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.188 -0.945 . . . . 0.0 109.971 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.636 ' O ' HG23 ' A' ' 18' ' ' VAL . 26.5 t-105 -58.33 -47.17 84.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.263 -0.898 . . . . 0.0 109.802 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -55.07 -23.73 21.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.323 -0.861 . . . . 0.0 109.979 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.475 ' CD1' HD12 ' A' ' 20' ' ' LEU . 0.2 OUTLIER -76.83 -51.17 11.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 110.006 179.916 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.735 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -59.53 -22.86 62.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.757 179.904 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.636 HG23 ' O ' ' A' ' 14' ' ' TRP . 33.9 t -85.36 -44.12 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -0.905 . . . . 0.0 110.078 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.72 -24.73 67.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.333 -0.854 . . . . 0.0 110.084 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.475 HD12 ' CD1' ' A' ' 16' ' ' TYR . 0.9 OUTLIER -88.02 -39.29 14.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.23 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -72.12 -21.44 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.232 -0.918 . . . . 0.0 110.158 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.5 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -81.06 -18.32 69.89 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.61 -18.45 60.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -1.168 . . . . 0.0 110.22 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -88.75 -29.27 19.92 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.929 . . . . 0.0 110.31 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.61 -4.13 32.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.206 -0.934 . . . . 0.0 110.213 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 22' ' ' GLY . 47.4 t -84.43 -20.17 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.249 -0.907 . . . . 0.0 110.22 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.8 -35.86 62.48 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 110.161 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.84 -31.86 20.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.214 -0.929 . . . . 0.0 110.165 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -103.56 134.91 46.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.216 -0.928 . . . . 0.0 110.178 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.216 179.995 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.482 0.796 0 N-CA-C 110.241 -0.715 . . . . 0.0 110.241 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.479 ' HA ' HG13 ' A' ' 5' ' ' ILE . . . -144.95 45.67 1.35 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.173 -0.954 . . . . 0.0 110.097 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.5 mm -96.82 -51.26 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.35 -0.844 . . . . 0.0 110.275 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -95.44 22.07 7.4 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 122.113 0.958 . . . . 0.0 110.107 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.764 HG22 ' O ' ' A' ' 5' ' ' ILE . 14.8 mm -94.27 26.37 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.077 0 CA-C-O 121.856 0.836 . . . . 0.0 110.061 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' ' HB3' ' A' ' 7' ' ' ALA . . . 96.15 -43.15 2.16 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 6' ' ' GLY . . . 55.63 30.76 16.0 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.257 -1.143 . . . . 0.0 110.362 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -85.28 156.23 21.03 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.288 -0.882 . . . . 0.0 110.323 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 94.2 t -118.81 -22.68 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 110.163 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.523 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . 52.64 51.73 42.31 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.523 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 44.3 Cg_endo -72.65 -58.66 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.025 1.539 . . . . 0.0 110.63 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.415 ' O ' ' C ' ' A' ' 13' ' ' VAL . 5.4 t -55.71 -63.68 1.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -0.918 . . . . 0.0 110.195 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.415 ' C ' ' O ' ' A' ' 12' ' ' SER . 60.6 t -42.88 -51.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.344 -0.847 . . . . 0.0 110.245 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.47 ' O ' HG23 ' A' ' 18' ' ' VAL . 40.9 t-105 -48.43 -47.13 38.19 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.232 -0.918 . . . . 0.0 110.276 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.52 -34.77 74.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.262 -0.899 . . . . 0.0 110.424 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.8 t80 -67.14 -48.35 68.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.235 -0.915 . . . . 0.0 110.417 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.755 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -64.96 -24.26 67.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.114 -0.991 . . . . 0.0 109.982 -179.901 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 14' ' ' TRP . 29.9 t -73.52 -62.96 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.337 -0.852 . . . . 0.0 110.248 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.55 -28.96 34.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.27 -0.894 . . . . 0.0 110.213 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 5.0 mt -67.87 -49.52 61.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 110.217 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.5 t -55.56 -48.48 77.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.216 -0.927 . . . . 0.0 110.204 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.486 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -62.73 -32.93 85.29 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.04 -30.12 70.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.185 -1.185 . . . . 0.0 110.39 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.46 -34.89 18.54 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.185 -0.947 . . . . 0.0 110.265 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.92 -13.17 14.11 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.208 -0.932 . . . . 0.0 110.25 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 22' ' ' GLY . 65.6 t -93.77 -23.59 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.311 -0.868 . . . . 0.0 110.26 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 m -72.41 -40.4 67.18 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.257 -0.902 . . . . 0.0 109.962 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.63 -47.15 33.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.399 -0.813 . . . . 0.0 110.082 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 30' ' ' ASN . . . -93.3 92.38 7.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.238 -0.914 . . . . 0.0 110.062 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.427 ' HB2' ' O ' ' A' ' 29' ' ' ALA . 13.7 m-80 . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.103 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.495 1.612 0 N-CA-C 110.188 -0.735 . . . . 0.0 110.188 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -175.09 56.25 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.314 -0.867 . . . . 0.0 110.142 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.4 mt -52.5 -52.9 22.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -0.917 . . . . 0.0 110.064 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.438 ' O ' ' N ' ' A' ' 6' ' ' GLY . 0.2 OUTLIER -111.74 23.28 14.04 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-O 122.111 0.958 . . . . 0.0 109.741 179.788 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.757 HG22 ' O ' ' A' ' 5' ' ' ILE . 38.9 mt 40.86 29.08 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.067 0 CA-C-O 121.967 0.889 . . . . 0.0 110.055 179.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 4' ' ' TYR . . . -177.3 43.06 0.1 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -152.28 28.4 0.58 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.38 -1.071 . . . . 0.0 110.183 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -82.06 6.42 16.31 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -0.86 . . . . 0.0 110.314 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.7 t -97.38 -67.62 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.337 -0.852 . . . . 0.0 109.978 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 71.52 65.49 2.4 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.46 -40.24 1.65 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.963 1.507 . . . . 0.0 110.24 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.6 t -73.37 -59.19 2.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.434 -0.791 . . . . 0.0 110.302 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 53.1 t -53.36 -40.42 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.256 -0.903 . . . . 0.0 110.317 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.642 ' O ' HG23 ' A' ' 18' ' ' VAL . 36.2 t-105 -58.65 -36.95 74.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.353 -0.842 . . . . 0.0 110.119 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.88 -32.41 69.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.931 . . . . 0.0 110.257 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -70.74 -41.02 72.38 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.136 -0.978 . . . . 0.0 110.064 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.776 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -72.43 -30.64 64.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.213 -0.93 . . . . 0.0 109.469 179.708 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 14' ' ' TRP . 72.9 t -77.92 -27.78 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.435 -0.79 . . . . 0.0 109.891 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.72 -45.13 38.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 110.138 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -66.1 -52.12 51.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.866 . . . . 0.0 110.211 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 45.5 t -69.21 -12.28 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 110.262 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.18 -41.45 31.52 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.74 -33.57 68.61 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.25 -1.147 . . . . 0.0 110.149 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.433 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -87.22 -23.87 24.61 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.268 -0.895 . . . . 0.0 110.275 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.5 -1.46 30.56 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.931 . . . . 0.0 110.192 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.412 ' O ' HG12 ' A' ' 26' ' ' VAL . 86.4 t -113.66 -6.83 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.231 -0.918 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.433 HG22 ' HA ' ' A' ' 24' ' ' ALA . 13.8 t -116.41 -23.23 8.41 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.131 -0.981 . . . . 0.0 110.193 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.57 6.23 15.58 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.284 -0.885 . . . . 0.0 110.126 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.92 112.01 13.08 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.344 -0.848 . . . . 0.0 110.233 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 14.6 p-10 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.231 179.987 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo . . . . . 0 N--CA 1.497 1.696 0 N-CA-C 110.272 -0.703 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 53.7 31.55 13.03 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.266 -0.896 . . . . 0.0 110.229 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 55.5 mt -95.7 -46.55 13.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.238 -0.914 . . . . 0.0 109.973 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -110.46 23.33 14.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.244 -0.91 . . . . 0.0 110.005 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.693 HG22 ' O ' ' A' ' 5' ' ' ILE . 16.9 mt -101.57 27.01 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.16 0 CA-C-O 121.872 0.844 . . . . 0.0 110.15 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.524 ' O ' ' HB3' ' A' ' 7' ' ' ALA . . . 103.7 -44.7 1.43 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.524 ' HB3' ' O ' ' A' ' 6' ' ' GLY . . . 59.48 28.05 17.34 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -1.123 . . . . 0.0 110.38 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.4 t -84.65 -177.93 6.74 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.19 -0.944 . . . . 0.0 110.211 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 10.3 t -94.2 -37.43 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.25 -0.906 . . . . 0.0 109.94 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 111.86 87.08 1.68 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.1 -48.05 0.29 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.045 1.55 . . . . 0.0 110.373 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.51 -59.37 2.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.327 -0.858 . . . . 0.0 110.127 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.5 t -48.22 -29.49 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.277 -0.889 . . . . 0.0 110.161 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 32.0 t-105 -73.64 -59.47 2.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 110.158 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -57.76 -16.42 11.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.263 -0.898 . . . . 0.0 109.947 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.428 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.3 t80 -82.38 -42.3 18.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 110.104 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.919 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -75.2 -23.0 57.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.34 -0.85 . . . . 0.0 109.676 179.861 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -79.31 -56.69 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.48 -0.762 . . . . 0.0 109.941 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.76 -33.93 70.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.319 -0.863 . . . . 0.0 110.062 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.519 HD23 ' HA ' ' A' ' 20' ' ' LEU . 7.3 mt -67.86 -47.71 68.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.101 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 26.4 t -64.05 -16.28 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 110.175 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.29 -53.08 9.33 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -19.81 62.09 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -1.151 . . . . 0.0 110.209 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.59 ' O ' HG22 ' A' ' 27' ' ' THR . . . -83.62 -9.06 59.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.908 . . . . 0.0 110.134 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.29 3.85 26.01 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.36 -0.838 . . . . 0.0 110.122 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 20.8 t -101.58 -16.59 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 110.084 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.59 HG22 ' O ' ' A' ' 24' ' ' ALA . 15.1 t -90.29 -16.79 28.59 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.38 -28.78 67.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.259 -0.901 . . . . 0.0 110.218 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.447 ' O ' ' HB2' ' A' ' 30' ' ' ASN . . . -88.84 -23.39 22.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.261 -0.9 . . . . 0.0 110.198 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.447 ' HB2' ' O ' ' A' ' 29' ' ' ALA . 2.6 m120 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 117.903 -1.046 . . . . 0.0 110.289 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.502 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 46.9 Cg_endo . . . . . 0 N--CA 1.497 1.731 0 N-CA-C 110.328 -0.681 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.6 ' HA ' HD12 ' A' ' 5' ' ' ILE . . . 179.26 39.55 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.262 -0.899 . . . . 0.0 110.344 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 23.3 mm -90.89 -26.9 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.252 -0.905 . . . . 0.0 110.235 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -121.0 23.55 10.6 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 122.125 0.964 . . . . 0.0 110.014 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.718 HG22 ' O ' ' A' ' 5' ' ' ILE . 14.8 mt -96.48 26.5 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.114 0 CA-C-O 121.889 0.852 . . . . 0.0 109.999 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 130.02 -17.27 5.44 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 45.38 86.71 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.326 -1.102 . . . . 0.0 110.048 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 18.0 m -105.73 8.93 33.17 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.414 -0.804 . . . . 0.0 110.207 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 6.5 t -101.71 6.36 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.404 -0.81 . . . . 0.0 110.081 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.477 ' N ' ' CD ' ' A' ' 11' ' ' PRO . . . -162.59 53.83 0.3 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.477 ' CD ' ' N ' ' A' ' 10' ' ' GLY . 46.1 Cg_endo -73.25 -47.5 0.3 Allowed 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 123.973 1.512 . . . . 0.0 110.337 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 13' ' ' VAL . 4.4 m -62.45 -66.93 0.47 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 110.086 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.426 ' H ' HG23 ' A' ' 13' ' ' VAL . 21.8 t -44.03 -39.09 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 109.984 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.43 ' HB3' ' O ' ' A' ' 11' ' ' PRO . 30.6 t-105 -56.35 -52.22 65.37 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -56.83 -25.62 56.48 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.167 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 7.3 t80 -74.56 -34.22 62.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 110.198 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.644 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -73.03 -34.61 66.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.335 -0.853 . . . . 0.0 109.734 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.62 -35.26 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.408 -0.807 . . . . 0.0 110.082 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.04 -47.37 74.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.956 . . . . 0.0 110.119 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 17.1 mt -62.37 -54.82 34.8 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.277 -0.89 . . . . 0.0 110.085 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -64.71 -15.11 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.302 -0.874 . . . . 0.0 110.154 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.427 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -74.31 -36.74 49.53 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.27 -29.67 61.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 110.153 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.57 -34.07 73.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 110.233 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.67 -17.76 61.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.244 -0.91 . . . . 0.0 110.035 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 22' ' ' GLY . 39.8 t -83.34 -6.73 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.378 -0.826 . . . . 0.0 109.959 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.0 m -98.42 -50.0 4.46 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 110.057 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -92.89 63.46 3.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.158 -0.964 . . . . 0.0 110.148 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.422 ' O ' ' O ' ' A' ' 30' ' ' ASN . . . -81.62 -73.19 0.39 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.311 -0.868 . . . . 0.0 110.245 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.422 ' O ' ' O ' ' A' ' 29' ' ' ALA . 12.0 m-80 . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.205 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo . . . . . 0 N--CA 1.494 1.546 0 N-CA-C 110.173 -0.741 . . . . 0.0 110.173 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.585 ' HA ' HD12 ' A' ' 5' ' ' ILE . . . -173.75 96.53 0.11 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.218 -0.926 . . . . 0.0 110.097 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.6 mm -94.83 -59.46 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.194 -0.941 . . . . 0.0 110.136 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -102.6 23.88 11.3 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.217 -0.927 . . . . 0.0 110.022 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.735 HG22 ' O ' ' A' ' 5' ' ' ILE . 22.8 mt -92.58 26.74 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.092 0 CA-C-O 121.851 0.834 . . . . 0.0 110.158 -179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.5 ' O ' ' HB3' ' A' ' 7' ' ' ALA . . . 96.76 -18.58 57.25 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 -179.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' A' ' 6' ' ' GLY . . . 58.17 26.1 13.34 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.33 -1.1 . . . . 0.0 110.224 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.628 ' O ' HG22 ' A' ' 8' ' ' THR . 17.9 m -81.71 7.29 12.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.259 -0.9 . . . . 0.0 110.285 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.443 ' O ' ' HD3' ' A' ' 11' ' ' PRO . 8.7 p -125.04 -23.95 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.411 -0.805 . . . . 0.0 110.375 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 9' ' ' VAL . . . -42.91 102.35 0.03 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 9' ' ' VAL . 46.1 Cg_endo -72.99 -42.01 1.16 Allowed 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.974 1.512 . . . . 0.0 110.467 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.5 m -61.73 -61.75 2.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.905 . . . . 0.0 110.212 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.7 t -46.22 -39.13 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.28 -0.887 . . . . 0.0 110.256 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 34.5 t-105 -63.09 -51.41 66.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.339 -0.851 . . . . 0.0 110.329 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.72 -26.99 67.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.122 -0.986 . . . . 0.0 110.254 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -69.91 -47.75 61.24 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.02 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.799 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -67.2 -30.22 70.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.204 -0.935 . . . . 0.0 109.742 -179.964 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.2 t -79.11 -27.07 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.447 -0.783 . . . . 0.0 110.107 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.98 -42.44 60.44 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.309 -0.87 . . . . 0.0 110.141 179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 6.2 mt -71.29 -48.03 53.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.174 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.0 t -71.77 -21.6 21.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 110.079 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -23.07 78.51 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.58 -29.67 41.31 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.16 -1.2 . . . . 0.0 110.15 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.32 -20.94 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.252 -0.905 . . . . 0.0 110.176 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.24 -17.02 64.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 110.15 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 77.6 t -85.71 -19.24 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -0.854 . . . . 0.0 110.097 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.4 ' O ' HG22 ' A' ' 27' ' ' THR . 67.1 m -104.61 -5.77 21.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.353 -0.842 . . . . 0.0 110.033 179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.72 -28.23 19.54 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.292 -0.88 . . . . 0.0 110.228 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.68 134.75 36.42 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.283 -0.886 . . . . 0.0 110.186 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.075 -0.965 . . . . 0.0 110.241 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.466 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 50.2 Cg_endo . . . . . 0 N--CA 1.495 1.608 0 N-CA-C 110.213 -0.726 . . . . 0.0 110.213 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 1' ' ' PRO . . . -179.0 74.91 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.28 -0.887 . . . . 0.0 110.271 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.587 HG22 ' N ' ' A' ' 4' ' ' TYR . 35.8 mt -48.55 -91.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.225 -0.922 . . . . 0.0 110.01 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.587 ' N ' HG22 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -106.09 23.68 13.65 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.138 0.97 . . . . 0.0 109.843 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.723 HG22 ' O ' ' A' ' 5' ' ' ILE . 21.9 mt -92.01 26.17 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 CA-C-O 121.882 0.849 . . . . 0.0 110.107 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -132.29 49.2 0.93 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -118.49 24.97 10.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.353 -1.087 . . . . 0.0 110.084 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.544 HG22 ' N ' ' A' ' 9' ' ' VAL . 37.0 m -98.01 174.02 6.76 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.253 -0.904 . . . . 0.0 110.211 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.544 ' N ' HG22 ' A' ' 8' ' ' THR . 91.7 t -118.63 -70.73 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.169 -0.957 . . . . 0.0 110.202 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.491 ' O ' ' HB2' ' A' ' 14' ' ' TRP . . . 162.77 95.02 0.1 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.57 -47.56 0.14 Allowed 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.002 1.527 . . . . 0.0 110.457 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 p -70.39 -63.22 1.13 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.296 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 91.2 t -47.8 -32.36 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 110.166 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.54 ' O ' HG23 ' A' ' 18' ' ' VAL . 63.6 t-105 -70.13 -41.8 73.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.928 . . . . 0.0 109.96 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.9 -23.35 65.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.47 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.7 t80 -77.53 -47.14 20.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.33 -0.856 . . . . 0.0 110.043 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.884 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -68.69 -21.5 64.42 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.292 -0.88 . . . . 0.0 109.709 179.885 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.54 HG23 ' O ' ' A' ' 14' ' ' TRP . 55.6 t -82.6 -53.62 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -0.844 . . . . 0.0 110.207 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.47 -35.56 76.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.315 -0.866 . . . . 0.0 110.078 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 0.2 OUTLIER -72.1 -46.6 56.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.938 . . . . 0.0 110.171 179.935 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.2 t -66.95 -21.3 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.961 . . . . 0.0 109.902 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.16 -29.32 60.62 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.1 -22.98 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -1.078 . . . . 0.0 110.08 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.86 -35.98 75.15 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 110.207 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.51 -5.2 43.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 110.095 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.8 t -99.39 -13.54 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.207 -0.933 . . . . 0.0 110.223 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.1 t -110.18 -25.74 10.01 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.205 -0.934 . . . . 0.0 110.239 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -92.64 44.08 1.15 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.251 -0.906 . . . . 0.0 110.091 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -90.34 2.27 55.72 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.301 -0.875 . . . . 0.0 110.254 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.9 m120 . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.142 179.944 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo . . . . . 0 N--CA 1.496 1.666 0 N-CA-C 110.189 -0.735 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -149.58 41.55 0.87 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.231 -0.918 . . . . 0.0 110.21 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.47 ' O ' ' HB3' ' A' ' 7' ' ' ALA . 58.9 mt -72.82 -64.64 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.214 -0.929 . . . . 0.0 110.132 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -116.77 22.99 12.28 Favored 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 122.152 0.977 . . . . 0.0 110.037 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.742 HG22 ' O ' ' A' ' 5' ' ' ILE . 12.4 mm -96.8 26.51 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 CA-C-O 121.766 0.793 . . . . 0.0 110.167 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.46 -14.02 1.61 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' A' ' 3' ' ' ILE . . . -101.31 30.57 4.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.306 -1.114 . . . . 0.0 110.193 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.8 t -52.59 -177.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.311 -0.868 . . . . 0.0 110.377 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 85.7 t -95.24 -81.32 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.377 -0.827 . . . . 0.0 110.214 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -160.82 70.47 0.23 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.6 -54.57 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.047 1.551 . . . . 0.0 110.4 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -64.16 -51.26 64.68 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.181 -0.949 . . . . 0.0 110.146 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 38.5 t -57.48 -39.13 67.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.299 -0.876 . . . . 0.0 110.186 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 48.5 t-105 -64.88 -39.97 94.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.165 -0.959 . . . . 0.0 110.146 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.63 -25.66 64.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.181 -0.949 . . . . 0.0 110.196 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -75.79 -42.77 49.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 0.0 110.045 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.688 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -69.41 -29.85 67.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.321 -0.862 . . . . 0.0 109.827 -179.989 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 32.3 t -77.26 -44.87 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.336 -0.852 . . . . 0.0 110.12 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -61.19 -36.76 80.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 110.1 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.4 mt -67.75 -48.22 67.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 110.044 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.446 ' O ' HG12 ' A' ' 21' ' ' VAL . 64.0 t -77.43 -1.55 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.263 -0.898 . . . . 0.0 110.034 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.46 -21.51 31.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.17 -37.94 66.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.22 -1.165 . . . . 0.0 110.068 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 -7.05 58.4 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -78.3 -17.27 56.83 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.419 -0.8 . . . . 0.0 110.183 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.6 t -87.49 -16.29 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.371 -0.83 . . . . 0.0 110.031 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.88 -11.24 42.46 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.311 -0.868 . . . . 0.0 110.102 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.03 -31.33 18.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.256 -0.903 . . . . 0.0 110.152 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -108.67 177.03 4.9 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.265 -0.897 . . . . 0.0 110.157 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.207 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.607 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 46.2 Cg_endo . . . . . 0 N--CA 1.496 1.635 0 N-CA-C 110.333 -0.679 . . . . 0.0 110.333 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.607 ' HB2' ' O ' ' A' ' 1' ' ' PRO . . . 174.89 40.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 110.279 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.404 HD13 HG21 ' A' ' 3' ' ' ILE . 46.7 mt -93.55 -73.3 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.182 -0.949 . . . . 0.0 110.147 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -116.78 22.76 12.44 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.104 -0.997 . . . . 0.0 109.987 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.734 HG22 ' O ' ' A' ' 5' ' ' ILE . 16.8 mm -94.98 26.9 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.108 0 CA-C-O 121.783 0.801 . . . . 0.0 110.107 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.696 ' O ' ' HB3' ' A' ' 7' ' ' ALA . . . 123.25 -19.68 7.63 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.696 ' HB3' ' O ' ' A' ' 6' ' ' GLY . . . 67.73 33.09 5.06 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.188 -1.184 . . . . 0.0 110.119 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.49 174.92 10.98 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.88 . . . . 0.0 110.378 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 69.2 t -99.57 -22.46 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.346 -0.846 . . . . 0.0 110.166 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 107.17 67.59 0.65 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.03 -52.47 0.23 Allowed 'Trans proline' 0 C--N 1.307 -1.605 0 O-C-N 124.019 1.536 . . . . 0.0 110.394 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 p -65.71 -56.97 9.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.936 . . . . 0.0 110.132 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 67.0 t -49.32 -46.71 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.27 -0.894 . . . . 0.0 110.021 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.46 ' O ' HG23 ' A' ' 18' ' ' VAL . 48.7 t-105 -56.02 -52.55 63.83 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.358 -0.839 . . . . 0.0 109.991 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -58.47 -22.65 55.5 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 109.878 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.418 ' O ' HD12 ' A' ' 20' ' ' LEU . 0.6 OUTLIER -70.75 -46.91 62.11 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.368 -0.833 . . . . 0.0 110.021 179.844 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.671 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -65.43 -29.47 70.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.893 179.944 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 14' ' ' TRP . 47.9 t -74.11 -63.41 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.89 . . . . 0.0 110.149 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.51 -23.27 9.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 110.36 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.418 HD12 ' O ' ' A' ' 16' ' ' TYR . 10.5 mt -75.51 -46.06 34.49 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.144 -0.972 . . . . 0.0 110.187 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 17' ' ' LEU . 92.9 t -67.8 -11.26 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.311 -0.868 . . . . 0.0 110.138 179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -88.38 -26.52 27.76 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.88 -22.03 61.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 110.232 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.53 -24.54 17.22 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 110.136 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -76.37 -10.8 59.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.218 -0.926 . . . . 0.0 110.277 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.502 ' O ' HG12 ' A' ' 26' ' ' VAL . 54.2 t -97.99 -1.85 10.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.256 -0.902 . . . . 0.0 110.319 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 25.2 m -106.87 -31.06 8.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.186 -0.946 . . . . 0.0 110.093 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -91.96 40.23 1.04 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.29 -0.881 . . . . 0.0 110.173 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.83 95.14 8.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.329 -0.857 . . . . 0.0 110.145 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 22.9 p-10 . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.202 179.983 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 N--CA 1.496 1.64 0 N-CA-C 110.129 -0.758 . . . . 0.0 110.129 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -135.88 69.49 1.43 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.196 -0.94 . . . . 0.0 110.299 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.434 HG22 ' N ' ' A' ' 4' ' ' TYR . 82.0 mt -58.24 -93.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.229 -0.92 . . . . 0.0 110.014 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.434 ' N ' HG22 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -108.46 23.92 13.8 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.15 0.976 . . . . 0.0 109.768 179.763 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.728 HG22 ' O ' ' A' ' 5' ' ' ILE . 18.4 mm -91.73 26.12 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 CA-C-O 121.805 0.812 . . . . 0.0 110.115 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -122.24 -12.03 5.42 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.403 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -92.8 26.5 2.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.266 -1.137 . . . . 0.0 110.229 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 7' ' ' ALA . 1.0 OUTLIER -45.22 150.47 0.42 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 109.985 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.2 t -83.04 -66.8 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.122 -0.986 . . . . 0.0 110.246 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -158.13 93.42 0.13 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.431 ' O ' ' HB3' ' A' ' 14' ' ' TRP . 44.9 Cg_endo -72.97 -54.58 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.951 1.501 . . . . 0.0 110.22 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -58.53 -58.86 6.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.268 -0.895 . . . . 0.0 110.01 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 t -47.88 -41.39 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.874 . . . . 0.0 110.108 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.765 ' O ' HG23 ' A' ' 18' ' ' VAL . 32.9 t-105 -57.08 -53.34 59.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.252 -0.905 . . . . 0.0 110.03 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.87 -22.55 65.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.211 -0.931 . . . . 0.0 110.293 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.412 ' O ' ' HB2' ' A' ' 20' ' ' LEU . 2.4 t80 -75.27 -36.2 61.26 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.285 -0.885 . . . . 0.0 110.197 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.893 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -81.55 -28.53 33.85 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.165 -0.959 . . . . 0.0 109.805 179.964 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 14' ' ' TRP . 38.1 t -74.68 -32.48 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.37 -0.831 . . . . 0.0 109.979 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.1 -32.22 26.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.985 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.501 HD23 ' HA ' ' A' ' 20' ' ' LEU . 1.4 mt -68.4 -39.81 81.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.852 . . . . 0.0 110.159 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.5 t -64.58 -49.25 81.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.736 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -48.2 -40.54 21.84 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.72 -45.99 58.83 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -1.135 . . . . 0.0 110.176 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -66.0 -40.72 91.38 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.235 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.97 -8.01 40.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.169 -0.957 . . . . 0.0 110.205 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 22' ' ' GLY . 99.4 t -96.6 0.28 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.299 -0.876 . . . . 0.0 110.248 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 m -105.18 -26.07 12.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.217 -0.927 . . . . 0.0 110.258 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.97 -28.6 65.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.31 -0.869 . . . . 0.0 110.237 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 177.74 8.0 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.191 -0.943 . . . . 0.0 110.151 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.251 -179.988 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.443 ' HG2' HD12 ' A' ' 5' ' ' ILE . 47.4 Cg_endo . . . . . 0 N--CA 1.496 1.668 0 N-CA-C 110.15 -0.75 . . . . 0.0 110.15 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.3 42.69 0.28 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.169 -0.957 . . . . 0.0 110.128 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.439 HD13 ' HA ' ' A' ' 3' ' ' ILE . 21.2 mm -92.17 -64.41 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -0.9 . . . . 0.0 110.39 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -130.54 23.46 5.09 Favored 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 122.049 0.928 . . . . 0.0 110.267 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.661 HG22 ' O ' ' A' ' 5' ' ' ILE . 9.9 mt -110.76 26.17 2.99 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-O 121.896 0.855 . . . . 0.0 110.162 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 165.72 36.9 0.02 OUTLIER Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -161.6 23.19 0.12 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -1.142 . . . . 0.0 109.983 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.6 t -140.15 -176.06 4.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.341 -0.849 . . . . 0.0 110.293 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.5 t -65.51 -25.61 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.226 -0.921 . . . . 0.0 110.171 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.82 65.63 1.34 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -73.67 -42.43 0.85 Allowed 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 124.098 1.578 . . . . 0.0 110.388 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -69.42 -59.29 3.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.323 -0.861 . . . . 0.0 110.168 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 89.1 t -53.26 -30.12 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.85 . . . . 0.0 110.076 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 36.0 t-105 -64.8 -38.35 90.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 110.035 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.42 -29.06 65.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 110.111 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -73.12 -34.62 66.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.79 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -77.24 -30.89 54.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.249 -0.907 . . . . 0.0 109.728 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -42.06 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.345 -0.847 . . . . 0.0 109.967 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.43 -49.67 68.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.28 -0.887 . . . . 0.0 109.854 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.482 HD23 ' HA ' ' A' ' 20' ' ' LEU . 2.1 mt -60.05 -54.93 40.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.32 -0.862 . . . . 0.0 109.907 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.6 t -63.6 -19.11 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.391 -0.818 . . . . 0.0 110.047 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.64 -30.48 36.0 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -75.73 -33.23 60.27 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.358 -1.084 . . . . 0.0 110.199 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.402 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -84.93 -13.11 51.8 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.191 -0.943 . . . . 0.0 110.254 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.15 -3.87 32.32 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.225 -0.922 . . . . 0.0 110.141 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.414 ' O ' HG12 ' A' ' 26' ' ' VAL . 41.3 t -107.45 -7.7 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 110.243 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.402 HG22 ' HA ' ' A' ' 24' ' ' ALA . 11.0 t -113.47 -20.86 11.13 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.288 -0.882 . . . . 0.0 110.144 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.11 -11.94 54.04 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.226 -0.921 . . . . 0.0 110.205 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.44 ' O ' ' OXT' ' A' ' 30' ' ' ASN . . . -100.54 -25.9 14.02 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.182 -0.949 . . . . 0.0 110.287 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.44 ' OXT' ' O ' ' A' ' 29' ' ' ALA . 8.4 m-80 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.304 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo . . . . . 0 N--CA 1.496 1.648 0 N-CA-C 110.167 -0.743 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.489 ' HA ' HG13 ' A' ' 5' ' ' ILE . . . -136.92 44.47 2.32 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.262 -0.899 . . . . 0.0 110.08 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.3 mt -67.45 -39.24 82.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.248 -0.908 . . . . 0.0 110.314 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -111.96 22.12 15.21 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 122.013 0.911 . . . . 0.0 110.115 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.672 HG22 ' O ' ' A' ' 5' ' ' ILE . 14.6 mm -104.28 27.11 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 CA-C-O 121.788 0.804 . . . . 0.0 110.347 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -124.41 22.52 6.59 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -131.7 29.44 4.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -1.165 . . . . 0.0 110.02 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.83 ' O ' HG21 ' A' ' 13' ' ' VAL . 3.7 m -98.83 170.17 8.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.347 -0.845 . . . . 0.0 110.419 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.692 ' HA ' HG11 ' A' ' 13' ' ' VAL . 43.6 t -138.3 27.11 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.356 -0.84 . . . . 0.0 109.944 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.9 -143.67 0.03 OUTLIER Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.5 -52.42 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.095 1.577 . . . . 0.0 110.426 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -48.52 -43.34 35.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.265 -0.897 . . . . 0.0 110.272 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.83 HG21 ' O ' ' A' ' 8' ' ' THR . 75.8 t -63.17 -37.53 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.225 -0.922 . . . . 0.0 110.174 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 28.3 t-105 -65.13 -42.52 93.82 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.4 -0.813 . . . . 0.0 110.092 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.74 -27.11 66.51 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.267 -0.896 . . . . 0.0 110.228 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -76.14 -30.55 58.21 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -0.942 . . . . 0.0 110.168 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.764 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -80.98 -29.47 35.28 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.176 -0.952 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.1 t -79.03 -38.5 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.369 -0.832 . . . . 0.0 109.899 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.59 -49.72 44.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 109.985 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 13.7 mt -59.31 -50.72 72.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 110.224 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.3 t -73.4 -17.51 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.286 -0.884 . . . . 0.0 110.174 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.733 ' O ' HG23 ' A' ' 26' ' ' VAL . . . -77.37 -25.82 62.74 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -76.42 -39.91 52.23 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.296 -1.12 . . . . 0.0 110.154 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -78.93 -28.97 43.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.353 -0.842 . . . . 0.0 110.168 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -69.73 -13.45 62.29 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.323 -0.861 . . . . 0.0 110.177 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 22' ' ' GLY . 71.2 t -77.68 -15.68 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.255 -0.903 . . . . 0.0 110.161 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 86.2 m -108.25 -46.79 3.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 0.0 110.182 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.01 69.9 10.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 110.233 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -105.61 18.65 21.86 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.197 -0.94 . . . . 0.0 110.254 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 118.063 -0.97 . . . . 0.0 110.228 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo . . . . . 0 N--CA 1.498 1.761 0 N-CA-C 110.175 -0.74 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.93 45.61 2.13 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.281 -0.887 . . . . 0.0 110.157 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.412 HG23 HD12 ' A' ' 3' ' ' ILE . 46.3 mm -89.58 -80.15 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.149 -0.969 . . . . 0.0 110.11 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -131.98 24.94 4.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.133 -0.979 . . . . 0.0 110.041 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.712 HG22 ' O ' ' A' ' 5' ' ' ILE . 25.4 mm -91.83 26.87 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.107 0 CA-C-O 121.85 0.833 . . . . 0.0 110.376 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -137.63 13.0 3.7 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.693 ' O ' HG22 ' A' ' 8' ' ' THR . . . -149.09 27.79 0.84 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.199 -1.177 . . . . 0.0 110.386 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.693 HG22 ' O ' ' A' ' 7' ' ' ALA . 6.6 t 39.0 -160.93 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.566 -0.709 . . . . 0.0 110.528 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 25.5 t -127.54 -32.4 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.179 -0.951 . . . . 0.0 110.267 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.93 82.11 1.35 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.12 -60.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.001 1.527 . . . . 0.0 110.653 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -58.8 -47.2 85.59 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 110.327 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.76 -40.24 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 110.222 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.609 ' O ' HG23 ' A' ' 18' ' ' VAL . 36.8 t-105 -64.75 -42.42 95.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 110.158 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.48 -29.64 70.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 110.24 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -74.72 -56.74 4.48 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.264 -0.898 . . . . 0.0 110.104 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.674 ' O ' HD12 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -58.42 -22.3 53.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.198 -0.939 . . . . 0.0 109.954 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.609 HG23 ' O ' ' A' ' 14' ' ' TRP . 55.9 t -83.22 -42.77 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.287 -0.883 . . . . 0.0 110.27 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.95 -23.57 67.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.338 -0.851 . . . . 0.0 110.262 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.88 -61.28 1.75 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.263 -0.898 . . . . 0.0 110.258 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.4 t -54.01 -30.07 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -0.967 . . . . 0.0 110.181 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.11 -44.34 67.29 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.09 -28.09 69.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -1.125 . . . . 0.0 110.194 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.454 ' HA ' HG22 ' A' ' 27' ' ' THR . . . -85.82 -19.22 31.0 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.267 -0.896 . . . . 0.0 110.19 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.99 -9.53 59.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.221 -0.924 . . . . 0.0 110.149 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.433 ' O ' HG12 ' A' ' 26' ' ' VAL . 50.9 t -105.83 -6.63 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.93 . . . . 0.0 110.253 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.454 HG22 ' HA ' ' A' ' 24' ' ' ALA . 14.6 t -116.52 -18.15 10.45 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.269 -0.895 . . . . 0.0 110.194 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.73 -20.64 62.62 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.228 -0.92 . . . . 0.0 110.195 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -80.74 -7.91 59.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.136 -0.978 . . . . 0.0 110.134 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 27.0 m120 . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.276 -179.98 . . . . . . . . 0 0 . 1 stop_ save_